Zymeworks will be attending the Jefferies Global Healthcare Conference in London for one-on-one meetings and will participate in a fireside chat on November 17 at 9:30 am GMT. If you’ll be there, we’d love to connect — please reach out to schedule a meeting.
Listen to the webcast here: ir.zymeworks.com/events/event-details/jefferies-global-he…
Zymeworks
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. More on Wikipedia
-
Zymeworks Inc.
@ZymeworksInc
-
Zymeworks Inc.
@ZymeworksInc
A look back at #sitc26, where our scientists presented new preclinical research on our novel PD-1 x VEGF x IL-7 multispecific immunocytokine.
The research explores an innovative approach to delivering IL-7 to PD-1-positive T cells, designed to preferentially activate anti-tumor T cells while limiting activity on bystander T cells. By advancing from PD-1 bispecific to trispecific antibodies, this approach also aims to address some of the clinical limitations of current checkpoint inhibitor strategies.
Read the poster: www.zymeworks.com/wp-content/uploads/2026/11/ZW-SITC2026-… -
Zymeworks Inc.
@ZymeworksInc
Today, we honor and remember those who have served on Remembrance Day in Canada and Veterans Day in the United States. Thank you to all veterans and active service members for your dedication and sacrifice.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks will present preclinical research on multispecific programs and cytokine engineering programs at PEGS Europe, taking place November 16–19 in Lisbon, Portugal.
Our presentations will explore next-generation tumor-targeted masked cytokines, including conditionally active IL-12 and IL-7 x PD-1 x VEGF molecules, a multispecific approach to inflammatory disease, and a differentiated T cell engager platform.
We look forward to connecting with the protein engineering community in Lisbon – learn more about our presentations: www.zymeworks.com/zymeworks-to-present-on-preclinical-and…
#pegseurope #antibodyengineering -
Zymeworks Inc.
@ZymeworksInc
Management today reported third quarter 2026 financial results, providing an update on our financial performance and business progress.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew…This media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Zymeworks will participate in upcoming investor conferences this month, engaging with members of the investment community on our strategy and portfolio.
This week our schedule includes:
- November 11 – @Stifel Healthcare Conference
- November 12 – @Truist BioPharma Symposium
We’ll also participate in the @Jefferies London Healthcare Conference next week on November 17.
Visit our website for event details: ir.zymeworks.com/events-and-presentations -
Zymeworks Inc.
@ZymeworksInc
Tomorrow at the Society for Immunotherapy of Cancer Annual Meeting, our team will present new preclinical data on a novel approach to targeted IL-7 delivery.
The approach incorporates IL-7 into a multispecific antibody designed to deliver the cytokine to tumor-specific T cells, with engineering strategies intended to limit activity on bystander T cells.
Presentation: Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence
Abstract: 810
Date: Saturday, November 7
Location: PCC-North Building, Lower Level, Exhibition Halls 4–5–6
Learn more: www.zymeworks.com/zymeworks-presents-new-preclinical-data…
#sitc2026 -
Zymeworks Inc.
@ZymeworksInc
Zymeworks will be presenting at the 2026 American Society of Hematology Annual Meeting, sharing preclinical data on ZW1953, a new CD3 multispecific T cell engager designed to target FLT3, CLEC12A, and CD33 with conditional CD28 co-stimulation for AML.
Learn more: www.zymeworks.com/zymeworks-to-present-preclinical-data-o…
#ash26 -
Zymeworks Inc.
@ZymeworksInc
Today at #esmo26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer.
The results reinforce our confidence in the potential of this approach to help expand treatment options for patients with ovarian cancer.
Read the key data highlights here: ir.zymeworks.com/news-releases/news-release-details/zymew…
#ovariancancer #adc -
Zymeworks Inc.
@ZymeworksInc
Zymeworks has entered into an exclusive global license and collaboration agreement with @Roche for ZW209, a DLL3-targeting trispecific T cell engager.
Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, and up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales.
Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization.
The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success.
Read the full announcement: ir.zymeworks.com/news-releases/news-release-details/zymew…
Zymeworks management will host a conference call on October 27 at 8:30 am ET.
#oncology #rocheinnovation #pred -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to welcome Suzanne Monahan to Zymeworks as Senior Vice President, Commercial and General Manager, Theravance Biopharma.
Suzanne brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with expertise in product launches, market access, strategic partnerships and respiratory markets.
In her new role, Suzanne will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of COPD. Read today's announcement: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks will report its third quarter 2026 financial results on November 9, and participate in several investor conferences throughout November, including the Wolfe Research, Stifel, Truist Securities, and Jefferies Healthcare Conferences.
We look forward to engaging with the investment community and sharing updates on our business and strategic priorities.
Read today’s announcement: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Giving back to the communities where we live and work is an important part of who we are at Zymeworks.
This week, employees across our hubs in Vancouver, Bellevue, New York City, Dublin, and Singapore came together for our annual all-staff giving-back event. Through hands-on activities and community initiatives, we helped bring support and a little joy to more than 1,000 children receiving care in hospitals, as well as their families and caregivers.
We’re proud of what we accomplished together and grateful to everyone who gave their time and energy to make the day such a success. -
Zymeworks Inc.
@ZymeworksInc
We’re heading into a busy fall conference season, with Zymeworks researchers presenting new clinical and preclinical data across multiple medical conferences.
At #esmo26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer.
At #sitc26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells.
At #pegseurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering.
Learn more here: www.zymeworks.com/zymeworks-to-present-on-preclinical-and… -
Zymeworks Inc.
@ZymeworksInc
Today, on the National Day for Truth and Reconciliation and Orange Shirt Day, we pause to remember the children who never came home and honour Survivors, their families and communities.
We recognize that reconciliation is an ongoing journey, and an opportunity to learn, reflect and build a better path forward together.
We encourage everyone to take time to learn more about the history and significance of this day through resources from the National Centre for Truth and Reconciliation, today and throughout the year.
Learn more: nctr.ca
#nationaldayfortruthandreconciliation #orangeshirtday -
Zymeworks Inc.
@ZymeworksInc
As Ovarian Cancer Awareness Month comes to a close, the need for awareness and support continues on.
For patients, caregivers and loved ones navigating a gynecologic cancer diagnosis, finding the right information and support can make a meaningful difference. Resources are available to help with everything from managing a diagnosis and finding support to navigating financial assistance and other challenges along the way.
Explore resources for patients and caregivers from the Ovarian Cancer Research Alliance: ocrahope.org/resources-support/additional-resources/
#ovariancancer #cancerawareness #oncology -
Zymeworks Inc.
@ZymeworksInc
We’ve completed the acquisition of Theravance Biopharma, advancing our strategy to build a productive R&D company with a growing portfolio of revenue-generating assets and diversified, durable cash flows.
We’re also pleased to welcome Stuart Knight as EVP & CIO and Jesse Fecker, Ph.D., J.D., as VP, Intellectual Property.
Read the full announcement: ir.zymeworks.com/news-releases/news-release-details/zymew…
Join our conference call today at 8:30 am ET: edge.media-server.com/mmc/p/midqpich/ -
Zymeworks Inc.
@ZymeworksInc
Our Zymeworks team came together at Stanley Park this past weekend to run, walk and support @TerryFoxCanada's vision of a world without cancer. The Terry Fox Run continues to bring people together across Canada to raise funds for cancer research and carry forward Terry’s incredible legacy.
A huge congratulations to our team on an amazing fundraising effort, and thank you to everyone who ran, walked, donated, fundraised or cheered us on.
Well done, Team Zymeworks!
#terryfoxrun #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Today, we announced the completion of our acquisition of Theravance Biopharma.
With the transaction now complete, Theravance Biopharma is officially part of Zymeworks, marking an important step in our strategy to build a diversified, revenue-generating biotechnology company combining innovative R&D with growing commercial and royalty-based cash flows.
We’ll host a conference call for investors and the general public on Monday, September 28 at 8:30 am ET to discuss the final transaction details.
Learn more and access the webcast: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to share that our FRα-targeting antibody-drug conjugate (#adc) has been selected for a Rapid Oral Presentation at the 2026 @myESMO Congress in Madrid.
The presentation will feature new clinical results from our Phase 1 randomized dose optimization study in heavily pretreated patients with platinum-resistant ovarian cancer (PROC).
Title: Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer
Date/Time: Saturday, October 24 at 8:30–10:00 am CET
View this year's program: cslide.ctimeetingtech.com/esmo2026/attendee/confcal/sessi…
We look forward to sharing these findings with the oncology community at #esmo26!
#ovariancancer #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
September is Ovarian Awareness Month — an opportunity to recognize the patients and families affected by these cancers and highlight the importance of continued research and innovation.
We’re proud to share a recently published study from our scientists exploring the preclinical profile of our folate receptor alpha (FRα)-targeting antibody-drug conjugate. The research demonstrated promising anti-tumor activity across multiple tumor models, including ovarian and endometrial cancers, and provided insights into the differentiated properties of the antibody and payload.
Read the publication: login.ezzym.infotrieve.com/login?qurl=https://aacrjournal…
#ovariancancer #adc #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to share that Bijal Desai, SVP, Finance at Zymeworks, will participate in a panel discussion at Informa’s Life Sciences Product Launch Summit next week.
Bijal will join industry leaders for “Optimizing Gross-to-Net (GTN) and Financial Planning for Launch Success,” exploring the role of financial planning in supporting successful product launches.
Tuesday, September 22
10:45–11:15 am ET
Learn more about the event: informaconnect.com/product-launch/
#lifesciences #biotech #finance -
Zymeworks Inc.
@ZymeworksInc
This week Zymeworks’ management team will participate in two healthcare investor conferences in New York:
Morgan Stanley Healthcare Conference — September 14
Fireside chat at 4:50 pm ET
H.C. Wainwright Annual Global Investment Conference — September 15
Fireside chat at 3:30 pm ET
Learn more: ir.zymeworks.com/events-and-presentation -
Zymeworks Inc.
@ZymeworksInc
Zymeworks’ management team will participate in two healthcare investor conferences this week:
Wells Fargo Healthcare Conference — September 8 in Boston, MA
Fireside chat at 3:45 pm ET
Citi’s Biopharma Back to School Summit — September 9 in New York, NY
Fireside chat at 3:40 pm ET
Learn more: ir.zymeworks.com/events-and-presentations -
Zymeworks Inc.
@ZymeworksInc
As we recognize Ovarian Awareness Month, we’re highlighting our ongoing work to explore new approaches for patients with difficult-to-treat gynecological cancers.
In June, we shared new clinical findings from the Phase 1 study of our folate receptor alpha (FRα)-targeting antibody-drug conjugate at the ESMO Gynaecological Cancers Congress. Among response-evaluable patients with platinum-resistant ovarian cancer, the investigational therapy demonstrated anti-tumor activity across both FRα-positive and FRα-negative tumors, reinforcing the potential of this approach.
Zymeworks is currently evaluating strategic partnering opportunities to support the continued development of this program and maximize its long-term potential.
Learn more about the clinical findings: www.zymeworks.com/wp-content/uploads/2026/06/ESMO-Gyn-202…
#ovariancancerawarenessmonth #ovariancancer #gynecologiccancers #adc #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
September is Ovarian Cancer Awareness Month — a time to recognize the patients, families and communities affected by these cancers and to raise awareness of the signs, symptoms and resources available to those seeking information and support.
Early symptoms of ovarian and other gynecologic cancers can sometimes be difficult to recognize or may be mistaken for other conditions. We encourage anyone looking to learn more to explore resources from the American Association for Cancer Research, including information about ovarian cancer, treatment options and resources for patients and caregivers: www.aacr.org/patients-caregivers/cancer/ovarian-cancer/ov…
#ovariancancerawarenessmonth #gynecologiccancers #ovariancancer -
Zymeworks Inc.
@ZymeworksInc
Today, we recognize Women’s Equality Day — an opportunity to celebrate the progress made toward gender equality and recognize the work that continues to ensure women have equal opportunities to lead, contribute and make an impact.
At Zymeworks, we’re proud to celebrate the women across our organization whose expertise, leadership and contributions help advance science and make a difference for patients.
#womensequalityday #womeninscience #genderequality -
Zymeworks Inc.
@ZymeworksInc
The latest approval of Ziihera® (zanidatamab-hrii) for first-line HER2-positive gastroesophageal adenocarcinoma (GEA) marks another important milestone for a medicine discovered and engineered by Zymeworks using our proprietary Azymetric™ platform.
Together with our partners, we’re proud to see zanidatamab bring a new treatment option to more patients with difficult-to-treat cancers.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/us-fd… -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to participating in the Cell Engager Microsummit this week, where Prajwal Raghunatha will present on our approach to advancing innovative T-cell engager therapies on August 18 at 10:00 am PT.
Learn more about our antibody technologies: www.zymeworks.com/antibody-science
#tcellengagers #immunooncology #biotech -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to participating in several investor conferences this September, where members of our leadership team will share updates on Zymeworks' strategy, business priorities and diversified portfolio.
Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks reports second quarter 2026 financial results - read the full press release and financial results: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today, on Lung Cancer Awareness Day, we recognize the millions of people impacted by lung cancer and the importance of continued innovation to improve treatment options.
At Zymeworks, we're committed to advancing next-generation therapeutics designed to address difficult-to-treat cancers. Through scientific innovation and collaboration, we remain focused on developing new treatment approaches that have the potential to make a meaningful difference for patients living with this challenging disease.
#lungcancerawarenessday #oncology #cancerresearch #biotech -
Zymeworks Inc.
@ZymeworksInc
From conference presentations to peer-reviewed publications, we've recently shared new insights into our research and development efforts. If you missed them, here are a few recent highlights:
- World Bispecific Summit Europe – view our presentation, Optimising Multispecific Antibody Design for Therapeutic Application: www.zymeworks.com/wp-content/uploads/2026/07/Moore-World-…
- Annals of Oncology – read Re-evaluating antibody—drug conjugate linker stability: assessment, interpretation, and clinical translation: www.sciencedirect.com/science/article/pii/S09237534260014…
- Clinical Cancer Research – read ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile: aacrjournals-org.ezzym.infotrieve.com/clincancerres/artic…
To learn more about our research and antibody platforms, visit: www.zymeworks.com/antibody-science/
#drugdiscovery #adc #antibodyengineering #oncology -
Zymeworks Inc.
@ZymeworksInc
Great science starts with great people.
One of our favorite summer traditions is our annual employee-hosted patio party, where a different team takes the lead each year. This year's Summer Bytes event, co-hosted by our IT and HR teams, brought our Vancouver colleagues together for an afternoon of great food, fun, and connection.
A big thank you to our organizers for such a fantastic event — we're already looking forward to seeing which team takes the reins next year!
#lifeatzymeworks #oneteam #biotech -
Zymeworks Inc.
@ZymeworksInc
If you're attending AACR D3 today, be sure to join our company presentation on our latest advances in antibody-drug conjugate (ADC) development.
Company presentation: Grand Ballroom at 3:10 pm ET
Dr. Raffaele Colombo will also be moderating "Drugging the Surfacesome – Session 1" from 4:45–6:15 pm ET in the Grand Ballroom.
We hope to see you there!
Learn more about our antibody platforms: www.zymeworks.com/antibody-science/
#aacrd3 #adc #oncology #drugdiscovery -
Zymeworks Inc.
@ZymeworksInc
Our scientists continue to push the boundaries of next-generation immunotherapies, and we're proud to see their work featured at the Cell Engagers Microsummit.
Join Gursev Anmole, Scientist & Group Lead at Zymeworks, on July 21 at 10 am PT as he presents "TriTCE Co-stim: A T-cell Engager Platform with Conditional cis CD28 Co-stimulation."
Learn about more about our science: www.zymeworks.com/innovation/
#tcellengagers #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Antibody-drug conjugates (ADCs) have emerged as an important class of anticancer therapeutics. Their highly modular design offers multiple opportunities to tune their properties and potentially improve clinical performance by modifying individual components, including the antibody, linker, and payload.
In this article, our ADC Therapeutic Development team examines common assumptions regarding ADC linker stability, highlights limitations of preclinical models in predicting human payload exposure, outlines appropriate methods to assess ADC stability, and discusses the clinical implications of altering ADC linker stability.
By re-evaluating the role of linker stability in #adc design, this work aims to inform more rational strategies for the development of next-generation ADCs.
Read the full article in Annals of Oncology (free access for 50 days): authors.elsevier.com/a/1nKG73I2OQqHvL -
Zymeworks Inc.
@ZymeworksInc
Zymeworks will report its second quarter 2026 financial results after market close on August 6, 2026. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We're looking forward to the AACR D3 Conference in Boston next week. Raffaele Colombo will be presenting and participating in discussions on the latest advances in antibody-drug conjugate (ADC) development.
Sessions:
- Company Presentation: July 23 at 3:10 pm ET
- Drugging the Surfacesome – Session 1: July 23 at 4:45–6:15 pm ET
If you're attending, we'd love to connect!
Learn more: www.aacr.org/meeting/aacr-d3-2026/program-thursday-july-23/
#aacrd3 #aacr #adc -
Zymeworks Inc.
@ZymeworksInc
This week, Zymeworks' Chief Scientific Officer, Paul Moore, presented "Optimising Multispecific Antibody Design for Therapeutic Application" at the World Bispecific Summit Europe.
The presentation explored key considerations in the design of next-generation multispecific antibodies and highlights how our Azymetric™ platform enables the efficient generation of stable multispecific antibodies across a range of therapeutic formats. Case studies featured the breadth of the platform, spanning the approved HER2-targeting bispecific antibody, investigational bispecific antibody-drug conjugates and next-generation T-cell engagers.
View the presentation here: www.zymeworks.com/wp-content/uploads/2026/07/Moore-World-…
#worldbispecificsummit #multispecificantibodies #biotech -
Zymeworks Inc.
@ZymeworksInc
Happy Independence Day!
Today we recognize and celebrate our colleagues, collaborators and communities across the United States.
We wish everyone celebrating a safe and enjoyable Fourth of July.
#fourthofjuly #biotech -
Zymeworks Inc.
@ZymeworksInc
In case you missed it! At the 2026 T-Cell Engager Therapeutics Summit, Genevieve Desjardins presented "Enhancing the Activity of T-Cell Engagers in Solid Tumors with CD28 Co-Stimulation."
The presentation highlights Zymeworks' innovative trispecific T-cell engager approach, which leverages conditional cis CD28 co-stimulation to enhance T-cell activation and anti-tumor activity while maintaining a favorable safety profile.
Read the presentation: www.zymeworks.com/wp-content/uploads/2026/06/GDesjardins-…
#tcellengagers #oncology -
Zymeworks Inc.
@ZymeworksInc
Happy Canada Day!
Today we're celebrating our Canadian roots and the people who help drive our science forward every day.
From our headquarters in Vancouver and across our global teams, we’re proud to contribute to Canada’s thriving life sciences ecosystem as we work to discover and develop new therapies for patients with difficult-to-treat diseases.
Wishing everyone celebrating a safe and happy Canada Day.
#canadaday #biotech #lifesciences -
Zymeworks Inc.
@ZymeworksInc
Today, we announced that we have entered into a definitive agreement to acquire Theravance Biopharma for approximately US$929 million. The proposed acquisition would add commercial and development-stage assets spanning COPD, inflammation and immunology, while further advancing Zymeworks' strategy to build a diversified biotechnology company with durable cash flows to support long-term innovation.
More details here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Summer is officially here, and our annual company summer closure will run from June 26 to July 3, giving our dedicated team time to rest, recharge, and reconnect.
We’re grateful for the opportunity to pause before an exciting second half of the year — one that includes important milestones across our pipeline, continued scientific collaboration, and presentations at key industry conferences.
Thank you for your continued support as we prioritize employee well-being alongside innovation for patients.
We’ll be back refreshed and ready for what’s ahead.
#biotech #wellbeing -
Zymeworks Inc.
@ZymeworksInc
Today, we recognize Juneteenth — the oldest nationally celebrated commemoration marking the end of slavery in the United States and honoring the ongoing pursuit of freedom, justice, and equity.
At Zymeworks, we recognize that advancing healthcare innovation also means helping address disparities in care and working toward a more equitable future in science and medicine.
Learn more about Juneteenth here: nmaahc.si.edu/explore/moments/juneteenth
#juneteenth #healthequity -
Zymeworks Inc.
@ZymeworksInc
We’re looking forward to attending the BIO International Convention next week!
Join Dr. Sabeen Mekan, Chief Medical Officer, for Zymeworks’ company presentation on June 24 at 3:45 pm PT.
The presentation will provide an overview of our company, differentiated pipeline, and approach to developing next-generation antibody-based therapeutics.
Members of our Business Development team will be onsite throughout the conference and available to connect. If you'll be attending BIO, we’d love to meet with you and share more about Zymeworks' approach to developing next-generation therapeutics. Learn more about partnering with us here: www.zymeworks.com/partners/
#bio2026 -
Zymeworks Inc.
@ZymeworksInc
At the annual ESMO Gynaecological Cancers Conference this week, we will present an efficacy analysis of our folate receptor alpha (FRα) -targeting antibody-drug conjugate by (FRα) expression level.
“We are highly encouraged by these data, which continue to demonstrate the differentiated profile of ZW191 and its potential to deliver meaningful clinical benefit across a broad population of patients with ovarian and endometrial cancers,” said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer of Zymeworks. “The response rate observed in FRα-positive ovarian cancer patients compares favorably with currently available therapies, while maintaining meaningful activity in patients with lower levels of FRα expression. Together these encouraging data on durability, progression-free survival, and manageable safety profile further strengthen our confidence in the program and reinforce the ability of our ADC platform to generate differentiated therapeutics.”
View the poster: www.zymeworks.com/wp-content/uploads/2026/06/ESMO-Gyn-202…
Read our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
#adc #esmogyne #ovariancancer #endometrialcancer -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to attending the BIO International Convention later this month and connecting with colleagues, partners, and innovators from across the global life sciences community.
Join Dr. Sabeen Mekan, Zymeworks' Chief Medical Officer, for the panel discussion "The Next Generation of ADCs: Building Kinder, Gentler Cancer Therapeutics" on June 25 at 10:15–11:15 am PT.
We’ll also be delivering a company presentation highlighting Zymeworks' approach to developing novel antibody-based therapeutics on June 24 at 3:45 pm PT.
Members of our Business Development and leadership teams will be onsite throughout the conference and available to connect. We look forward to discussing our science and partnership opportunities.
See you at #bio2026!
#adcs #tcellengagers #businessdevelopment -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to share that Dr. Sabeen Mekan will be participating in the CMO Summit panel discussion, “Existing Pipelines: Maintaining Clinical Progress” on June 16 at 8:30 am ET.
The session will explore evolving regulatory considerations shaping the future of biotech innovation and drug development.
Learn more: www.longwoodhealthcareleaders.com/events/mitceo2026 -
Zymeworks Inc.
@ZymeworksInc
Today, on National Cancer Survivors Day, we recognize and celebrate the strength, resilience, and journeys of cancer survivors everywhere.
At Zymeworks, patients remain at the center of everything we do. We are inspired by the courage of survivors and remain committed to advancing innovative therapies that aim to improve outcomes for people living with difficult to treat diseases.
Learn about our programs: www.zymeworks.com/pipeline/
#cancersurvivorsday #oncology -
Zymeworks Inc.
@ZymeworksInc
We’re excited to participate in the World Bispecific Summit in South Korea next week.
Dr. Alexey Berezhnoy, Zymeworks' Senior Director of Immunology, will present “ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation” and share insights into our continued work advancing next-generation multispecific therapeutics.
View the conference program:worldbispecifics-tce-kr.com
#copd #bispecifics -
Zymeworks Inc.
@ZymeworksInc
We’re looking forward to participating in the Jefferies Global Healthcare Conference in New York this week.
Management will take part in a fireside chat on June 3 at 8:45 a.m. ET to discuss our continued progress advancing innovative therapeutics for patients with difficult-to-treat cancers and other serious diseases.
Join the webcast here: event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/guest_bo… -
Zymeworks Inc.
@ZymeworksInc
Happy #pridemonth!
This month, we recognize and celebrate the history and contributions of the #lgbtq+ community and the ongoing pursuit of equality, inclusion, and acceptance.
At Zymeworks, we believe that different perspectives, experiences, identities, and backgrounds make us stronger. We are committed to fostering a culture where employees feel supported, valued, and empowered to bring their authentic selves to work.
We’re proud to celebrate Pride and amplify the voices of the LGBTQ+ community across the life sciences industry.
#pride2026 #biotech -
Zymeworks Inc.
@ZymeworksInc
This Memorial Day, we honor and remember the courageous individuals who gave their lives in service to their country.
Their sacrifice serves as a lasting reminder of the freedoms we value and the responsibility we share to uphold them. At Zymeworks, we are grateful to those who served and to the families who continue to carry their legacy forward.
Wishing everyone a meaningful Memorial Day. -
Zymeworks Inc.
@ZymeworksInc
We’re looking forward to participating in the @Stifel Virtual Targeted Oncology Forum this week. Management will take part in a fireside chat on May 20 at 9:00 am ET - join the webcast: event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/guest_bo…
-
Zymeworks Inc.
@ZymeworksInc
We just wrapped a great week at PEGS Boston and appreciated the opportunity to connect with so many colleagues advancing the field of antibody engineering.
Our team was proud to share some of our latest work — thank you to everyone who stopped by to connect! If you missed the presentations or want to revisit the data, access the presentations here: www.zymeworks.com/publications/
Curious about our ADC and multispecific programs? Learn more at www.zymeworks.com/innovation/
#adc #antibodydrugconjugate #trispecifics #pegsboston -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to welcome Paul Schneider as our new General Counsel.
With more than 20 years of legal experience advising on strategic transactions across the life sciences sector – including in-licensing, out-licensing, collaborations, and M&A – his combination of legal expertise and scientific background will be valuable as we continue advancing our pipeline and business.
We also extend our sincere thanks to our outgoing General Counsel, Daniel Dex, for his contributions over the past several years. Since joining Zymeworks in 2017, he has played an important role in helping shape the company and has been a trusted advisor to leadership. We are grateful for his impact and wish him all the best in his next chapter. -
Zymeworks Inc.
@ZymeworksInc
Management are pleased to present at the following investors conferences in May and June - learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re heading to the 2026 Respiratory Innovation Summit in Orlando, FL (May 15–16), hosted by the American Thoracic Society!
Our team will present “ZW1528: IL-4Rα x IL-33 Bispecific Antibody for Treatment of COPD” (poster no. 117), showcasing our work on our novel IL-4Rɑ x IL-33 bispecific molecule targeting respiratory inflammation, including mixed-type chronic obstructive pulmonary disease (COPD). Stop by to connect with our team and learn more about our AIID programs.
Learn more: www.zymeworks.com/zymeworks-to-present-at-respiratory-inn…
#respiratoryinnovation #copd #bispecific #aiid
American Thoracic Society (ATS)
@atscommunity
⏰Don't miss out! The ATS 2026 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments and tools.
ATS Thanks Boehringer Ingelheim Pharmaceuticals, Inc., Insmed Incorporated, Genentech, GSK, Catalent, Lovelace Biomedical, Ritedose Corp., SMSBiotech, and Vitalograph for their generous support of the ATS 2026 Respiratory Innovation Summit.
Get your ticket today - space is limited! site.thoracic.org/conference/program/respiratory-innovati… -
Zymeworks Inc.
@ZymeworksInc
Ovarian cancer remains one of the most challenging cancers to diagnose and treat — with many patients facing limited options, especially in later stages.
Advancing new approaches is critical to changing this reality.
On World Ovarian Cancer Day, we recognize the urgency of continued research and innovation — and the importance of working toward better outcomes for patients.
#worldovariancancerday #ovariancancer #oncologyresearch #ovariancancerawareness -
Zymeworks Inc.
@ZymeworksInc
Today we reported our Q1 2026 financial results. Join our management team for a live webcast at 4:30 pm ET as we review business updates and progress across our pipeline.
Join the webcast: edge.media-server.com/mmc/p/d5i66787/
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re heading to PEGS Boston next week! Join us for:
Panel
Advancing Multispecific Antibodies and Combination Therapies to the Clinic
May 13 | 2:40 pm ET
Presenter: Dr. Nina E. Weisser
Posters
Uniting Discovery Strategy and Engineering for the Best-in-Class Antibodies for ADC
May 12 | 4:00 pm ET
May 13 | 6:20 pm ET
Presenter: Dr. Germanna Righetto
TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional cis CD28 Co-Stimulation
May 14 | 8:50 am ET
Presenter: Dr. Genevieve Desjardins
If you’re attending, we’d welcome the opportunity to connect. Learn more about our ADC and multispecific programs: www.zymeworks.com/antibody-science/
#pegsboston #adc #multispecifics #biotech -
Zymeworks Inc.
@ZymeworksInc
May is National Cancer Research Month.
Our mission is rooted in advancing science that makes a meaningful difference for patients with difficult to treat cancers. Through our fully integrated, in-house R&D engine, we’re working to translate innovative science into potential new treatment options.
To the researchers, clinicians, and patients driving progress forward — we’re proud to be part of this effort.
Learn more: www.zymeworks.com/innovation/
#cancerresearch #biotech #innovation #oncology -
Zymeworks Inc.
@ZymeworksInc
May is Mental Health Awareness Month — a reminder that taking care of our mental well-being is just as important as physical health.
At Zymeworks, we’re committed to fostering a workplace where our people feel supported, balanced, and empowered to do their best work — for themselves and for the patients we serve. Our Health & Wellness benefits programs, such as ZymeLife and Flexible Time-off, are designed to support employees in prioritizing their well-being. Learn more: www.zymeworks.com/careers/
#mentalhealthawarenessmonth #mentalhealthatwork -
Zymeworks Inc.
@ZymeworksInc
Congratulations to the team at @BeOneMedicines on this important milestone! The FDA’s Priority Review highlights the potential of this combination approach in the first-line treatment of HER2-positive gastroesophageal adenocarcinoma—an area with significant unmet need for patients.
#gea #oncology
BeOne Medicines
@BeOneMedicines
#news for #investors and #media: BeOne Medicines is pleased to announce the FDA has granted Priority Review for our PD-1 inhibitor in combination with a HER2-directed antibody and chemotherapy for the first-line treatment of HER2+ gastroesophageal adenocarcinoma.
Read the full press release here: ir.beonemedicines.com/news/us-fda-grants-priority-review-…
#oncology #cancerresearch #gea -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to share news from our partner, @JazzPharma! Backed by Phase 3 data, this sBLA highlights an important step forward to redefine care for people living with HER2+ gastroesophageal adenocarcinoma, where significant unmet need remains.
Jazz Pharmaceuticals
@JazzPharma
#news for U.S. media and investors: Today, the U.S. FDA accepted and granted Priority Review for the supplemental Biologic License Application (sBLA) for our potential treatment for HER2+ unresectable locally advanced or metastatic GEA. Learn more: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
AACR 2026 was amazing! A week full of science, collaboration, and connection — and a great reminder of the collective effort driving progress in cancer research. We couldn't be more proud of our team for their hard work that goes into the science behind our programs and leading up to our presentations.
Explore all that Zymeworks shared at AACR: www.zymeworks.com/publications/
#aacr26 #oncology
Zymeworks Inc.
@ZymeworksInc
-
Zymeworks Inc.
@ZymeworksInc
Today we celebrate Earth Day and reaffirm our commitment to taking actions to protect our planet and environment. As we work to develop novel medicines for patients with difficult-to-treat cancers and other serious diseases, we recognize the importance of minimizing our environmental footprint and are actively working towards sustainable solutions. Read our 2025 ESG report: ir.zymeworks.com/static-files/f8ed2c4d-215f-4538-9180-f7a…
-
Zymeworks Inc.
@ZymeworksInc
On National Administrative Professionals Day, we extend our deepest thanks to our administrative team at Zymeworks—your professionalism, care, and behind-the-scenes leadership are essential to advancing our mission.
#collaboration #administrativeprofessionalsday -
Zymeworks Inc.
@ZymeworksInc
Today we presented new Phase 1 Data for our folate receptor alpha-targeting antibody-drug conjugate at #aacr26. The ADC demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression.
“We are highly encouraged by the initial clinical data for ZW191, which reinforce the strength of our ADC platform and its ability to generate differentiated therapeutics. The breadth and durability of responses, along with activity across varying levels of FRα expression, support further development of ZW191 as a potential best-in-class agent for patients with ovarian and endometrial cancers.” - Dr. Sabeen Mekan, SVP and Chief Medical Officer.
View the presentation: www.zymeworks.com/wp-content/uploads/2026/04/AACR-2026_ZW…
Read our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
#aacr26: Samuel Lawn, Principal Scientist, will be presenting "ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer" at Poster Board 10 in Poster Section 10 from 2 pm - 5 pm PT.
His poster is also available on our website: www.zymeworks.com/wp-content/uploads/2026/04/ZW439-CLDN18… -
Zymeworks Inc.
@ZymeworksInc
Live at #aacr26 - Associate Director Dunja Urosev and Scientist Ambroise Wu are presenting "ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers."
Stop by Poster Board 9 in Poster Section 12 between 9:00 am to Noon PT to learn more! The poster is also available online: www.zymeworks.com/wp-content/uploads/2026/04/ZW427-a-Ly6E… -
Zymeworks Inc.
@ZymeworksInc
#aacr26: Mark Petersen, Senior Scientist, ADC Therapeutic Development presents "Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads" from 9:00 am to Noon PT at Poster Board 8 in Poster Section 38.
Check out his poster here: -
Zymeworks Inc.
@ZymeworksInc
#aacr26: Today Vincent Fung, Scientist and Group Lead for Bioconjugation, is presenting "Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer" between 9:00 am and Noon PT at Poster Board 15 in Poster Section 12.
We hope to see you in person! And if not, check out the poster here: www.zymeworks.com/wp-content/uploads/2026/04/ZW418_bipara… -
Zymeworks Inc.
@ZymeworksInc
This morning at #aacr26 we invite you to join Senior Scientist Graham Garnett to learn about our new pan-RASi ADC platform, which integrates novel tricomplex pan-RAS inhibitors into ADCs to enable tumor-selective delivery and improved therapeutic index.
Graham's presentation entitled "A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers" will take place today from 9:00 AM to Noon PT at Poster Board 1 in Poster Section 11.
Not at the conference? View the poster here: www.zymeworks.com/wp-content/uploads/2026/04/5140-A-pan-R… -
Zymeworks Inc.
@ZymeworksInc
Now live at #aacr26 — join Sam Lawn for “ZW191 – a differentiated FRα-targeted topoisomerase I antibody-drug conjugate active in combination with standard-of-care therapies.”
If you’re onsite, stop by Poster Board 4 in Poster Section 13 between 9:00 am - 12:00 pm PT to connect with our team and learn more. The presentation is also available on our website: www.zymeworks.com/wp-content/uploads/2026/04/ZW191-Combo-…
#antibodydrugconjugates #adc #ovariancancer -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to attending the Bloom Burton & Co. Healthcare Investor Conference on April 21 in Toronto. We'll be holding one-on-one meetings as well as participating in a company presentation on April 21 at 9:30 am ET. Let's connect!
Listen to the company presentation: ir.zymeworks.com/events/event-details/2026-bloom-burton-c… -
Zymeworks Inc.
@ZymeworksInc
We’re thrilled to share new preclinical data at #aacr26, showcasing the breadth of our antibody-drug conjugate (ADC) programs and introducing our novel RAS-targeting platform. Our senior research leaders will present recent advancements across six poster sessions—mark your calendars:
ZW191 - a differentiated FRα-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs - Abstract: 1707 / April 20 at 9 am – 12 pm PST / Poster Section 13
A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers - Abstract: 1642 / April 20 at 9 am – 12 pm PST / Poster Section 11
Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer - Abstract: 1686 / April 20 at 9 am – 12 pm PST / Poster Section 12
ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers - Abstract: 4431 / April 21 at 9 am – 12 pm PST / Poster Section 12
ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer - Abstract: 5640 / April 21 at 2 – 5 pm PST / Poster Section 10
Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads - Abstract: 2400 / April 20 at 9 am – 12 pm PST / Poster Section 38
Learn more about the data being presented next week: ir.zymeworks.com/news-releases/news-release-details/zymew…
#antibodydrugconjugates #adc #biotechThis media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Nina Weisser, Senior Director, Multispecific Antibody Therapeutics, will be giving an invited talk at #aacr26. Her topic: "Unlocking novel biologies with bi- and trispecific antibodies: the importance of antibody format."
We hope to see you there! Learn more about our multispecific antibody programs: www.zymeworks.com/antibody-science/ -
Zymeworks Inc.
@ZymeworksInc
Management will report first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). ir.zymeworks.com/news-releases/news-release-details/zymew…
The event will be webcast live with dial-in details and webcast replays available on our website at ir.zymeworks.com/events-and-presentations. -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to #aacr26! Our team will be at AACR to discuss our novel ADC design approach and proprietary technologies.
Our proprietary Topoisomerase 1 inhibitor (TOPO1i), ZD05619, uses a novel fit-for-purpose camptothecin payload with moderate potency and strong bystander activity in conjunction with a traceless, plasma-stable, cleavable peptide linker. Used in our folate-receptor alpha targeting ADC and GPC3-targeting ADC programs both currently in Phase 1 trials.
Learn more about our antibody platforms: www.zymeworks.com/antibody-science/
#antibodydrugconjugates #bitoech #drugdiscovery -
Zymeworks Inc.
@ZymeworksInc
Interested in the latest research on treatments for RAS mutated cancers? We're presenting new preclinical data from our emerging RAS inhibitor ADC platform and several novel candidates designed to target treatment of RAS mutated cancers at #aacr26. Learn More:
-
Zymeworks Inc.
@ZymeworksInc
SVP Finance Bijal Desai will give a company presentation at Life Science Washington's Life Science Innovation Northwest conference at the Seattle Convention Center on April 22. Her talk is during the afternoon session between 1:35 and 3:10 PM in the Oncology II track, room, 609. See you there!
Details: lifesciencewa.org/events/life-science-innovation-northwes… -
Zymeworks Inc.
@ZymeworksInc
We are thrilled to be sharing new clinical data from our first-in-human multicenter open-label study of our folate receptor α (FRα)–targeting antibody-drug conjugate (ADC).
Abstract CT306, will be held Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST).
Presenter: Dr. Patricia LoRusso
We hope to see you there!
Learn more about our AACR presentations here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Needham & Company's Virtual Healthcare Conference starts today! Zymeworks’ management will participate in virtual one-on-one meetings and present on April 15 at 10:15 am ET.
-
Zymeworks Inc.
@ZymeworksInc
We invite you to "link up" with our incredible team and talk about ADCs at #aacr26! Our team of researchers will be onsite to discuss our recent advances in ADC therapeutics, including the unveiling of our novel RAS ADC platform.
Join our BD team ahead of the Annual Meeting at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients on April 16-17 in San Diego. Head of R&D Adam Schayowitz will be presenting on our recent progress at 5:40 pm PT - learn more: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo… -
Zymeworks Inc.
@ZymeworksInc
We’re pleased to announce the full-time appointments of Dr. Adam Schayowitz as Executive Vice President and Head of Research & Development, and Scott Platshon as Executive Vice President and Chief Business Officer at Zymeworks!
Together with the recent appointment of Kristin Stafford as CFO, these leadership updates come at a pivotal time as we drive progress across our pipeline, partnerships, and broader corporate strategy.
Read the announcement: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re excited to share that Sabeen Mekan, SVP and CMO, will be speaking at @FierceBiotech’s CMO 360 Summit—one of the largest gatherings of physician leaders in biotech. Hope to see you there!
www.cmosummit360.com -
Zymeworks Inc.
@ZymeworksInc
Today is World Health Day. Under the @WHO 's theme “Together for health. Stand with science”, this year’s observance launches a year‑long campaign celebrating the power of scientific collaboration. We are all in!
#standwithscience #worldhealthday -
Zymeworks Inc.
@ZymeworksInc
We are looking forward to attending @UBC's Transforming Health Symposium which will bring together global thought leaders, clinicians, researchers, trainees and industry experts to explore how innovations can be translated into tangible health solutions. We hope to see you there! Learn more: www.med.ubc.ca/transforming-health-symposium/
-
Zymeworks Inc.
@ZymeworksInc
Looking to make a meaningful impact for patients with difficult-to-treat cancers and other serious diseases?
We’re hiring a Medical Director to join our team in Dublin/UK.
Learn more and apply here: www.zymeworks.com/careers/ -
Zymeworks Inc.
@ZymeworksInc
We’re looking for great people to join us across a range of functions:
-Senior Director, Business Development
-Senior Manager, IT Applications (G&A)
-Clinical Data Manager (6-month contract)
-Investment Analyst
If you’re looking to make an impact in a science-driven organization, explore the opportunities here: www.zymeworks.com/careers/ -
Zymeworks Inc.
@ZymeworksInc
We're thrilled to welcome Kristin Stafford as our new Chief Financial Officer!
She brings deep experience across the life sciences industry and a proven track record in strategic planning, disciplined capital allocation, and complex transactions. We look forward to her contributions as we continue building a differentiated business and strengthening our long-term growth.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Azymetric™ antibodies can be customized to enhance therapeutic activity through our proprietary complementary technologies. The foundational Azymetric antibody technology is compatible with glyco-engineering, Fc fusions and other Fc binding modifications, including our EFECT™ technology, T Cell engager technology: TriTCE co-stim and TriTCE checkpoint technology (TriTCE CPI), and antibody-drug conjugate technologies.
Our other technologies can all combine with Azymetric™ to engineer the antibody backbone of a bispecific antibody-drug conjugate or the base of a multispecific therapeutic, to overcome known therapeutic barriers resulting in best-in-class bi-specifics and trispecifics. Learn more about our Azymetric platform: www.zymeworks.com/antibody-science/ -
Zymeworks Inc.
@ZymeworksInc
We're excited to share that we have received U.S. FDA Fast Track Designation for our FRα-targeting antibody-drug conjugate for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC). Our ongoing Phase 1 clinical trial of of the ADC is enrolling patients with advanced solid tumors to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity.
Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Azymetric™ antibodies are multifunctional and can simultaneously bind to multiple distinct locations on one or more targets. They can unlock novel biologies by blocking multiple signaling pathways, recruiting immune cells to tumors, enhancing receptor clustering and internalization, increasing tumor-specific targeting and more. Learn more about our Azymetric platform: www.zymeworks.com/antibody-science/
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials
ADC payload chemistry and antibody engineering are widening therapeutic windows and reshaping early-phase development. In a wide-ranging conversation, @ClinicalLeader1's Abby Proch and Zymeworks CMO
Sabeen Mekan discuss these scientific gains, their influence on early study design, evolving regulatory expectations, and the growing role of modeling, simulation, and Al-enabled biomarker analysis.
www.clinicalleader.com/doc/zymeworks-shares-its-design-ra… -
Zymeworks Inc.
@ZymeworksInc
Management are pleased to present at the following investors conferences in April - learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-Needham 25th Annual Virtual Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present on April 15 at 10:15 am ET
-2026 Bloom Burton & Co. Healthcare Investor Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on April 21 in Toronto -
Zymeworks Inc.
@ZymeworksInc
#aacr26 is an incredible opportunity to connect with the life sciences community, exchange insights, and help drive cancer research forward.
We’re excited to present clinical and preclinical data from our #adc programs at at this year’s AACR Annual Meeting, including:
- New clinical data from our Phase 1 trial of ZW191 in an oral presentation on April 21
- Preclinical data highlighting combination potential for ZW191
- New ADC candidates, including ZW427 and ZW418, demonstrating strong activity across RAS-mutated cancers using our novel pan-RAS inhibitor ADC platform
Read more here: ir.zymeworks.com/news-releases/news-release-details/zymew…
#antibodydrugconjugates -
Zymeworks Inc.
@ZymeworksInc
Zymeworks’ Nina E. Weisser on targeted therapies in the @myESMO Daily Reporter: “From bispecific to multispecific antibodies: a highly promising field”
www.esmo.org/insights-by-esmo/all-news/from-bispecific-to… -
Zymeworks Inc.
@ZymeworksInc
In case you missed it, here is Zymeworks Senior Director for Multispecific Antibody Therapeutics Nina Weisser's #esmotat talk, Engineering trispecific and multivalent molecules: Design for selectivity and potency www.zymeworks.com/wp-content/uploads/2026/03/ESMO-TAT-202…
#anticancer #antibodies #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
We're excited to share that our partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating our HER2-targeted therapy at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA.
Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
#aacr26 -
Zymeworks Inc.
@ZymeworksInc
#aacr26 is an incredible opportunity to connect with the life sciences community, exchange insights, and help drive cancer research forward. We’re excited to present clinical and preclinical data from our #adc programs at at this year’s AACR Annual Meeting, including:
- New clinical data from our Phase 1 trial of ZW191 in an oral presentation on April 21
- Preclinical data highlighting combination potential for ZW191
- New ADC candidates, including ZW437 and ZW418, demonstrating strong activity across RAS-mutated cancers using our novel pan-RAS inhibitor ADC platform
Read the full announcement here: ir.zymeworks.com/news-releases/news-release-details/zymew…
#antibodydrugconjugates -
Zymeworks Inc.
@ZymeworksInc
Efficient assembly of unique antibody geometries is a key advantage of our Azymetric platform.
Engineering optimal antibody geometries allows interrogation of unique antibody formats that can unlock novel biologies. This requires proprietary amino acid modifications in the heavy and light chains of an IgG-like antibody that enable the transformation of monospecific (single target) antibodies into multispecific antibodies that have alternative target binding formats (e.g. Fabs, scFvs, and VHHs). Learn more about our Azymetric platform: www.zymeworks.com/antibody-science/ -
Zymeworks Inc.
@ZymeworksInc
In case you missed it! Our Festival of Biologics presentations are now live:
Senior Scientist and Group Lead for Multispecific Antibody Therapeutics Anna von Rossum's "Engineering Multispecific Antibodies With Optimal Activity For Oncology and Autoimmune Diseases" is available here: www.zymeworks.com/wp-content/uploads/2026/03/2026-Festiva…
Senior Scientist Robert Nechanitzky's "ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways" is available here: www.zymeworks.com/wp-content/uploads/2026/03/ZW1528-Festi… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks Senior Director, Multispecific Antibody Therapeutics Nina E. Weisser and Director, Medicinal Chemistry Raffaele Colombo will be presenting at ESMO Targeted Anticancer Therapies Congress: March 16-19 (Paris)
Raffaele will present on The Path to ADC Discovery on 3/17 at 3:30 PM CET
Nina will present on Engineering Trispecific and Multivalent Molecules: Design for Selectivity and Potency on 3/18 at 11:00 AM CET
Learn more: www.esmo.org/meeting-calendar/esmo-targeted-anticancer-th… -
Zymeworks Inc.
@ZymeworksInc
This #internationalwomensday, we’re celebrating the power of shared knowledge. Inspired by this year’s theme “Give to Gain,” women across our company shared advice and lessons that helped shape their careers—and that they now pass on to others. Proud to feature insights from 10 incredible women in our organization. When knowledge is shared, everyone gains.
-
Zymeworks Inc.
@ZymeworksInc
Today on Employee Appreciation Day, we want to say thank you to everyone at Zymeworks. Every day, our teams bring passion and commitment to advancing our work on behalf of patients around the world. We’re grateful for the people across our company who make this mission possible.
-
Zymeworks Inc.
@ZymeworksInc
It's a busy conference week in Miami! We hope to see you at Leerink or Citizens - details below.
Leerink Annual Global Healthcare Conference: Management will participate in one- on-one meetings and a fireside chat on March 9, 2026 at 15:00 ET in Miami FL. ir.zymeworks.com/events/event-details/leerink-annual-glob…
Citizens Life Science Conference: Management will participate in one-on-one meetings and a fireside chat on March 11, 2026, at 10:10 ET in Miami, FL. ir.zymeworks.com/events/event-details/citizens-life-scien… -
Zymeworks Inc.
@ZymeworksInc
In case you missed it, check out Stuart Barnscher 's presentation at World ADC London. ZW191: Preclinical Performance Insights to Clinical Potential: www.zymeworks.com/wp-content/uploads/2026/03/2026-02-25_Z…
#antibodydrugconjugates #drugdevelopment #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Chief Scientific Officer Paul Moore, PhD will be presenting at The ADC Asia Congress 2026 in Singapore March 11-12. This key congress brings together leaders from Singapore, China, Japan, South Korea, Australia, and the broader Asia-Pacific region. We hope to see you there!
#antibodydrugconjugates #cancerresearch #drugdevelopment -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to announce a $250 million royalty-backed note financing with Royalty Pharma . Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to announce our Q4 Fourth Quarter and Full Year 2025 Financial Results. To learn more, please see our press release ir.zymeworks.com/news-releases/news-release-details/zymew… or join the webcast with management today at 8:30 am ET ir.zymeworks.com/events/event-details/zymeworks-fourth-qu….
-
Zymeworks Inc.
@ZymeworksInc
March is Autoimmune Awareness Month. It is a time to recognize the 50 million people in the US—and many more globally—impacted by autoimmune diseases. Together we can help their voices be heard, and to advocate for enhanced understanding, support, and research.
To learn more about the more than 100 identified autoimmune diseases and their impact, please visit the Autoimmune Association: autoimmune.org -
Zymeworks Inc.
@ZymeworksInc
As we wrap up our 2026 series on Black History Month and turning scientific innovation into meaningful impact, we highlight Dr. Percy Lavon Julian (1899-1975) and innovation in inflammation. Dr. Julian was a US research chemist, entrepreneur, and early trailblazer in the chemical synthesis of medicinal drugs from plants.
Julian's pioneering research helped make cortisone, a crucial anti-inflammatory, affordable and widely available. Julian started his own company to synthesize steroid intermediates from yams. This sharply reduced production costs and significantly expanded the use of not only synthetic cortisone—but other key drugs as well.
Throughout his career, Julian was granted more than 130 patents.
#blackhistorymonth #inflammation #research #drugdevelopment -
Zymeworks Inc.
@ZymeworksInc
Zymeworks’ management is looking forward to the TD Cowen 46th Annual Health Care Conference in Boston. The team will join a fireside chat on March 2, 2026 at 2:30 pm ET and participate in one-on-one meetings throughout.
Listen to the webcast: ir.zymeworks.com/events/event-details/td-cowen-46th-annua… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks Senior Scientist and Group Lead for Multispecific Antibody Therapeutics Anna von Rossum and Senior Scientist Robert Nechanitzky will be presenting at @festofbiologics USA March 4-5 in San Diego.
Anna's presentation: Engineering Multispecific Antibodies With Optimal Activity For Oncology and Autoimmune Diseases.
Robert's presentation: ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways.
See you in San Diego! -
Zymeworks Inc.
@ZymeworksInc
As our Black History Month series continues, we’re honoring Dr. LaSalle D. Leffall Jr. (1930-2019) — a surgical oncologist, educator, and national leader who advanced equity in #cancer care.
In 1978, he became the first Black president of @AmericanCancer , launching its first national cancer disparities initiative to address the rising burden of cancer in Black communities — a program that became a model for equitable care. He later served as the first Black president of @AmCollSurgeons , led @SocSurgOnc, and chaired the @SusanGKomen Breast Cancer Foundation, championing minority outreach, screening, and access to treatment.
Appointed by both George W. Bush and @BarackObama to lead the President’s Cancer Panel, Dr. Leffall advised the White House on cancer policy, disparities, and national prevention strategies — leaving a lasting impact on cancer care in the United States.
#blackhistorymonth #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Our series on Black History Month and turning scientific innovation into meaningful impact continues. Today we are highlighting the "Mother of Chemotherapy" and @ASCO co-founder Dr. Jane Cooke Wright (1919-2013).
Dr. Cooke- Wright's career was filled with incredible achievements that pushed #cancer research and care forward, some of which include:
-Developed the technique of using human tissue culture to test the effects of potential drugs on cancer cells
-Pioneered the use of methotrexate to treat breast cancer and skin cancer
-Was appointed by President Lyndon B. Johnson, Wright served on the National Cancer Advisory Board
-Helmed the Chemotherapy Department, New York Medical College
-Elected first female president of the New York Cancer Society
#blackhistorymonth #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to attending and presenting at @World_ADC in London next week! Senior Director, Preclinical Programs, ADC Therapeutic Development Stuart Barnscher will present "ZW191: Connecting ADC Preclinical Performance Insights to Clinical Potential" on Wednesday, February 25 at 2:00 PM GMT.
Learn more: worldadc-europe.com/full-event-guide/ -
Zymeworks Inc.
@ZymeworksInc
Lunar New Year marks the Year of the Fire Horse, a symbol of energy, momentum, and transformative change—themes that strongly resonate with the work we do every day.
We wish all our colleagues and communities who celebrate a joyful and meaningful holiday! -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to Citi’s Virtual Oncology Leadership Summit on Feb 18-19! Management will participate in one-on-one meetings virtually.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks US offices are closed in honor of Presidents' Day today. We wish everybody a well-deserved break.
-
Zymeworks Inc.
@ZymeworksInc
Azymetric™ is the foundation to how Zymeworks designs and builds unique multispecific and multifunctional antibodies: www.zymeworks.com/antibody-science/
Azymetric is an antibody platform technology with highly efficient antibody assembly properties. This enables us to perform multi-parameter engineering and screening to effectively choose optimally multi-functional therapeutics.
These customized therapeutic antibodies are engineered to simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies.
Learn more about Azymetric: www.zymeworks.com/antibody-science/
#drugdevelopment #multispecificantibodies -
Zymeworks Inc.
@ZymeworksInc
Management will report fourth quarter and full year 2025 financial results on March 2, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and provide a corporate update.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Science moves forward because of the people behind it. On International Day of Women and Girls in Science, we celebrate the women in our labs who are advancing drug discovery in oncology and autoimmune inflammatory disease.
To the next generation of women and girls in STEM: your ideas, your questions, and your ambition have the power to shape what’s next. The next breakthrough could start with you.
Learn more about International Day for Women and Girls in Science here: www.womeninscienceday.org/index.html
#womeninscience #womeninstem #girlsinstem #stemcareers #futurescientists -
Zymeworks Inc.
@ZymeworksInc
As part of our series on Black History Month and turning scientific innovation into meaningful impact, we are highlighting Dr. May Edward Chinn (1896-1980).
Early #cancer detection is one of the most important methods for improving outcomes for patients and Dr. Chinn played a crucial role in advocating for and popularizing early detection.
In the 1930s, Dr. Chinn studied cytological methods for cancer detection with Pap smear inventor, George Papanicolaou. Throughout her career as an internist in Harlem, Chinn promoted cancer screening for asymptomatic patients, routine Pap smears, as well as taking family medical histories to predict cancer risk. Her work earned her a citation from the New York City Cancer Committee of the @AmericanCancer Society as well as an honorary doctorate of science from @Columbia University. She was the first Black woman graduate of Bellevue Hospital Medical College and the first Black woman to serve as an intern at Harlem Hospital. -
Zymeworks Inc.
@ZymeworksInc
On #worldcancerday, we pause to recognize the profound ways cancer touches lives across the globe - affecting patients and the families who stand with them. This day reminds us why our work at Zymeworks matters: to advance novel therapeutic approaches that can make a meaningful difference for patients. Today, we stand in solidarity with researchers, clinicians, patients, and caregivers worldwide who are united in the fight against this disease.
-
Zymeworks Inc.
@ZymeworksInc
As we recognize Black History Month this February, we’re honoring the profound impact Black pioneers have made in #cancer and #autoimmune and #inflammatory disease research and care. Throughout the month, we’ll spotlight individuals whose groundbreaking work has helped shape modern hashtag#oncology and hashtag#autoimmune and hashtag#inflammatory treatments and continues to influence patient outcomes today.
Follow along each week as we take a deeper look at their lasting legacies and contributions to science and medicine.
#blackhistorymonth #cancerresearch #autoimmuneresearch #inflammationresearch -
Zymeworks Inc.
@ZymeworksInc
We’re pleased @GovCanHealth has approved our HER2-targeted therapy for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This milestone reflects years of dedication from our teams and partners—and reinforces our commitment to developing therapies for patients with high unmet medical need.
We’re grateful to the patients, investigators, and teams who made this possible and remain focused on delivering meaningful impact where it’s needed most. -
Zymeworks Inc.
@ZymeworksInc
This week at the Tumor Models Summit in San Francisco Diana Canals, PhD and Andrew Sharon presented on our novel multispecifc antibody programs.
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity - view here: www.zymeworks.com/wp-content/uploads/2026/01/TMSF_2026_IL…
Advancing ZW209 Trispecific Design with In Vitro & In Vivo Models to Improve DLL3-Directed Responses - view here: www.zymeworks.com/wp-content/uploads/2026/01/ZW209-10th-T…
#trispecifics #drugdevelopment -
Zymeworks Inc.
@ZymeworksInc
Here is a great watch/listen in case you missed it! "A Royalty Model For Value Creation" with Zymeworks Chair and CEO Kenneth Galbraith. Ken joins host @BenMComer on @BioProcessOL's Business of Biotech podcast. www.bioprocessonline.com/doc/a-royalty-model-for-value-cr… (free registration required).
The two discuss how Zymeworks is developing multispecific therapies internally and through partnerships with companies including @JazzPharma, @BeOneMedicines, @JNJNews, @Merck , @DaiichiSankyoUS, and @GSK.
www.bioprocessonline.com/doc/a-royalty-model-for-value-cr… -
Zymeworks Inc.
@ZymeworksInc
February and March are busy months for investor conferences! We hope to see you in person or virtually. Details can be found here: ir.zymeworks.com/news-releases/news-release-details/zymew…
Citi’s 2026 Virtual Oncology Leadership Summit: Zymeworks’ management will participate in one-on-one meetings February 18-19, 2026 virtually.
TD Cowen's 46th Annual Health Care Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on March 2, 2026 at 14:30 – 15:00 ET in Boston, MA.
Leerink Annual Global Healthcare Conference: Zymeworks’ management will participate in one- on-one meetings and a fireside chat on March 9, 2026 at 15:00 ET in Miami FL.
Citizens Life Science Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on March 11, 2026, at 10:10 ET in Miami, FL. -
Zymeworks Inc.
@ZymeworksInc
Congratulations to six amazing Zymeworks stars – winners of the @UBC Co-op Employer Recognition Award!
The #ubc award celebrates exceptional employers who have supported the Science Co-op Program and its students through work-integrated learning opportunities. This year, we’re honored to share that six of our team members have been recognized.
A big congratulations goes out to Rehan Higgins, Catherine Wu, Diego Perez, Adele Chan, Manuel Lasalle, and Scott Lien!
#leadership #teamwork #coop #recognition -
Zymeworks Inc.
@ZymeworksInc
In case you missed it! Zymeworks Inc. Senior Scientist, Protein Engineering, Desmond Lau presented on "Engineering Next-Generation T Cell Engagers: A Trispecific Platform for Cancer Immunotherapy" at @chi_peptalk this week - check out Desmond's presentation here: www.zymeworks.com/wp-content/uploads/2026/01/Peptalk-2026…
#chipeptalk #immunotherapy #oncology #proteins -
Zymeworks Inc.
@ZymeworksInc
Looking back on a great #jpm2026 and #gi26! ASCO GI showcased meaningful clinical progress with our partners Jazz Pharmaceuticals and BeOne Medicines, followed by a productive JPM spent engaging with investors and the BD community. In cased you missed Chair & CEO Kenneth Galbraith's presentation at JPM you can listen to the replay here: ir.zymeworks.com/events/event-details/44th-annual-jp-morg…
-
Zymeworks Inc.
@ZymeworksInc
On MLK day 2026 we wish our US colleagues – and people all around the world – a day of reflection and hope.
-
Zymeworks Inc.
@ZymeworksInc
Today at the Biotech Showcase, our Acting Chief Development Officer Adam Schayowitz joined “Oncology’s Next Act: Forging the Future with Combination Therapies” panel.
“The key word is innovator. You have to be different. At Zymeworks, we are some of the world experts in protein engineering. We understand protein scaffolding, and we understand aspects of T cell engagers that we believe are special and differentiated from everybody else.”
Missed the session? Listen to the replay: informaconnect.com/biotech-showcase/agenda/2/
Learn more about how our protein engineering capabilities drive innovation across modalities: www.zymeworks.com/innovation/
#biotechshowcase #oncology #proteinengineering #combinationtherapies #jpm2026 #jpmweek26 -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is excited to announce key leadership appointments and transitions aligned with our strategic evolution.
Brian Cherry has been appointed to the Zymeworks Board of Directors. He has led buyout and growth equity investments in companies totaling over $25 billion in enterprise value. Previously, Mr. Cherry was a Managing Partner at Oak Hill Capital. His board experience includes over a dozen private and public companies, the U.S. Air Force Academy Foundation, and the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania.
Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer. Dr. Sabeen Maken has been promoted to Senior Vice President and Chief Medical Officer. The following people have been promoted or appointed to the leadership team:
- Laura O’Connor, Senior Vice President and Chief Human Resources Officer
- Bijal Desai, Senior Vice President, Finance
- Dr. Lindsey Foulkes, Senior Vice President, Corporate Development and Strategy
- Dr. Charles Chen, Vice President, Translational Sciences
- Shrinal Inamdar, Vice President, Investor Relations
- Diana Papove, Vice President, Corporate Communications
- Victoria Spencer, Vice President, Treasury and Tax
- Dr. Lingxing Zheng, Vice President, Regulatory Affairs.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
As Zymeworks enters 2026 with a solid financial foundation, visibility of substantial future cashflows from partnered programs, and a clear strategy to compound long-term value, we are pleased to outline our strategic priorities and outlook for the year.
Learn more: -
Zymeworks Inc.
@ZymeworksInc
Zymeworks Chair & CEO Kenneth Galbraith on Bloomberg Intelligence (@BBGIntelligence) with @SamFazeli8 to talk about the company's new strategic initiatives. www.bloomberg.com/news/audio/2026-01-06/vanguards-of-heal…
Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances scientific innovation with capital discipline. The conversation covers Zymeworks' path to market, lessons from partnering with @JazzPharma and @BeOneMedicines, the value of Azymetric antibody design, and why retaining upside through milestones and royalties could reshape long-term value creation. -
Zymeworks Inc.
@ZymeworksInc
We look forward to seeing you during JPM Week in San Francisco!
Jan 13 @ 8:00 AM: Zymeworks Acting Chief Development Officer Adam Schayowitz will speak on Oncology's Next Act: Forging the Future with Combination Therapies & Early Detection at Biotech Showcase. Learn more: informaconnect.com/biotech-showcase/speakers/adam-schayow…
Jan 14 @ 3:00 PM PST: Zymeworks Chair & CEO Kenneth Galbraith will present at the JPM Healthcare Conference - listen to the webcast here: investor.agenusbio.com/events-and-presentations/ -
Zymeworks Inc.
@ZymeworksInc
Zymeworks and our partners @JazzPharma and @BeOneMedicines are presenting at ASCO-GI #gi26. For details please see ir.zymeworks.com/news-releases/news-release-details/zymew…
Zymeworks Presentation
Friday, Jan. 9, 11:30 am – 1:00 PM PT
ZW251 —A Phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
Partner Presentations
Friday, Jan. 9, 11:30 am – 1:00 pm PT
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): post hoc analysis of the HERIZON-BTC-01 trial
In case you missed it:
Thursday, Jan. 8
Zanidatamab (zani) + chemotherapy (chemo) ± tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): first results from the phase 3 HERIZON-GEA-01 study. View the presentation: www.zymeworks.com/wp-content/uploads/2026/01/ASCO-GI-2026… -
Zymeworks Inc.
@ZymeworksInc
We are excited to share positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 clinical trial. The data is being presented by our partners, @JazzPharma and @BeOneMedicines at the ASCO Gastrointestinal Cancers Symposium on January 8 in San Francisco.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/ziihe…
#gi26 -
Zymeworks Inc.
@ZymeworksInc
Wishing everyone a wonderful new year!
-
Zymeworks Inc.
@ZymeworksInc
2025 was an incredible year for Zymeworks and we could not be be prouder. We: - Announced positive topline results from the Phase 3 HERIZON-GEA-01 trial along with partners @JazzPharma and @BeOneMedicines
- Presented preliminary Phase 1 results for ZW191 at the AACR-NCI-EORTC Conference - Initiated Phase 1 global studies for ZW251, a novel glypican-3-targeted antibody-drug conjugate (ADC) for the treatment of hepatocellular carcinoma - Presented preclinical data for ZW1528, a novel IL-4Rα x IL-33 bispecific molecule designed to address respiratory inflammation, and the first program from our ADVANCE research strategy - Strengthened our leadership team through the addition of Dr. Sabeen Mekan as Senior Vice President, Clinical Development, Dr. Adam Schayowitz as Acting Chief Development Officer and Mr. Scott Platshon as Acting Chief Investment Officer - Strengthened our board of directors through the addition of three new members: Oleg Nodelman, Robert Landry, and Greg Ciongoli We look forward to sharing details at the upcoming J.P. Morgan Annual Healthcare Conference on Wednesday, January 14, 2026 at 3:00 pm PT
Zymeworks Inc.
@ZymeworksInc
Zymeworks Inc.
@ZymeworksInc
-
Zymeworks Inc.
@ZymeworksInc
Season’s greetings! ✨
From all of us at Zymeworks, we wish you a safe and happy holiday season filled with peace and celebration. As we take this time to rest and recharge, please note that all Zymeworks offices will be closed from December 22 to January 2.
To all our Zymeworks teams, partners, and advocates in patient communities: we’re grateful for your ongoing commitment and support as we work towards making a meaningful difference for patients impacted by challenging diseases.
Happy Holidays! -
Zymeworks Inc.
@ZymeworksInc
Zymeworks CEO Kenneth Galbraith joined the host of the BioSpace Denatured podcast Jennifer Smith-Parker and Josh Smiley, CEO of Zai Lab. The three discussed key themes leading up to #jpm2026. Tune in here: www.biospace.com/deals/inside-the-2026-biotech-landscape-…
-
Zymeworks Inc.
@ZymeworksInc
For decades, the paradigm in healthcare was to find drugs that could treat a wide range of patients. But now, it’s becoming increasingly possible to tailor treatments with more precision in a way that’s tailored to a specific patient. Zymeworks Senior Vice President, Clinical Development Sabeen Mekan, MD joined a @Forbes panel to explore the possibilities of this new era in medicine along with Forbes Senior Editor for Science & Health Alex Knapp, Shalabh Gupta, M.D., Founder, Chairman & CEO, @unicycive , and Serge Saxonov, Cofounder & CEO, @10xGenomics.
Watch the discussion: www.forbes.com/video/99a25e89-fd98-4172-9e08-9b411d7201c7… -
Zymeworks Inc.
@ZymeworksInc
Tomorrow, Dr. Nina E. Weisser, Senior Director of our Multispecific Antibody Therapeutics group, will present at the T-Cell Engager Therapeutics Summit Europe. She’ll be joined by Kara Olson from Regeneron as they share perspectives on advancing next-generation multispecific antibody therapeutics. Learn more about the event: t-cell-engager-autoimmune-disease.com
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is proud to be @JazzPharma's partner on these innovative treatment options for patients. See you at ASCO #gi26
Jazz Pharmaceuticals
@JazzPharma
#news for U.S. media and investors: At the ASCO #gi26 Symposium, we'll be presenting Phase 3 data in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more here: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is proud to be a committed and active partner in Singapore’s vibrant biotechnology and pharmaceutical ecosystem. We are fortunate to collaborate with key groups like the Biomedical Sciences Industry Partnership Office (BMSIPO). Please join us in extending congratulations to BMSIPO on their 15th anniversary! Learn about BMSIPO's 15 Years of Biomedical Innovation here: www.youtube.com/watch?v=gVBmMGW9PcI
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is thrilled to share our continued progress at upcoming conferences in January.
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
As Gastric Cancer Awareness Month comes to a close, Zymeworks teams across the globe are wearing periwinkle to honor patients, their loved ones, researchers, and all healthcare professionals advancing care and hope every day. Stomach cancer is the third leading cause of cancer death worldwide - learn about common signs and symptoms here: nostomachforcancer.org/about-stomach-cancer/signs-symptom…
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks wishes everyone who celebrates a very happy Thanksgiving. We give thanks to our teams, our partners and everybody working to improve the health and wellbeing of patients around the world.
-
Zymeworks Inc.
@ZymeworksInc
We’re proud to celebrate Dr. Raffaele Colombo, recipient of the 2024 George R. Pettit Individual Input to the Field Award at this year’s @World_ADC Conference in San Diego.
This award recognizes the individual who made the most significant contribution to the #adc field over the past year — and we’re thrilled to see Raffaele’s leadership, innovation, and dedication to advancing ADC science recognized at this level.
Congratulations, Raffaele, and thank you for your impact on the field and on our team!
@raffcolo -
Zymeworks Inc.
@ZymeworksInc
Looking back on our time at #sitc2025, as the society celebrated 40 years of advancing immunotherapeutic innovation in cancer research!
This year, we were proud to present three posters highlighting preclinical progress in #tcellengagers and #antibodydrugconjugates - learn more about the data presented: www.zymeworks.com/zymeworks-presents-new-preclinical-data…
#immunotherapy #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is thrilled to meet investors one-on-one and share our continued progress at upcoming investor conferences in December.
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
This week marked an exciting new chapter for Zymeworks Inc. as we announced our transition into a new era for the company, following the positive Phase 3 results for zanidatamab in HER2-positive gastric and gastroesophageal cancer and our strategic shift toward a royalty-pharma–focused business model.
A special thank you to Nasdaq for celebrating this milestone with us, and to our employees, partners, and supporters who helped make this moment possible.
We’re also pleased to share some of our media coverage:
• Fierce Biotech: www.fiercepharma.com/pharma/ziihera-wins-rolling-zymework…
• BioPharma Dive: www.biopharmadive.com/news/zymeworks-data-royalty-restruc…
• Endpoints News: endpoints.news/zymeworks-and-jazz-tout-her2-bispecific-su…
• The Globe and Mail: www.theglobeandmail.com/business/article-zymeworks-stock-…
• BioSpace: www.biospace.com/drug-development/jazz-zymeworks-bispecif…
Sharing the press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
More to come as we continue building momentum in this next phase of Zymeworks’ growth. -
Zymeworks Inc. reposted
BiotechTV
@BiotechTV
𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧: @ZymeworksInc had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model. $ZYME
Full video: www.biotechtv.com/post/zymeworks-jefferies-london-novembe…This media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is thrilled to announced that Scott Platshon will be joining the company as Acting Chief Investment Officer.
"Following the positive topline data from the Phase 3 HERIZON-GEA-01 trial, we are strategically positioned to drive long-term returns by building a diversified portfolio of revenue-generating assets," said Kenneth Galbraith, Chair and Chief Executive Officer at Zymeworks. "Scott’s deep investment expertise, in-depth knowledge of the Company and our strategic objectives, and global network make him uniquely suited to help accelerate these efforts and protect and manage value arising from our royalty portfolio."
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Today we're excited to announce a significant evolution in our long-term strategy, one that positions Zymeworks for a more durable, predictable, and value-generating future. Building on the positive Phase 3 data for Ziihera® and the continued advancement of pasritamig, we are transitioning from a biotech model to a royalty-driven organization supported by a productive internal R&D engine.
This approach allows us to optimize the value of our licensed products, expand a diversified portfolio of revenue-generating healthcare assets, and reinvest in differentiated innovation where we can make the greatest impact for patients.
This is an important moment for Zymeworks as we align our business to pursue sustainable growth, capital efficiency, and long-term shareholder value while delivering meaningful advances through our scientific platforms.
Read the full announcement here ir.zymeworks.com/news-releases/news-release-details/zymew… and join our conference call today at 8:30 am ET to learn more ir.zymeworks.com/events/event-details/zymeworks-business-… -
Zymeworks Inc.
@ZymeworksInc
We're excited to announce positive results from the HERIZON-GEA-01 Phase 3 trial, in collaboration with @JazzPharma and @BeOneMedicines. This pivotal study investigated our HER2-targeted bispecific antibody in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks will be attending the Jefferies Global Healthcare Conference in London from November 17–19 for one-on-one meetings. If you’ll be there, we’d love to connect — please reach out to schedule a meeting.
-
Zymeworks Inc.
@ZymeworksInc
November is Gastric Cancer Awareness Month. Today, we’re taking a closer look at what gastric (stomach) cancer is. According to the AACR, the stomach wall has five layers of tissue: the mucosa, submucosa, muscle layer, subserosa, and serosa. Gastric cancer typically begins in the cells lining the mucosa before spreading outward.
Join us in raising awareness and supporting those affected by this disease. -
Zymeworks Inc.
@ZymeworksInc
Today, we honor and remember those who have served on Remembrance Day in Canada and Veterans Day in the U.S. Thank you to all veterans and active service members for your dedication and sacrifice.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is looking forward to meeting investors one-on-one and sharing our continued progress at the Stifel Healthcare Conference on November 11 in New York.
#biotech #conferences -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to provide our corporate update and report third quarter 2025 financial results. To learn more, please see our press release ir.zymeworks.com/news-releases/news-release-details/zymew….
-
Zymeworks Inc.
@ZymeworksInc
November is Gastric Cancer Awareness month, a time to honor the patients, families, and caregivers whose lives are touched by this challenging disease.
The National Cancer Institute estimates that more than 25,000 people in the U.S. are diagnosed with gastric (stomach) cancer each year, and almost 11,000 lives are lost. These numbers remind us of the urgent need for earlier detection, new treatment options, and continued support for those living with and fighting gastric cancer.
#gastriccancer #stomachcancerawareness -
Zymeworks Inc.
@ZymeworksInc
We are excited to announce three poster presentations at the @sitcancer 40th Annual Meeting, taking place this week in National Harbor, MD.
Title: Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Abstract Number: 853
Title: TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies
Abstract Number: 1196
Title: High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Abstract Number: 57
Learn more: www.zymeworks.com/zymeworks-presents-new-preclinical-data…
#immunotherapy #immunooncology #cancer #sitc25 -
Zymeworks Inc.
@ZymeworksInc
We’re excited to be at World ADC San Diego this week, sharing our learnings and innovations in ADC development!
Tuesday, November 4 at 11:00 am
Geoff Winters, Director & Functional Lead, ADC Process Development presents "Lessons learned from discovery and CMC development"
Wednesday, November 5 at 3:00 pm
Stuart Barnscher, Senior Director, Preclinical Programs, ADC Therapeutic Development presents "Development and therapeutic potential of a novel Zymeworks Ly6E-targeting ADC against solid tumors"
If you’ll be at #worldadc, we’d love to connect! -
Zymeworks Inc.
@ZymeworksInc
As Liver Cancer Awareness Month comes to a close, our Zymeworks team proudly wore green to honor patients, their loved ones, researchers, and all healthcare professionals advancing care and hope every day.
Zymeworks Inc.
@ZymeworksInc
-
Zymeworks Inc.
@ZymeworksInc
Reflecting on the #targets25 (AACR-NCI-EORTC) Conference in Boston, where we presented initial Phase 1 data from our ADC targeting Folate Receptor-⍺ — a proud moment for our team.
Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is thrilled to meet investors one-on-one and share our continued progress at upcoming investors conferences in November.
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks presents preliminary Phase 1 clinical data for our antibody-drug conjugate (ADC) targeting folate receptor-⍺ at the AACR-NCI-EORTC International Conference today in Boston. The data provides insights into the potential of the ADC in patients with advanced solid tumors, including #ovariancancer, #endometrialcancer, and non-small cell lung cancer.
Join our Investor & Analyst webcast today at 3:30 pm ET with lead author Patricia LoRusso, DO, PhD (hc), FAACR and Zymeworks senior management to discuss the data presented - register here: ir.zymeworks.com/events/event-details/initial-results-pha…
Read key data highlights from the presentation here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
As Liver Cancer Awareness Month continues, we ask What Are Risk Factors for Developing HCC?
Certain pre-existing conditions or life-style choices can increase a patient’s chance of a hepatocellular carcinoma (HCC) diagnosis. Cirrhosis, or severe scarring of the liver that happens over many years, increases a patient’s risk. Cirrhosis can be caused by alcohol consumption as well as long-term undiagnosed or untreated hepatitis B or hepatitis C infections. Hepatitis B can also put a patient at risk for HCC even if they do not develop cirrhosis.
There are many other risk factors for developing HCC. To learn about these risks—and how to reduce the risk of developing HCC—please visit the website of @liverUSA liverfoundation.org/liver-diseases/cancer/hepatocellular-… -
Zymeworks Inc.
@ZymeworksInc
We're excited to be part of @lifesciences_bc's upcoming Invest in BC event taking place October 28-29 in Vancouver! Stuart Barnscher, Senior Director, ADC Therapeutic Development will present on behalf of Zymeworks and participate in a panel session. Learn more:
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks management team will report third quarter 2025 financial results on November 6. Following the announcement, the team will host a conference call at 4:30 pm ET to discuss financial results and provide a corporate update.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re excited to join the global oncology community at #esmo25 as it celebrates 50 years of innovation in cancer research. If you’re attending, we’d love to connect and discuss how together we can shape the future of oncology.
#cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Zymeworks will present preliminary Phase 1 clinical data for our antibody-drug conjugate (ADC) targeting folate receptor-⍺ at the AACR-NCI-EORTC International Conference on October 23. The data will provide insights into the potential of the ADC in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.
Title: Preliminary results from a phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α-targeting antibody-drug conjugate, in patients with advanced solid tumors
Date/Time: Thursday, October 23, 2025 at 12:30-4:00 pm Eastern Time (ET)
In addition, a live webcast will be held with lead author Patricia LoRusso, DO, PhD (hc), FAACR and Zymeworks senior management on October 23, 2025 at 3:30 pm ET to discuss the data presented.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
#antibodydrugconjugate #targets25 #ovariancancer #nsclc #endometrialcancer -
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we’re thankful for so much — our dedicated team and their families, our partners, and everybody on the front lines of cancer research and care. Wishing you all a happy and peaceful Thanksgiving.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is proud to announce the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. Dr. Schayowitz brings nearly 20 years of experience in oncology drug development to Zymeworks, having led dozens of global development programs from initiation through approval and commercialization.
“Adam joins Zymeworks at a pivotal moment, as we continue to advance a range of therapeutic candidates in areas of high unmet need, and prepare additional candidates for the clinic,” said Kenneth Galbraith. “With recent milestones including the investigational new drug clearance for ZW251 and expanded global approvals of zanidatamab, we are focused on execution across our development pipeline and expanding our strategic partnerships. Adam’s deep expertise in oncology, R&D, and strategic business development make him uniquely suited to help accelerate these efforts and unlock additional value from our R&D portfolio.”
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to presenting at SITC's 40th Anniversary Annual Meeting in November!
Presentations:
November 7: Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
November 8: TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies
Thank you @sitcancer for driving breakthroughs in cancer immunotherapy for four decades.
Learn more: www.zymeworks.com/zymeworks-announces-upcoming-scientific…
#immunotherapy #immunooncology #cancer #sitc -
Zymeworks Inc.
@ZymeworksInc
We are incredibly honored to receive the @lifesciences_bc Company of the Year Award! Last week we celebrated with colleagues, friends, and fellow winners at the LSBC Award Dinner. Thank you LSBC for a great event and all the work you do to support the life sciences community. And congratulations to all winners, including recipients of the Company & Organizational Awards:
Emerging Company of the Year – Biotech: Variational AI
Emerging Company of the Year – MedTech: Arbutus Medical
Strategic Partner of the Year: Providence Health Care Ventures
Deal of the Year: NanoVation Therapeutics -
Zymeworks Inc.
@ZymeworksInc
October is Liver Cancer Awareness Month. We will be sharing information about Hepatocellular carcinoma (HCC)—the most common type of liver cancer among adults in the USA. Most patients develop many nodules, or small clusters of cancer cells, in their liver. A smaller number of patients develop a single tumor in their liver that grows in time. Source: @liverusa liverfoundation.org/liver-diseases/cancer/hepatocellular-…
-
Zymeworks Inc.
@ZymeworksInc
Today, on Canada’s National Day for Truth and Reconciliation, we honor the children who never came home, Survivors, their families, and the ongoing impacts of residential and Indian Day schools. We also mark Orange Shirt Day: Every Child Matters.
We recognize that reconciliation is a long-term commitment to respectful relationships with Indigenous Peoples, grounded in truth, accountability, and action.
We encourage learning and reflection through resources from the National Centre for Truth and Reconciliation, today and every day. -
Zymeworks Inc.
@ZymeworksInc
At the @EuroRespSoc Congress starting this weekend, Blair Hardman will present "ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL-33 pathways." The poster presentation will be held on Sept. 30 from 8:00 - 9:30 AM CET in Room PS-11, Board 18.
Learn more: www.zymeworks.com/zymeworks-presents-preclinical-data-on-… -
Zymeworks Inc.
@ZymeworksInc
One Team. One Relay. To celebrate both World Cancer Research Day and 22 years of the Zymeworks team making a meaningful difference together, employees at each of our hubs sent a baton across our global offices. We started in Singapore and continued to our Dublin and UK teams, Redwood City, Bellevue, and finally Vancouver. It was an incredible 24 hours. Fun, energizing and meaningful. Here are some photos featuring the winning relay teams in each office — to give you a taste.
-
Zymeworks Inc.
@ZymeworksInc
As Gynecological and Ovarian Cancer Awareness Month comes to a close, we have been heartened to see so many people and organizations helping to raise awareness of these difficult conditions. For example, please see the incredible work of the Foundation for Women's Cancer who lit up Times Square with powerful and moving imagery: www.linkedin.com/posts/foundation-for-womens-cancer_askhe…. Awareness months are important to help us all focus. But we cannot stop during the rest of the year. As the foundation says:
Awareness begins with a question. Learn the signs. Start the conversation. Save a life. hashtag#AskHer
💬 Have you noticed unusual bleeding, bloating, pressure, or pain?
💬 When was your last pelvic exam?
💬 Have you talked to your doctor about your gynecologic cancer risk? -
Zymeworks Inc.
@ZymeworksInc
We're excited to be part of the HBM Biopharma Summit in Zurich. CEO Kenneth Galbraith will be participating in a panel presentation entitled Global Forces Reshaping Biopharma Strategy at noon on Sept. 23. In addition Lucas Donigian, Zymeworks Vice President and Head of Business Development and Commercial, will be presenting a corporate update at 4 PM CET on Sept. 22. The team will be available one-on-one investor meetings during the conference.
Event details can be found here: hbmbiopharmasummit2025.events.hbmpartners.com -
Zymeworks Inc.
@ZymeworksInc
Raffaele Colombo, PhD, (@raffcolo) Zymeworks Associate Director for Medicinal Chemistry—along with Matthew Vogel and Paolo Tarantino, MD, PhD (@PTarantinoMD) of the @DanaFarber Cancer Institute and @Harvard University—have published a paper called "Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates" in the @ASCO @JCO_ASCO. As ADCs experience tremendous expansion as cancer therapies, the paper dives into the latest evidence on their mechanism of action and rich complexity.
The full text can be found here: ascopubs.org/doi/10.1200/JCO-25-01235 -
Zymeworks Inc.
@ZymeworksInc
On Sunday, the Zymeworks team laced up for the Terry Fox Run in Vancouver! Employees, families, and friends came together to honor Terry’s legacy, show our support for cancer research, and celebrate the spirit of making a meaningful difference — both through advancing multifunctional therapeutics for difficult-to-treat cancers and through community initiatives like the #terryfoxrun. Way to go, team!
#teamupforterry -
Zymeworks Inc.
@ZymeworksInc
ICYMI: At the World Bispecific Summit in Boston this week, Alexey Berezhnoy, Director of Immunology, presented "ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways,” which discusses how bispecific therapeutics may benefit patients with #autoimmune and #inflammatorydisease.
Check out his presentation: www.zymeworks.com/wp-content/uploads/2025/09/20250910-Ber…
#worldbispecific #bispecifics -
Zymeworks Inc.
@ZymeworksInc
Zymeworks CEO Kenneth Galbraith will participate in one-on-one meetings during the @MorganStanley Annual Global Healthcare Conference—and a fireside chat on September 8 at 3:20 PM ET in New York, NY. We look forward to seeing you there. Learn more: ir.zymeworks.com/events/event-details/morgan-stanley-annu…
-
Zymeworks Inc.
@ZymeworksInc
Today is “Wear Teal Day” — an important part of Gynecological and Ovarian Cancer Awareness Month. Teal represents strength, hope, and unity for people living with ovarian cancer—and their family, friends and caregivers. The Zymeworks team is proud to join people across the world in showing support, raising awareness, and sparking conversation about ovarian cancer.
#raisingawareness #ovariancancer #strength #hope #weartealday -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is excited to meet investors one-on-one and share our continued progress during fireside chats at three investor conferences this week.
@Citi Biopharma Back to School Conference, Boston
Sabeen Mekan, Senior Vice President, Clinical Development, will participate in one- on-one meetings on September 3.
ir.zymeworks.com/events/event-details/citis-biopharma-bac…
@WellsFargo Healthcare Conference, Boston
Lucas Donigian, Vice President and Head of Business Development and Commercial, will participate in one-on-one meetings and a fireside chat on September 4 at 4:30 pm Eastern Time (ET).
ir.zymeworks.com/events/event-details/wells-fargo-healthc…
@Official_Cantor Global Healthcare Conference, New York
Sabeen Mekan, Senior Vice President, Clinical Development, will participate in one- on-one meetings and a fireside chat on September 5 at 8:35 am ET
ir.zymeworks.com/events/event-details/cantor-global-healt… -
Zymeworks Inc.
@ZymeworksInc
While many of us will be relaxing on Monday — Labour Day for our Canadian teams and Labor Day for our US teams — we also want to pause and reflect on the meaning of the holiday, and of work itself.
Developing medicines that have the potential to improve lives is, for many of us at Zymeworks, a true labor of love. But it is also hard work — work that demands commitment, skill, and perseverance across every role in our organization. We are deeply grateful for the dedication and contributions of each one of you. -
Zymeworks Inc.
@ZymeworksInc
We're looking forward to the European Respiratory Society Congress! This year’s theme is 'Respiratory health around the globe' and we are proud to present information on Zymeworks’ IL-4R⍺ x IL-33 bispecific molecule. Stay tuned for more information and we hope to see you there
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is thrilled to meet investors one-on-one and share our continued progress during fireside chats at the following upcoming investors conferences.
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
Highlights:
@Citibank Biopharma Back to School Conference: Zymeworks’ management will participate in one- on-one meetings on September 3 in Boston, MA.
@WellsFargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 4 at 4:30 pm Eastern Time (ET) in Boston, MA.
Cantor Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 5 at 8:35 am ET in New York, NY.
@MorganStanley Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on September 8 at 3:20 pm ET in New York, NY. -
Zymeworks Inc.
@ZymeworksInc
ICYMI: At Cambridge Healthtech Institute’s #immunooncologysummit, Genevieve Desjardins, Zymeworks Principal Scientist in Protein Engineering, presented “Engineering Trispecific T Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors,” which discusses our methods for engineering multispecific antibodies, specifically our lead TriTCE program designed to target DLL3-expressing solid tumors.
Check out her presentation: www.zymeworks.com/wp-content/uploads/2025/08/GDesjardins_… -
Zymeworks Inc.
@ZymeworksInc
Zymeworks EVP and Chief Business and Financial Officer Leone Patterson will join a fireside chat tomorrow (August 13) at 9:00 AM ET during the @Stifel #biotechsummersummit in Newport, RI. Zymeworks will also meet investors one-on-one throughout the summit.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to welcome Greg Ciongoli and Robert Landry to our Board of Directors. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
Zymeworks Chair and Chief Executive Officer Kenneth Galbraith says “With recent progress in regulatory approvals in key international markets, including the U.S., Europe, and China, a much-anticipated, upcoming topline data readout for HERIZON-GEA-01 in the fourth quarter of 2025, and continued progress across our novel, wholly-owned pipeline, we believe Zymeworks is entering a significant period of opportunity for value creation. We look forward to Greg and Bob’s contributions, as we focus on both enhancing value for our shareholders and bringing innovative therapies to more patients around the world.” -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to welcome Robert E. Landry and Greg Ciongoli to our Board of Directors. Learn more: .ir.zymeworks.com/news-releases/news-release-details/zymew…
Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continue to advance our development programs and execute our long-term growth strategy. -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to provide our corporate update and report second quarter 2025 financial results. To learn more, please see our press release ir.zymeworks.com/news-releases/news-release-details/zymew… or join our Q2 Earnings Call at PM ET ir.zymeworks.com/events/event-details/zymeworks-second-qu…
This media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Zymeworks feels incredibly at home in the dynamic, innovative, energetic San Francisco Bay Area—where you will find one of our global offices and quite a few of our team! And we’re proud to be a @biocom partner. Biocom recently released their 2025 Economic Impact Report www.biocom.org/news/eir/ and the Bay Area numbers, despite recent challenges, remain impressive:
- 3,809 life sciences organizations
- $123.6B total economic output
- 150,491 directly employed life science workers
- 254,365 total jobs generated by life sciences
- $43.2B total labor income generated by life sciences -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is proud to join the many voices honoring World Lung Cancer Day today, including the @lcrf_org, which is sharing stories of patients, survivors, family members, caregivers, and the fighters among us.
Meet Sydney, a lung cancer survivor who now champions for life-changing research: www.instagram.com/p/DMkqE4fu79y/
#worldlungcancerday #freetobreathewalk #lungcancerawareness -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is currently hiring for the following positions:
• Manager, Clinical Supply Chain (Bellevue)
• Manager, Program & Alliance Management (Bellevue)
• Director, IT Infrastructure & Security (Vancouver)
Apply now and learn more about our work: www.zymeworks.com/careers/
#hiring #biotech #careers #itjobs -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is pleased to share that the US Federal Drug Administration has granted Investigational New Drug Application clearance for our novel glypican 3-targeted antibody-drug conjugate (ADC) using our proprietary TOPO1i payload for the treatment of hepatocellular carcinoma (HCC).
Zymeworks expects to initiate a phase 1 clinical trial evaluating the ADC in HCC this year.
Learn more:ir.zymeworks.com/news-releases/news-release-details/zymew…
#livercancer #hepatocellularcarcinoma
#antibodydrugconjugate -
Zymeworks Inc.
@ZymeworksInc
Zymeworks Pride flags hang in our Vancouver HQ – not just during Pride, but all year long. They are a symbol of our ongoing commitment to creating a safe, inclusive, and affirming workplace for all.
During Pride season especially, we take time to reflect, celebrate, and stand in solidarity with the 2SLGBTQIA+ community, both within our labs, offices, ecosystem and beyond.
Zymeworks is proud to support Zyme & Proud, an internal employee group who organize and promote events that hope to create a nurturing environment where everyone is accepted for who they are and their diverse perspectives and experiences. -
Zymeworks Inc.
@ZymeworksInc
Are you passionate about turning data into insights that drive scientific progress? Interested in leading with impact in a company pushing the boundaries of biotech innovation?
Zymeworks is hiring a Director, Biostatistics & Programming—and we’re looking for a leader who thrives at the intersection of strategy, science, and statistics.
Apply now and learn more about our work: www.zymeworks.com/careers/
#nowhiring #biotechcareers #lifesciences -
Zymeworks Inc.
@ZymeworksInc
Join our management team on August 7, 2025 at 4:30 pm ET for a webcast as they share Q2 2025 financial results and provide corporate updates.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We are thrilled that @lifesciences_bc has once again named Zymeworks Company of the Year! It’s a great honour. It’s an even greater honour to be a part of British Columbia’s thriving life sciences community and to witness the passion with which so many people are working to change patients’ lives for the better. We cannot wait to see everyone and celebrate at the awards event on October 2nd.
Learn more: lifesciencesbc.ca/lsbc-news/life-sciences-bc-announces-20…
#lsbcawards -
Zymeworks Inc.
@ZymeworksInc
Wishing our U.S. colleagues, partners, and communities a happy and safe Independence Day! 🇺🇸
As we celebrate this holiday, we’re reminded of the shared values—collaboration, determination and compassion —that fuel both our work and the broader life sciences community.
Happy #independenceday! -
Zymeworks Inc.
@ZymeworksInc
We’re proud to share Jazz’s announcement that the European Commission has granted conditional approval of our treatment for adults with advanced HER2+ #biliarytractcancer— a significant milestone in our journey to bring innovative therapies to patients in need.
Jazz Pharmaceuticals
@JazzPharma
The European Commission has granted conditional approval of our treatment for adults with advanced HER2+ biliary tract cancer (BTC). Learn more: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
Today, we celebrate the spirit of innovation, diversity, and resilience that defines Canada—and inspires our work every day. As a proudly Canadian-founded company, we’re grateful to be part of a life sciences community that’s driving impact both locally and globally.
Wishing everyone a safe and joyful #canadaday! -
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, our team is at the heart of everything we do. United by a shared mission to make a meaningful difference for patients with difficult-to-treat diseases, we combine a collaborative environment with deep scientific expertise to advance antibody-based therapeutics. Our world-class R&D engine is designed to drive innovation with global impact.
We’re hiring for several key roles:
• Director, IT Infrastructure & Security – Vancouver
• Senior Manager, GMP Quality Assurance – Bellevue
• Associate Director, Clinical Pharmacology/Pharmacometrics – Vancouver, Bellevue, or Redwood City
Learn more and apply today: www.zymeworks.com/careers/
#biotechcareers #itjobs #pharmacology -
Zymeworks Inc.
@ZymeworksInc
Summer is officially here and our annual summer office closure will run from June 27 to July 4, giving our dedicated team time to rest, recharge, and reconnect.
We're grateful for the chance to pause before an exciting second half of the year—one that includes key milestones across our wholly-owned pipeline of ADCs and T-cell engagers, new opportunities to deepen partnerships, and continued engagement at leading industry conferences.
Thank you for your support and understanding as we take this moment to prioritize well-being.
We’ll be back soon—refreshed and ready for what’s ahead.
#summerbreak #rest -
Zymeworks Inc.
@ZymeworksInc
Today at the 7th Annual T-Cell Engager Therapeutics Summit, Dr. Nina Weisser will present on our 2026 IND candidate—a novel DLL3-targeted trispecific T-cell engager.
Attending the summit? Let us know in the comments and be sure to catch this insightful seminar at 3:15 pm ET.
The presentation will be available on our website at the close of the conference: www.zymeworks.com/publications/
#oncology #tcellengagers #biotech #innovation #boston -
Zymeworks Inc.
@ZymeworksInc
Hiring Alert: We’re seeking a passionate Medical Director (based in Redwood City, CA or Bellevue, WA) to bring scientific and clinical leadership to our Early-Stage Development team—working on cutting-edge MSAT and ADC therapies.
You'll collaborate cross-functionally, influence strategy, and contribute meaningfully to patient outcomes.
If you're ready for a career that challenges and rewards, join Zymeworks and help shape the future of cancer care: www.zymeworks.com/careers/
#biotech #lifesciences #hiring -
Zymeworks Inc.
@ZymeworksInc
Today is Juneteenth, the oldest African-American holiday and commemoration marking the ending of slavery in the United States and honoring the enduring fight for freedom, justice, and equity.
As a biotech company, we recognize that advancing health and medicine means addressing disparities in care and ensuring that innovation reaches everyone — regardless of background, race, or zip code.
In reflecting on this holiday, we hope to build a more inclusive future in science, medicine, and beyond.
Learn more about Juneteenth here: www.juneteenth.com
#juneteenth #healthequity #biotech -
Zymeworks Inc.
@ZymeworksInc
Meet us today at the Citi European Healthcare Conference today in London. Our leadership team will be there to share how our fully integrated R&D engine is advancing a wholly-owned pipeline of novel ADCs and T-cell engagers.
#adcs #tcells -
Zymeworks Inc.
@ZymeworksInc
We’re excited to participate in the biggest partnering event of the year, BIO’s International Convention!
Join us in Boston, MA as we meet with peers, industry groups and scientific leaders all looking to drive innovation forward. Plus, don’t miss our presentation featuring Emily Chen, Associate Director, Business Development, on June 18 at 11:15 AM in Room 153C. #bio2025 -
Zymeworks Inc. reposted
Biotechnology Innovation Organization
@IAmBiotech
In less than a week, #biotech innovators and community advocates from across the globe will descend on Boston for #bio2025 - to share ideas and stories, to forge partnerships, and to craft a blueprint that will drive innovation and inspire hope.
convention.bio.org/registrationThis media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Today, our management team will be participating in a fireside chat at the Goldman Sachs Global Healthcare Conference, starting at 2:00 pm ET.
Access the live webcast: ir.zymeworks.com/events-and-presentations
#biotech #conferences -
Zymeworks Inc.
@ZymeworksInc
#asco25 has come to a close — and it’s been an incredible showcase of collaboration, discovery, and momentum in oncology.
We’re grateful to all who joined us — from those who attended our presentations to those who shared in meaningful conversations with our team. We’re leaving inspired, and proud to be part of a community driving innovation in cancer care and improving the lives of patients everywhere.
#oncology #biotech #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Today, our management team will be participating in a fireside chat at Jefferies Global Healthcare Conference, starting at 2:35 p.m. EST.
Access the live webcast: ir.zymeworks.com/events-and-presentations
#biotech #conferences -
Zymeworks Inc.
@ZymeworksInc
Exciting News: We’re proud to share that our bispecific antibody has been approved in China for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) — a significant milestone for patients facing this difficult-to-treat disease.
This approval by the Center for Drug Evaluation of the NMPA marks the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in China.
Congratulations to all involved in bringing this important therapy to patients.
View the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
This Memorial Day, we pause to honor and remember the brave individuals who gave their lives in service to their country.
Their sacrifice is a powerful reminder of the freedoms we hold and the responsibility we share to uphold them. At Zymeworks, we are deeply grateful to those who served and to the families who carry their legacy forward.
Wishing everyone a meaningful Memorial Day.
#memorialday #gratitude #service -
Zymeworks Inc.
@ZymeworksInc
We’re thrilled to be presenting continued progress across our oncology portfolio at upcoming medical conferences.
Key highlights include:
• Partner-led presentations showcasing the strength and versatility of our Azymetric™ platform
• Phase 2 long-term outcomes and survival data for our bispecific antibody in patients with HER2-positive metastatic gastroesophageal adenocarcinoma
• Trials-in-Progress posters for our clinical programs
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Next month, our management team will be participating in meetings and presentations at the following investor conferences:
June 4: Jefferies Global Healthcare Conference
June 11: Goldman Sachs Global Healthcare Conference
June 17: Citi European Healthcare Conference
Learn more here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re excited to share new preclinical data at #ats2025 on our novel IL-4Rα x IL-33 bispecific antibody designed to address chronic obstructive pulmonary disease (COPD).
This work reflects our continued commitment to expanding therapeutic options for patients with difficult-to-treat respiratory disorders through the design of unique multispecific antibodies. We look forward to connecting with the scientific and clinical community in San Francisco!
Read the full PR: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
In a recent episode of Empowered Patient Podcast with Karen Jagoda, our Chief Scientific Officer Paul Moore shares how Zymeworks is pushing the boundaries of biotherapeutics with a clear focus: improving patient outcomes.
Listen to the full episode: empoweredpatientradio.com/multispecific-antibodies-and-an… -
Zymeworks Inc.
@ZymeworksInc
Two Zymeworks researchers, one mission: engineering therapies that make a meaningful impact for patients.
At #ats2025, Alexey Berezhnoy and Blair Hardman will present new preclinical data on our IL-4Rα x IL-33 bispecific to treat respiratory inflammation.
Learn more: ats2025.d365.events/directory/sessions/d6e0a78d-5625-4d06…
#immunology #biotech -
Zymeworks Inc.
@ZymeworksInc
Zymeworks announces its Q1 2025 financial results. Join our senior management team for a webcast today at 4:30 PM ET as they walk through the highlights and key updates.
Read the press release: ir.zymeworks.com/news-releases/news-release-details/zymew…This media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Applications are now open for our Fall 2025 co-op program! If you're a student passionate about science, technology, and making an impact in healthcare, this is your chance to gain hands-on experience for eight months with a team driving innovation in biotherapeutics.
📌 Available positions include:
• Co-op Student, Antibody Discovery and Engineering
• Co-op Student, In Vitro Biology
• Co-op Student, Analytics
… and more!
Explore opportunities and apply now: www.zymeworks.com/careers/
#coop #fall2025 #biotechcareers #studentjobs #hiring -
Zymeworks Inc.
@ZymeworksInc
We’re happy to announce that Zymeworks is headed to #ats2025! 🌟 Bringing together the #thoracic research and clinical care communities, the American Thoracic Society’s Annual Meeting offers an opportunity to engage and connect over exciting new research from our respiratory and immunology programs.
Stay tuned as we highlight our presenters and the innovative work we’ll be sharing leading up to the big event!
#immunology #biotech
Learn more: www.zymeworks.com/zymeworks-to-present-on-preclinical-dat… -
Zymeworks Inc.
@ZymeworksInc
Today, Paul Moore will be presenting and attending one-on-one meetings during the Bloom Burton & Co. Healthcare Investor Conference in Toronto. The annual convening brings together global investors who are interested in the latest developments in Canadian healthcare companies.
View the webcast: ir.zymeworks.com/events/event-details/bloom-burton-co-hea… -
Zymeworks Inc.
@ZymeworksInc
And that's a wrap for #aacr25! Last week, our team gathered in Chicago for an insightful and connection-building experience amongst hundreds of the best and brightest in cancer research. We are grateful for the opportunity to attend and present the latest advancements in our ADC and T cell engager programs with the global research community. Thank you to the American Association for Cancer Research organizers and community members for organizing a great event; we look forward to next year's programming!
A special thanks and congratulations to our amazing Zymeworks team members who presented throughout the week: Desmond Lau, Diana Canals, Peter Repenning, Meghan Hogan, Dunja Urosev, Nicole Afacan, Patricia Zwierzchowski, Vincent Fung, Lucas Donigian, Raffaele Colombo, and Kenneth Galbraith.
View all of our presentations from AACR 2025: www.zymeworks.com/publications/This media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we know that innovation thrives in a culture of collaboration, curiosity, and continuous growth. As we participate in conferences like #aacr25, we’re not only inspired by groundbreaking discussions in oncology research but also driven by connections with passionate professionals who are leading the future of biotech.
Whether you're an experienced scientist, a biotech innovator, or exploring new career opportunities, check out our current openings at Zymeworks: www.zymeworks.com/careers/ -
Zymeworks Inc.
@ZymeworksInc
In a recent issue of Drug Development & Delivery, Paul Moore, Raffaele Colombo, and Jamie Rich delve into the history of antibody-drug conjugate development and how recent advancements on novel camptothecin payloads can unlock new breakthroughs in biotherapeutics.
Read the full article: drug-dev.com/adc-payloads-progress-in-development-of-camp…
#adcs #biotherapeutics #biotech #lifesciences -
Zymeworks Inc.
@ZymeworksInc
It’s the final day of poster presentations at #aacr25 and we’re closing it out with a presentation showcasing new preclinical data on our novel trispecific T cell engager integrated with CD28 co-stimulation. Come by Section 40 and meet research leads Diana Canals, Desmond Lau, and Peter Repenning!
View "ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer": www.zymeworks.com/wp-content/uploads/2025/04/ZYME-AACR-20…
#cancerresearch #tcellengager #trispecific -
Zymeworks Inc.
@ZymeworksInc
Today at #aacr25, Raffaele Colombo presents our collaboration poster with Discovery Life Sciences, titled "In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload (submitted with Discovery Life Sciences)!
View the poster here: www.zymeworks.com/wp-content/uploads/2025/04/DLS-ZW-AACR2…
#cancerresearch #oncologyinnovation #adcs -
Zymeworks Inc.
@ZymeworksInc
Heading to the afternoon sessions at #aacr25? Don’t miss our poster presentations starting at 2 pm CT, featuring Dunja Urosev, Nicole Afacan, and Patricia Zwierzchowski, who will share new preclinical data on our antibody-drug conjugate and T cell engager programs. Stop by and say hello!
View "ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload": www.zymeworks.com/wp-content/uploads/2025/04/ZW327-AACR-P…
View "ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin expressing cancers": www.zymeworks.com/wp-content/uploads/2025/04/ZW171-a-diff…
#oncology #innovation #cancerresearch #aacr25 #tcellengagers #antibodydrugconjugates -
Zymeworks Inc.
@ZymeworksInc
Kick off your Monday morning at #aacr25 with Zymeworks!
Check out our poster presentations from Vincent Fung and Meghan Hogan, showcasing our latest advances in cancer therapeutic research. We’re excited to share our work and connect with the research community—see you there!
View “Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7”: www.zymeworks.com/wp-content/uploads/2025/04/PTK7-BiP-ADC…
View “High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection”: www.zymeworks.com/wp-content/uploads/2025/04/ADC-NeoG_ZW_…
#zymeworks #cancerresearch #oncology #aacr25 -
Zymeworks Inc.
@ZymeworksInc
#aacr25 starts today! We’re looking forward to presenting six posters that showcase new preclinical data from our wholly-owned programs.
“The breadth of data shared at AACR,” says Chief Scientific Officer Paul Moore, “highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each modality.”
Read our press release on this year’s AACR presentations: ir.zymeworks.com/news-releases/news-release-details/zymew…
See you in Chicago!
#aacr25 #oncologyThis media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
Today kicks off AACR’s Second Oncology Industry Partnering Event: From Cancer Discoveries to Patients, where members of our senior management team will deliver presentations. We're honored to participate in this important gathering of industry leaders and innovators, and we look forward to connecting with others who share our commitment to advancing cancer research and enhancing patient outcomes.
#aacr2025 #oncologypartnering #cancerresearch #biotech #lifesciences #innovation -
Zymeworks Inc.
@ZymeworksInc
Today, we celebrate Administrative Professionals Day and extend our heartfelt thanks to the incredible support team at Zymeworks.
Their dedication, attention to detail, and behind-the-scenes support are essential to our success—from keeping us organized and on track to enabling the science that drives our mission. While their work may not always be forward-facing, its impact is felt across every part of the organization—and ultimately, in the lives of patients we're working to help.
On behalf of the entire Zymeworks global team, thank you for all that you do.
#administrativeprofessionalsday #lifesciences -
Zymeworks Inc.
@ZymeworksInc
On April 23, Principal Scientist of Protein Engineering Chayne Piscitelli will be present at Festival of Biologics San Diego 2025, starting at 3 pm PST. The presentation will delve into how our trispecific T cell engagers (TriTCE) can tackle both primary and acquired resistance in cancer treatment.
Learn more here: www.terrapinn.com/conference/festival-of-biologics-usa/ag…
#tcellengagers #oncology -
Zymeworks Inc.
@ZymeworksInc
This Earth Day, we acknowledge our shared responsibility to protect our planet. At Zymeworks, we are actively working to integrate environmental, social, and governance (ESG) principles across our entire organization. Our goal is to ensure these values guide both our daily decisions and long-term strategy as we build a more sustainable, responsible tomorrow.
Read our latest ESG Report: ir.zymeworks.com/static-files/dce2ec53-0524-4341-89e7-633…
#earthday2025 -
Zymeworks Inc.
@ZymeworksInc
We are thrilled to announce Dr. Sabeen Mekan is joining Zymeworks as Senior Vice President, Clinical Development. Bringing a wealth of experience from pharmaceutical and oncology development, Dr. Mekan will have a key role in the clinical development strategy for Zymeworks’ clinical-stage oncology portfolio and in diversifying our R&D strategy into autoimmune and inflammatory diseases and hematological cancers.
Read more: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Our multidisciplinary R&D team, like Principal Scientist and Group Lead Dunja Urosev, is at the core of our ability to design innovative therapeutics and generate high-quality data that drives discovery forward. Joining our #aacr25 presenter lineup, Dunja will share insights on a novel antibody-drug conjugate that could target antigens primarily in lung, breast, and digestive cancerous tumors.
Learn more about our presentations at this year’s AACR Annual Meeting: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo… -
Zymeworks Inc.
@ZymeworksInc
Join our management team on May 8, 2025 at 4:30 pm ET for a webcast as they share Q1 2025 financial results and provide corporate updates.
Read the full press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re proud to highlight the work of three powerhouse researchers on our team who will bring their expertise and passion for making a meaningful difference in patients’ lives to #aacr25. Desmond Lau, Diana Canals, and Peter Repenning will present their team’s latest research on our novel trispecific T cell engager targeting DLL3-expressing tumor cells.
View our full lineup of presentations at AACR: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo… -
Zymeworks Inc.
@ZymeworksInc
Behind our novel research and transformative advancements in biotech are world-class scientists with specialized expertise in the field. Zymeworks is happy to witness Vincent Fung and other team members’ diligent work and passion at AACR 2025 this April.
Check out more about our presentations throughout the annual meeting: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo… -
Zymeworks Inc.
@ZymeworksInc
Meghan Hogan’s journey into the biotech field began through a personal connection after being diagnosed with juvenile diabetes as a child. Her exposure to life sciences sparked a lifelong curiosity about the biology behind disease, which has since evolved into a passion for exploring molecular markers to better diagnose and treat conditions like diabetes, Alzheimer’s, and cancer.
We’re thrilled to cheer on Meghan, who will present a collaborative project using expression panel data in preclinical models to identify differentially expressed genes—work that brings us one step closer to developing more precise, targeted therapies for patients.
Learn more: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo… -
Zymeworks Inc.
@ZymeworksInc
We’re excited to follow our Zymeworks researchers and scientists as they prepare to present at AACR 2025 in Chicago from April 25-30!
Read more about our scheduled presentations: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo…
#aacr25 #oncologyinnovation #biotech #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Our senior leadership team will be presenting at the AACR Oncology Industry Partnering Event this April in Chicago.
Learn more about our scheduled presentations here: www.zymeworks.com/zymeworks-to-present-at-the-aacr-oncolo…
#aacr2025 #biotech #businessdevelopment #cancerresearch -
Zymeworks Inc.
@ZymeworksInc
Today, our management team will be participating in one-on-one meetings during the Stifel 2025 Virtual Targeted Oncology Forum and will present a fireside chat at 12:30 pm ET.
Learn more: ir.zymeworks.com/events-and-presentations -
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and present during the Needham 24th Annual Virtual Healthcare Conference today starting at 9:30 am ET.
Access the webcast here: ir.zymeworks.com/events-and-presentations -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is at the forefront of developing next-generation therapeutics for complex diseases. Our expertise in protein engineering and multispecific therapeutics is driving new possibilities in drug development. Curious to learn more about our technologies, partnerships, and pipeline?
Visit our website to explore our work: www.zymeworks.com
#biotechinnovation #transformingtreatment #zymeworks -
Zymeworks Inc.
@ZymeworksInc
This May, Zymeworks will present preclinical data at the American Thoracic Society (ATS) Annual Meeting in San Francisco. Spotlighting a new approach to addressing respiratory inflammation, this presentation reinforces our commitment to developing novel therapies for diseases with limited treatment options.
We look forward to sharing our progress with the biotech community at #ats2025!
Read more: ir.zymeworks.com/press-releases
#biotechinnovation #immunology -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is excited to participate in upcoming investor conferences this April!
Our management team will be engaging in one-on-one meetings and presentations at:
🔹 Needham 24th Annual Virtual Healthcare Conference – April 8
🔹Stifel 2025 Virtual Targeted Oncology Forum – April 9 (including a fireside chat)
We look forward to connecting and sharing our progress in advancing novel biotherapeutics for difficult-to-treat diseases.
#biotech #investorconferences -
Zymeworks Inc.
@ZymeworksInc
We’re excited to announce six poster presentations at this year’s AACR Annual Meeting in Chicago taking place April 25-30!
#aacr25 is an incredible opportunity to connect with the life sciences community, exchange insights, and drive research forward. We’re thrilled to share our latest advancements in novel therapeutics designed to address difficult-to-treat cancers at this year’s meeting.
Stay tuned for more details on our presentations and the people behind them!
Read the full announcement here: ir.zymeworks.com/news-releases/news-release-details/zymew…
#biotech #oncologyresearch -
Zymeworks Inc.
@ZymeworksInc
Next week, our Chief Scientific Officer Paul Moore will participate in “Building the science that builds biotech companies in the Pacific Northwest” hosted by Seattle PBSS in partnership with @LifeScienceWA. This highly anticipated, fully booked event will bring together industry leaders to discuss how the region's #biotech ecosystem is growing.
A special thank you to the event planners for inviting Zymeworks to engage with Seattle’s biotech community and contribute to important discussions shaping the future of life sciences.
Join the waitlist here: www.pbss.org/eventDetails/958
#lifesciences #seattlepbss -
Zymeworks Inc.
@ZymeworksInc
Great discussions, novel science, and new connections—ADC Asia Congress was a fantastic experience! Our Chief Scientific Officer, Paul Moore, presented on our ADC programs and met with local industry leaders to explore Singapore’s thriving biotech and pharma ecosystem.
Thank you to everyone who made this conference a success! We’re excited to participate in the industry’s progress in this region.
#adcasia #biotechinnovation #singaporebiotech -
Zymeworks Inc.
@ZymeworksInc
Looking back at our time at #aacr2024, we drove thoughtful conversations, gained invaluable knowledge, and forged meaningful connections. As we prepare for #aacr25, we’re excited to carry that momentum forward—diving deeper into groundbreaking research and building new collaborations. Here’s to an even bigger and more memorable experience in Chicago!
Zymeworks Inc.
@ZymeworksInc
Join us at the @AACR Annual Meeting this week as we present 5 posters exploring our pipeline of novel multifunctional therapeutics. For additional details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… #aacr24
-
Zymeworks Inc.
@ZymeworksInc
Thank you to all who made World ADC London such an outstanding event. It was a valuable chance to engage with industry leaders and exchange insights on the advancements shaping ADC development. We look forward to continuing these important discussions at World ADC San Diego later this year. #worldadc #adcinnovation #biotechleadership
-
Zymeworks Inc.
@ZymeworksInc
We’re looking forward to attending this year’s American Association for Cancer Research Annual Meeting alongside thousands of the best and brightest in cancer medicine and research!
Stay tuned as we share more details on our presentations and work in #antibody-drug conjugates and T cell engagers leading up to the conference.
#aacr25 #biotech #innovation -
Zymeworks Inc.
@ZymeworksInc
We’ve got a busy week ahead in Miami, as we attend the following conferences:
• Today, March 10: Leerink Annual Global Healthcare Conference (including a presentation from our management team)
• Tomorrow, March 11: Barclays Annual Global Healthcare Conference
• Wednesday, March 12: Jefferies Biotech on the Beach Summit
Learn more: ir.zymeworks.com/events-and-presentations -
Zymeworks Inc.
@ZymeworksInc
Today, we honor women throughout the world who are pushing the limits across various industries, but particularly in the sciences. Because of their curiosity, expertise, and determination, we are able to discover what’s possible in cancer treatment. On behalf of the Zymeworks team, Happy International Women’s Day!
#internationalwomensday #womeninscience #drivingdiscovery -
Zymeworks Inc.
@ZymeworksInc
Behind the innovation and clinical progress at Zymeworks are the brilliant minds and passionate hearts of our global team. This Employee Appreciation Day, we celebrate their incredible dedication, collaborative spirit, and tireless commitment to advancing next generation treatments for serious diseases. From our five offices around the world, every team member plays a vital role in our mission. Thank you for working to make a meaningful difference in patients' lives every day!
#employeeappreciation #biotech #innovation -
Zymeworks Inc.
@ZymeworksInc
Check out the latest update from our Chair & CEO, Ken Galbraith, as we announce our fourth quarter and full year 2024 financial results. Last quarter, we advanced our wholly owned pipeline, expanded our R&D scope, and celebrated accelerated #fda approval for the treatment of HER2-positive biliary tract cancers with our HER2-targeted bispecific antibody.
Watch the full video to see how Zymeworks is shaping the future of next-generation therapeutics. -
Zymeworks Inc.
@ZymeworksInc
Today, members of our executive team are in Boston for the TD Cowen 45th Annual Health Care Conference. At 10:30 a.m. today, our Chief Scientific Officer Dr. Paul Moore will deliver a corporate presentation.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is excited to be attending and presenting at ADC Asia Congress 2025! As leaders in antibody-drug conjugate innovation, we look forward to sharing our latest advancements and engaging with experts driving the future of ADC therapeutics. See you soon in Singapore!
#adcasia2025 #biotech #oncologyresearch -
Zymeworks Inc.
@ZymeworksInc
March marks Autoimmune Awareness Month, highlighting the over 100 autoimmune diseases that impact an estimated 50 million Americans—nearly 1 in 5 people—with women making up 80% of those affected. These conditions are a leading cause of chronic illness, yet on average, it takes over four years and multiple doctors for a patient to receive a proper diagnosis.
At Zymeworks, we are committed to developing innovative therapeutics to address these high unmet needs. Through cutting-edge research and collaboration, we strive to bring better treatments and new hope to those living with autoimmune diseases.
#autoimmunedisease #research -
Zymeworks Inc.
@ZymeworksInc
With every advancement in ADC development comes broadened possibilities for improving the state of cancer care. This year’s World ADC London conference focuses on maximizing the therapeutic index and bringing these transformative therapies to wider patient populations.
Catch Jamie Rich, Senior Director, Technology, ADC Therapeutics Group on Tuesday, March 4 at 6 p.m. GMT for a presentation centered on the impact of antibody-drug conjugate design philosophy across topoisomerase ADCs.
Learn more: worldadc-europe.com #worldadc -
Zymeworks Inc.
@ZymeworksInc
ADCs have rapidly taken the center stage for dealmaking and oncology research and development partnerships. As more biopharma and biotech companies specializing in ADCs are formed, questions arise on how innovation, data, and risk-taking influence partnerships, licensing deals and investments across the industry.
Hear from Lucas Donigian, Vice President and Head of Business Development and Commercial, as he joins other esteemed panelists on Monday, March 3 at 3 p.m. GMT to discuss the risks, rewards, and realities behind recent deals in the ADC field.
Learn more: worldadc-europe.com #worldadc -
Zymeworks Inc.
@ZymeworksInc
Are you passionate about Clinical Quality Assurance and ready to take the next step in your career? We're looking for a Clinical Quality Assurance Manager to join our team and play a critical role in ensuring the highest standards in clinical research.
This role is available in Bellevue or Redwood City.
Learn more and view other current openings: www.zymeworks.com/careers/
#hiring #lifesciences #biotech #careers -
Zymeworks Inc.
@ZymeworksInc
Our management team will be attending and presenting at four investor conferences in March.
Presentations and webcasts will be available on our website at ir.zymeworks.com/events-and-presentations. -
Zymeworks Inc.
@ZymeworksInc
Behind the innovative progress we see happening in cancer medicine are collaboration and investments toward a better tomorrow. We’re happy to share that Lucas Donigian, Vice President of Business Development will participate in a panel session at B. Riley Securities Oncology & Radiopharma Conference this Friday
#oncology #researchanddevelopment -
Zymeworks Inc.
@ZymeworksInc
Our team is growing, and we’re looking for top talent to join us in shaping the future. If you're passionate about innovation and thrive in a collaborative environment, we’d love to hear from you!
We’re currently hiring for:
🔹 Senior Site Reliability Engineer (Vancouver)
🔹 Research Associate I, In Vitro Biology (Vancouver)
🔹 Senior Research Associate II, In Vitro Biology (Vancouver)
Learn more: www.zymeworks.com/careers/ -
Zymeworks Inc.
@ZymeworksInc
We’re excited to share that Leone Patterson and Dr. Nina Weisser will participate in a virtual fireside chat tomorrow, February 20 at 2:00 pm ET for Citi’s 2025 Virtual Oncology Leadership Summit.
Access the webcast: ir.zymeworks.com/events/event-details/citis-2025-virtual-… -
Zymeworks Inc.
@ZymeworksInc
We’re thrilled to attend and participate in the 15th World ADC London! This four-day event features thought-provoking seminars and workshops along with poster presentations, networking gatherings, and plenary sessions. Our very own Lucas Donigian and Dr. Jamie Rich will be featured speakers at this year’s event.
Learn more: worldadc-europe.com -
Zymeworks Inc.
@ZymeworksInc
The Zymework management team will report on fourth quarter and full year 2024 financial results during a conference call and webcast on March 5, 2025 at 4:30 pm ET. Executive leadership will also present corporate updates during the virtual event.
Learn more: -
Zymeworks Inc.
@ZymeworksInc
Today, on International Day of Women and Girls in Science, we are proud to stand alongside the incredible women driving breakthroughs in biotherapeutics, pioneering new treatments for difficult-to-treat cancers, and inspiring the next generation of scientists.
Join us as we continue to champion, empower, and elevate women in STEM! #idwgs -
Zymeworks Inc.
@ZymeworksInc
Our Chair and CEO Kenneth Galbraith will be speaking during a fireside chat today at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference.
View the webcast here: ir.zymeworks.com/events/event-details/oppenheimer-35th-an… -
Zymeworks Inc.
@ZymeworksInc
Earlier this month, Meghan Verstraete, Senior Scientist in the Protein Engineering group at Zymeworks, delivered an insightful presentation during CHI’s PepTalk conference in San Diego, CA!
A huge thank you to @chi_peptalk for fostering an inspiring environment for knowledge-sharing and connections. We can’t wait to continue the conversation and drive innovation in biotech—see you next year!
ICYMI: Check out Meghan’s presentation here: www.zymeworks.com/wp-content/uploads/2025/01/PepTalk_2025… -
Zymeworks Inc.
@ZymeworksInc
Today, on World Cancer Day, we reflect on the remarkable advancements in science, technology, and medicine that have reshaped cancer care and continue to drive progress in the fight against this disease. Together, we will continue pushing boundaries, advancing treatments, and working toward a future where cancer is no longer a life-threatening disease.
#cancerresearch #worldcancerday #oncology #biotech #progress -
Zymeworks Inc.
@ZymeworksInc
Today marks the first day of Black History Month and we’re honored to recognize the resilience and contributions of Black communities. This month—and every month—we commit to driving change in biotech and honoring the lives impacted by cancer through world-class research. Together, we can work toward a future where access, treatment, and outcomes are fair for all.
#blackhistorymonth #cancerawareness #healthequity #oncologyresearch -
Zymeworks Inc.
@ZymeworksInc
The results are in, and we have a winner—in fact, four winners! 🏆
A big congratulations goes out to Elizabeth Porter, Maggie Ling, Catherine Wu, and Karlton Scheu for receiving honors from @UBC 's 2024 Co-op Employer Recognition Awards!
#ubc #leadership #teamwork -
Zymeworks Inc.
@ZymeworksInc
Our management team will be attending and presenting at three conferences in February. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Are you passionate about advancing research in life sciences?
We’re hiring a Senior Scientist, Pathology to lead biomarker assay development and help drive novel therapies from preclinical research to clinical trials.
Learn more about this role and other current openings at -
Zymeworks Inc.
@ZymeworksInc
Happy Lunar New Year 2025! 🧧✨ This year, we celebrate the Year of the Snake, symbolizing wisdom, intuition, and transformation—qualities that inspire innovation and perseverance.
From all of us at Zymeworks, we wish you and your loved ones health, prosperity, and new opportunities in the year ahead.
#lunarnewyear #yearofthesnake -
Zymeworks Inc.
@ZymeworksInc
Tomorrow at 2 pm PT during the Tumor Models Summit, don’t miss our Associate Scientist, In Vivo Pharmacology & Pharmacokinetics, Diana Canals Hernaez, as she presents on “TriTCE Co-Stim: A Trispecific T Cell Engager Platform with Integrated CD28 Co-Stimulation to Improve T Cell Function and Antitumor Responses in Hard-to-Treat Cancers.”
View the full agenda: tumor-models-sf.com/program/day-one/
#tumormodelssummit #tcellengagers #cancerresearch #biotechinnovation -
Zymeworks Inc.
@ZymeworksInc
It’s Day 1 of the 9th Annual Tumor Models San Francisco Summit! Our Senior Scientist and Group Lead, In Vivo Pharmacology & Pharmacokinetics Multispecific Antibody Therapeutics, Nichole Escalante, will deliver a presentation today at 11 am PT about leveraging humanized mouse models as a means to support T cell engager development.
Learn more about the two-day event: tumor-models-sf.com -
Zymeworks Inc.
@ZymeworksInc
Come work with us at Zymeworks! We are currently hiring for the following positions:
• Manager, Drug Safety Operations
📍 Redwood City, Bellevue, or Vancouver
• Senior Research Associate II, In Vitro Biology
📍 Vancouver
• Clinical Data Manager
📍 Redwood City or Bellevue
• Manager, Clinical Quality Assurance
📍 Redwood City or Bellevue
For more details and to apply, visit: www.zymeworks.com/careers/ -
Zymeworks Inc.
@ZymeworksInc
Come work with us at Zymeworks! We are currently #hiring for the following positions:
· Manager, Drug Safety Operations
· SRA II, In Vitro Biology
· Clinical Data Manager
· Senior Manager, GCP Quality Assurance
For more details and to apply, visit: www.zymeworks.com/careers/
#biotech #careers -
Zymeworks Inc.
@ZymeworksInc
Our Zymeworks clinical team is geared up and eager to attend #ascogi2025! This annual conference is an immersive meeting for sharing new research and exploring the latest developments in #gastrointestinalcancer therapeutics.
We can’t wait to learn, collaborate, and advance the future of care together amongst our peers and partners.
#cancerresearch #biotech #gastriccancer -
Zymeworks Inc.
@ZymeworksInc
We’re excited to participate in @lifesciences_bc’s sixth annual Career Connect Day this Friday! Our very own Talent Acquisition Manager Celine Chartrand will be presenting and sharing more about career opportunities available at Zymeworks to students and job seekers.
Visit our careers page to explore our current open roles: www.zymeworks.com/careers/
#careers #hiring #lifesci #biotech #vancouver -
Zymeworks Inc.
@ZymeworksInc
Today, in observance of Martin Luther King Jr. Day, we celebrate the legacy of a global humanitarian whose fervent pursuit and passion for civil rights in America inspired generations.
On behalf of the entire Zymeworks team, we hope you have a safe and happy #mlkday!
#service #community #nationaldayofservice -
Zymeworks Inc.
@ZymeworksInc
We’re ready to hit the slopes during this year’s LifeSci Capital Biotech Ski Outing in Aspen, CO!
Happening today at 7:30 am MT, Paul Moore, our Chief Scientific Officer, will deliver a fireside chat during this event that brings together industry leaders for executive networking opportunities.
#lifesci #biotech #networking -
Zymeworks Inc.
@ZymeworksInc
We’re proud to share that our Chair and CEO Kenneth Galbraith was recently featured in Scrip Asks, offering his valuable insights into the evolving landscape of mergers and acquisitions (M&A), funding, and partnerships within the biotech industry.
Read more: insights.citeline.com/scrip/scrip-asks/scrip-asks-what-do… -
Zymeworks Inc.
@ZymeworksInc
Meghan Verstraete, Senior Scientist, Protein Engineering at Zymeworks presents today at 3:20 pm PT during PepTalk 2025. Her presentation is titled “Parallelization of Paratope Optimization and Antibody Format Screening for Efficient Characterization and Development of Multispecific T Cell Engagers.”
Learn more: www.chi-peptalk.com/characterization-of-biotherapeutics
#chipeptalk -
Zymeworks Inc.
@ZymeworksInc
This Thursday, our Chair and Chief Executive Officer Kenneth Galbraith will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. His presentation will focus on a company overview and strategic priorities for 2025-2026.
Read more details here: ir.zymeworks.com/events-and-presentations
#jpmhc25 -
Zymeworks Inc.
@ZymeworksInc
From advancing clinical development of our wholly-owned pipeline targeting cancer and autoimmune and inflammatory diseases to exploring next-generation multifunctional therapeutics, we’re advancing rapidly on our mission to make a difference in patients’ lives.
Read more here: -
Zymeworks Inc.
@ZymeworksInc
Students, are you looking for an exciting opportunity in life sciences?
We are currently hiring for student co-op positions, including roles in protein engineering, in vitro biology, and more!
Apply today: www.zymeworks.com/careers/
#lifesciences #stemjob #studentcoop #biotech -
Zymeworks Inc.
@ZymeworksInc
Looking back on this year, we’re reminded of the remarkable progress and achievements that brought us closer to our mission of making a meaningful difference in patients' lives.
Here’s to a new year filled with happiness, prosperity and peace.
#happynewyear #2024milestones -
Zymeworks Inc.
@ZymeworksInc
Thank you to all who joined our R&D Day last week. Led by our esteemed researchers and scientists, we were pleased to present advancements from our wholly-owned pipeline alongside key opinion leaders. Here’s to an exciting future in developing transformative therapies for patients.
#biotech #researchanddevelopment #innovation -
Zymeworks Inc.
@ZymeworksInc
Success doesn’t happen overnight when finding advancements in cancer therapy.
At Zymeworks, we’re proud to celebrate the remarkable people behind the journey to developing an FDA-approved therapy, powered by our Azymetric™ technology platform.
#biotech #innovation -
Zymeworks Inc.
@ZymeworksInc
We’re hiring! Exciting roles are available at Zymeworks. Join us in advancing the mission to improve the lives of patients with difficult-to-treat cancers and other serious diseases. Apply now! zymeworks.com/careers/ #hiring #biotechcareers
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is attending the Antibody Engineering & Therapeutics (AET) Conference in San Diego, Dec 15–18, 2024! Excited to connect with industry leaders and discuss the latest advancements in antibody therapeutics.
@AntibodyEngIC
#antibodytherapeutics #biotech #innovation -
Zymeworks Inc.
@ZymeworksInc
We’re thrilled to kick off R&D Day and share our excitement for the potential of our growing wholly-owned pipeline of novel, differentiated, and multifunctional antibody-based therapeutics as we work to address difficult-to-treat diseases with traditionally poor outcomes.
Join the live webcast of R&D Day or watch a replay here: zymeworksrdday.us.chime.live/app/
Led by Zymeworks’ research leadership alongside key opinion leaders, featured presentations will highlight the fifth candidate in our solid tumor program, a novel trispecific T cell engager, as well as introduce our first bispecific antibody in AIID, which demonstrates a dual blockade of two complementary pathways of respiratory inflammation and offers potential benefit in mixed-type chronic obstructive pulmonary disease.
#biotech #innovation #researchanddevelopment -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is attending the R&D Procurement & Outsourcing in Biopharma Summit, Dec 11-12 in San Diego. Business support functions like procurement play a critical role in drug development—collaboration across teams makes a difference for patients!
#biopharma #innovation -
Zymeworks Inc.
@ZymeworksInc
Join Zymeworks for R&D Day on Dec 12 at 8:30 AM ET!
Updates include:
• Solid tumor ADCs & TCEs
• New candidate nomination from our Trispecific TCE platform
• Plans for potential expansion into new therapeutic areas
Register now: zymeworksrdday.us.chime.live/app/ -
Zymeworks Inc.
@ZymeworksInc
“It’s a scientist’s dream to have something you worked on be approved.” – Dr. Nina Weisser shares the journey behind our recent FDA-approved therapy. This milestone is a testament to the passion and collaboration of our team as we strive to make a meaningful difference in the lives of patients.
This media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
The Zymeworks team is attending #esmoasia2024 in Singapore, Dec 6-8! Excited to connect with experts and industry leaders to discuss advances in cancer research and treatment.
@myESMO #cancerresearch #biotech -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is at @EvercoreISI HealthCONx on Dec 4! Joe Woolery will join a fireside chat at 7:55 am ET. 1x1 meetings are also available—connect with us!
#healthconx #oncology #biotech -
Zymeworks Inc.
@ZymeworksInc
Zymeworks is at the 2024 @Citi Global Healthcare Conference on Dec 3! Catch Joe Woolery on the "Novel Mechanisms in Oncology I" panel at 3:15 pm ET. 1x1 meetings are also available—let’s connect! #oncology #biotech
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is at the 36th Annual Piper Sandler Healthcare Conference on Dec 3! Join CEO Kenneth Galbraith’s corporate presentation at 1:30 pm ET. 1x1 meetings are also available—reach out to connect! #pipersandlerhealthcare
-
Zymeworks Inc.
@ZymeworksInc
This Thanksgiving, we’re grateful for our incredible team, the patients who inspire us, and the communities and partners who support our mission. Together, we’re advancing science to make a difference. Wishing you a happy and meaningful holiday! #gratitude
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is at #pmwest 2024 in Vancouver November 28-29! Don’t miss Kari Frantzen & Michelle Chakraborti presenting on resilient project execution in drug discovery & development. Excited to connect with the PM community! @PMI_CWCC
#projectmanagement #drugdevelopment -
Zymeworks Inc.
@ZymeworksInc
Exciting months ahead! Join $ZYME at Piper Sandler, Citi Biopharma, Evercore ISI HEALTHCONx, our R&D Day on Dec 12 in NYC, and JPM Healthcare Jan 13-16 in SF! Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
NEWS: #fdaapproval for Ziihera® (zanidatamab-hrii), the first HER2-targeted therapy for #biliarytractcancer! With great partnerships, and our proprietary Azymetric™ tech, we’re transforming cancer treatment. Thank you to everyone who made this possible! ir.zymeworks.com/news-releases/news-release-details/fda-g…
-
Zymeworks Inc.
@ZymeworksInc
Excited to be at the #jefferieshealthcare Conference in London on Nov 20-21! Catch our CSO Paul Moore in a fireside chat on Nov 20 at 2:30pm GMT. We’re also open for 1-on-1 meetings—reach out to connect! #biotech #innovation
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is attending the #stifelhealthcareconference in NYC on Nov 19! Our team will be available for 1-on-1 meetings and participating in a fireside chat at 3:35 pm ET — let’s connect! #biotech #innovation #healthcare
-
Zymeworks Inc.
@ZymeworksInc
Honored to attend #sitc2024 in Houston! Thank you to all who discussed our work and joined our poster presentation, “Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3.”
-
Zymeworks Inc.
@ZymeworksInc
We’re hiring! Zymeworks is looking for a Director of Biostatistics & Programming to support our biotherapeutics pipeline. Join us in advancing science and making a difference. Apply today!
#hiring #biotechcareers #lifeatzymeworks #biostatistics -
Zymeworks Inc.
@ZymeworksInc
We’re at the @UBS Global Healthcare Conference in Rancho Palos Verdes, CA, and open for 1-on-1 meetings! Looking forward to connecting on advancing biotherapeutics and new collaborations. Let’s meet! #biotech #innovation #healthcare
-
Zymeworks Inc.
@ZymeworksInc
We’re hiring! Zymeworks has open roles across Immunology, Drug Safety, Clinical Data, Pathology, and In Vitro Biology. Join us in advancing biotherapeutics and making an impact. Apply today!
zymeworks.com/careers
#hiring #biotechcareers #lifeatzymeworks -
Zymeworks Inc.
@ZymeworksInc
Today, we remember and honor the sacrifices of those who have served on Remembrance Day in Canada and Veterans Day in the U.S. Thank you to all veterans and active service members for your unwavering commitment.
-
Zymeworks Inc.
@ZymeworksInc
Happy #worldscienceday! Today, we celebrate the incredible impact of science in improving lives. #scienceforgood #innovation #biotech
-
Zymeworks Inc.
@ZymeworksInc
Our VP, Finance & Strategy, Bijal Desai, presented at the 9th Annual #investinbc Conference in Vancouver, showcasing our wholly-owned pipeline. We’re excited to expand our community of supporters as we work to transform patient outcomes through innovation. Thanks @lifesciences_bc
-
Zymeworks Inc.
@ZymeworksInc
Thrilled to be at #sitc2024 in Houston! Join us 11/9 as Charles Chen presents on QSP modeling & translational strategy for our investigational bispecific T-cell engager therapeutic targeting mesothelin and CD3. #immunotherapy #biotech
Zymeworks Inc.
@ZymeworksInc
Learn more: www.zymeworks.com/zymeworks-presents-preclinical-data-on-…
-
Zymeworks Inc.
@ZymeworksInc
Thrilled to attend #pegseurope! Today, Nina Weisser presented on TriTCE Co-Stim to improve oncology treatment responses. Join us!
#biotech #innovation #tcellengagers -
Zymeworks Inc.
@ZymeworksInc
Excited to be at #pegseurope! On Nov 5, Thomas Spreter presented on Azymetric Fc-based therapeutic modalities for tumor-restricted immune cell activation. Join us in Barcelona! #biotech #innovation
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to announce that the first patient has been dosed in our Ph 1 trial targeting FR⍺-expressing solid tumors including ovarian, endometrial, and NSCLC cancers. Read more about this important step in advancing innovative #cancer therapies: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is headed to @World_ADC in San Diego from Nov 4-7! We’re excited to connect and explore new partnerships as we advance our biotherapeutics pipeline. See you there! #worldadc #adcdevelopment #noveldrugdevelopment #pharmainnovation
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks is headed to #bioeurope in Stockholm from Nov 4-6! Looking forward to connecting with peers and partners as we continue to advance our biotherapeutics pipeline. See you there! #drugdevelopment #biotech
-
Zymeworks Inc.
@ZymeworksInc
Great experience at #enasymp24! We’re excited to have presented new preclinical data on our antibody-drug conjugate programs, and showing progress for IND submissions in 2025. Thank you to everyone who joined us in Barcelona to support advancing oncology innovation! #biotech
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our third quarter 2024 financial results. Join us for a conference call and webcast at 4:30 pm ET hosted by our executive leadership team, where they will present recent corporate highlights.
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Happy #diwali to our friends, colleagues, partners, and team members around the world celebrating the Festival of Lights.
Wishing you all a joyous and prosperous celebration filled with happiness, peace, and new beginnings! -
Zymeworks Inc.
@ZymeworksInc
We recently attended #igcs2024! This was a great opportunity to meet with industry peers and clinicians to further discussions and exchange insights around #ovariancancer, #endometrialcancer, and #cervicalcancer
-
Zymeworks Inc.
@ZymeworksInc
We will participate in three upcoming conferences in November. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Tomorrow, our VP of Finance & Strategy, Bijal Desai, will present on our commitment to developing breakthrough therapies for patients with difficult-to-treat cancers during @lifesciences_bc’s 9th Annual Invest in BC event: lifesciencesbc.ca/event/invest-in-bc-2024/ #lsbcinvest #lsbcevents
-
Zymeworks Inc.
@ZymeworksInc
Today at #enasymp24, Andrea Hernandez Rojas, Scientist & Group Lead, In Vitro Biology, ADC Therapeutic Development explored our NaPi2b-directed topoisomerase I inhibitor ADC in #ovariancancer & #endometrial cancer models. Details: www.zymeworks.com/wp-content/uploads/2024/10/ZW220-ENA-AH…
-
Zymeworks Inc.
@ZymeworksInc
Thrilled to present preclinical data for our ADC programs at #ena2024! Data is supportive of 2025 IND submissions and demonstrate potential to address critical unmet needs in oncology. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today at #enasymp24, Raffaele Colombo (@raffcolo), our Associate Director of Medicinal Chemistry, delivered a presentation titled “Beyond ADC Target Expression: Understanding ADC Properties and Pharmacology.” Learn more: www.zymeworks.com/wp-content/uploads/2024/10/Raffaele-ENA…
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow, at #enasymp24, Laurence Madera will present a poster showcasing our innovative glypican-3-targeting antibody-drug conjugate that delivers a topoisomerase I inhibitor payload, focusing on its development in hepatocellular carcinoma.
www.zymeworks.com/wp-content/uploads/2024/10/ZW251-ENA-20… -
Zymeworks Inc.
@ZymeworksInc
Congrats @raffcolo, Dr. Jamie Rich, @Ptarantino, Dr. Patricia LoRusso, @VriesElisabeth and @AACRPres on showcasing this thought-provoking research!
#ena2024
Zymeworks Inc.
@ZymeworksInc
New paper: "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development" – leaders in #cancerresearch review four decades of ADC progress, sparked by discussions at #targets23. @CD_AACR -aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
-
Zymeworks Inc.
@ZymeworksInc
New paper: "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development" – leaders in #cancerresearch review four decades of ADC progress, sparked by discussions at #targets23. @CD_AACR -aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
-
Zymeworks Inc.
@ZymeworksInc
Join our VP of Business & Commercial Development, Lucas Donigian, on October 24 for a panel discussion hosted by @LifeScienceWA exploring the evolution of antibody-drug conjugates & highlighting Seattle's pivotal role in shaping the field. Register at lifesciencewa.org/events/how-antibody-drug-conjugates-are…
-
Zymeworks Inc.
@ZymeworksInc
Join us at #bioeurope November 4-6 in Stockholm! Our team looks forward to connecting with potential partners who share in our mission to make a meaningful difference in the lives of patients with difficult-to-treat cancers. Sign up to meet with us: informaconnect.com/bioeurope/
-
Zymeworks Inc.
@ZymeworksInc
We're excited to announce the initiation of the Phase 1 trial for our novel investigational therapy for mesothelin-expressing cancers including #ovariancancer and non-small cell #lungcancer.
Read more about this significant milestone: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Wishing our Canadian colleagues and friends a happy #thanksgiving! As we celebrate this special day of gratitude, we recognize the importance of community, connection, and reflection. Enjoy this time with family and loved ones!
-
Zymeworks Inc.
@ZymeworksInc
Today on #worldmentalhealthday, we recognize the theme, “It’s Time to Prioritize Mental Health in the Workplace.” Through our #zymelife benefits and #flexfriday program, we’re proud to maintain a work environment where employees are encouraged to prioritize their #mentalhealth.
-
Zymeworks Inc.
@ZymeworksInc
Join our executive leadership team on October 31 at 4:30pm ET for a conference call and webcast to discuss Q3 2024 financial results and corporate updates. See our press release for details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re excited to announce that we’ll be presenting new preclinical data on our antibody-drug conjugate programs at the upcoming #enasymp24. Learn more here: www.zymeworks.com/zymeworks-presents-new-preclinical-data…
-
Zymeworks Inc.
@ZymeworksInc
We are thrilled to share that Raffaele Colombo, PhD, our Associate Director, Medicinal Chemistry, has been selected as a 2024 @PharmaVoice 100 honoree! We’re proud to have Raffaele as a key member of our team. Congratulations! Learn more: www.zymeworks.com/dr-raffaele-colombo-honored-as-a-pharma…
-
Zymeworks Inc.
@ZymeworksInc
We are looking forward to attending #sitc2024 and presenting preclinical data on our novel 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers! Learn more: www.zymeworks.com/zymeworks-announces-upcoming-scientific…
Society for Immunotherapy of Cancer
@sitcancer
With over 1,400 abstract submissions, @sitcancer is pleased to share the #sitc24 Regular, YIA and Immune Engineering Abstract Titles and Authors. Browse Abstract Title & Authors: www.sitcancer.org/2024/abstracts/titles-and-publications
-
Zymeworks Inc.
@ZymeworksInc
Are you passionate about improving the lives of patients living with difficult-to-treat cancers and other serious diseases? If so, we invite you to become part of our dedicated team! Learn more about our available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
We are currently seeking a Vice President of #informationtechnology to join our team. This individual will drive our global #it strategy to support our clinical development and research efforts. Learn more about the position: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
We had an incredible time at our annual philanthropic event last week! We are proud of our team's dedication to making a meaningful difference, not only through our research but also through volunteer efforts that support the communities we serve.
-
Zymeworks Inc.
@ZymeworksInc
In recognition of National Day for Truth and Reconciliation, we honor the resilience and strength of those impacted by Indigenous residential schools. Join us in celebrating the rich cultures, voices, and stories of First Nations, Inuit, and Métis peoples: www.canada.ca/en/canadian-heritage/campaigns/national-day…
-
Zymeworks Inc.
@ZymeworksInc
Today on #worldcancerresearchday, we honor our team of researchers, experts, and partners who are dedicated to harnessing the potential of ADCs and multispecific antibody therapeutics to address high unmet needs in the treatment of difficult-to-treat cancers.
-
Zymeworks Inc.
@ZymeworksInc
Our Chief Executive Officer, Kenneth Galbraith, will deliver a presentation on September 23 at 10:00am CEST during the HBM BioPharma Summit. Learn more in our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today, we announced two presentations at the upcoming #enasymp24 highlighting new preclinical data on our ADC clinical candidates in #lungcancer, #ovarian, and #livercancer models. Find more information in our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Last weekend our team participated in @TerryFoxCanada’s #terryfoxrun, raising $8,306 for #cancerresearch! Huge thanks to our team, family, friends & the Vancouver community for your amazing efforts. Learn more: terryfox.org/terry-fox-run/ #terryfoxrun #dearterry #tryliketerry
-
Zymeworks Inc.
@ZymeworksInc
During the Cantor Global Healthcare Conference in New York this week, our management team will participate in one-on-one meetings and a fireside chaton September 18 at 3:05pm ET. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our partner, @JazzPharma presented updated results at #esmo24 and showcased the potential of our bispecific antibody in treating HER2-positive metastatic gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals
@JazzPharma
At #esmo24, we're presenting updated Phase 2 trial data evaluating the potential of our investigational dual HER2-targeted bispecific antibody in treating HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA). Learn more: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
We are seeking individuals to join our team and be part of our collective effort in making a meaningful difference in the lives of patients with serious diseases. If you’re ready to use your skills to make a real impact, check out available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
We’re lacing up our running shoes to participate in @TerryFoxCanada’s #terryfoxrun on September 15. This annual charity event honors the legacy of Terry Fox and raises funds for critical #cancerresearch. Learn more: terryfox.org/terry-fox-run/
-
Zymeworks Inc.
@ZymeworksInc
We are excited to invite undergraduate students to apply for our Co-Op Program at our Vancouver office! If you’re passionate about making a real impact and eager to grow your career in #biotech and #lifesciences, learn more: careers.zymeworks.com/go/Co-Op/2660117/
-
Zymeworks Inc.
@ZymeworksInc
Our team is excited to attend #esmo24 in Barcelona this weekend & showcase the potential of our investigational HER2-targeted bispecific #antibody in treating HER2-positive metastatic gastroesophageal adenocarcinoma with @JazzPharma. Learn more: www.esmo.org/meeting-calendar/esmo-congress-2024
-
Zymeworks Inc.
@ZymeworksInc
Join our management team at the @HCWCO Annual Global Investment Conference in New York as we participate in one-on-one meetings and a fireside chat on September 10 at 11:00am ET. Find more details here: ir.zymeworks.com/news-releases/news-release-details/zymew… #hcwainwrightglobal
-
Zymeworks Inc.
@ZymeworksInc
Together with our partner @JazzPharma, we look forward to presenting updated results for the potential treatment of HER2-positive metastatic gastroesophageal adenocarcinoma and other HER2-positive cancers at #esmo24.
Jazz Pharmaceuticals
@JazzPharma
At #esmo24, we will present 5 #oncology abstracts alongside partners, including updated results showing the potential of our bispecific antibody in treating HER2-positive metastatic gastroesophageal adenocarcinoma. Learn more: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
During the Morgan Stanley Healthcare Conference in New York, our management team will participate in one-on-one meetings and a fireside chat today at 7:00am ET. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today at 2:15pm ET during the 15th Annual World Bispecific Summit, our CSO Paul Moore, PhD, will deliver a presentation to discuss how we are leveraging our Azymetric™ platform to optimally format T-cell engagers and bispecific ADCs. See the agenda: bispecific.com
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to introduce Leone Patterson, who serves as EVP, Chief Business and Financial Officer. With more than 20 years of experience in #biotech & #biopharma, she will provide leadership surrounding financing & capital strategies & supporting strategic business decisions.
-
Zymeworks Inc.
@ZymeworksInc
In celebration of #womensequalityday, we honor the incredible achievements of women and their impact on the patients we serve. At Zymeworks, we’re proud of our inspiring female leaders who drive our mission to develop innovative biotherapeutics each day.
-
Zymeworks Inc.
@ZymeworksInc
We’re searching for an individual to join our team as the Director of Medical Writing. This individual will work with our research scientists to outline, write and coordinate the review and editing of medical writing deliverables. Learn more: careers.zymeworks.com/job/San-Francisco-Director%2C-Medic…
-
Zymeworks Inc.
@ZymeworksInc
We are proud to share recent #pride events from our global hubs in Dublin, Redwood City, Singapore, Bellevue & Vancouver, each showcasing unique celebrations and heartfelt messages of support for the #lgbtq+ community. #pridemonth #prideinbiotech #pride2024
-
Zymeworks Inc.
@ZymeworksInc
Collaboration and innovation are part of everything we do at Zymeworks, and we are always seeking new professionals to join our scientific and corporate teams to help fuel our pipeline of potential. Check out available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in four upcoming conferences in September. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Our Scientist, Medicinal Chemistry, Michael Brant, will deliver a poster presentation at #acsfall2024 today to discuss our novel camptothecin drug-linker platform engineered specifically for ADC application. Learn more: acs.digitellinc.com/live/32/page/1051
-
Zymeworks Inc.
@ZymeworksInc
Explore how advancements in ADCs are redefining cancer treatment and informing our unique approach to their design and development in this article from @DrugTargetRev article, featuring Paul Moore, PhD, Raffaele Colombo, PhD, & Jamie Rich, PhD: www.drugtargetreview.com/article/148392/unlocking-the-pot…
-
Zymeworks Inc.
@ZymeworksInc
We’re proud to be a member of @CAN_ASEAN, an organization committed to enhancing collaboration between Canada and the vibrant nations of the ASEAN region. Learn more about their efforts: www.canasean.com/about
-
Zymeworks Inc.
@ZymeworksInc
Our team is advancing next-generation T cell engagers using the TriTCE Co-Stim platform, which integrates CD28 costimulation to potentially enhance anti-tumor activity. Learn more in this interview with @DDWJournal: www.ddw-online.com/finding-protein-therapeutics-for-cance…
-
Zymeworks Inc.
@ZymeworksInc
During the @Wedbush PacGrow Healthcare Conference, our management team will participate in a panel discussion on August 14 at 8:45am ET and will participate in one-on-one meetings on August 13-14 in New York. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We had an amazing time at the first-ever Pride in Biotech event, bringing together the Vancouver community to celebrate #lgbtq+ professionals in #lifesciences and #biotech. A big thanks to our amazing ZYME&Proud team for leading this initiative!
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and a fireside chat on August 6 at 4:00pm ET at the BTIG Virtual Biotechnology Conference. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
One month to go! We’re looking forward to attending the World Bispecific Summit in Boston September 3-5. Explore the agenda at bispecific.com
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our second quarter 2024 financial results. Join us for a conference call and webcast at 4:30pm ET hosted by our management team where they will provide recent corporate highlights. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Join us this Thursday, August 1, at BrewHall in Vancouver as we continue to celebrate the voices of the #lgbtq+ community! Register at: www.tickettailor.com/events/zymeworksinc/1304050
-
Zymeworks Inc.
@ZymeworksInc
We look forward to participating in two upcoming conferences in August. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Harnessing our Azymetric™ technology, we developed two novel approaches to engineer differentiated next-generation trispecific T cell engagers: TriTCE Co-stim and TriTCE CPI. Learn more: www.zymeworks.com/technologies/t-cell-engagers/
-
Zymeworks Inc.
@ZymeworksInc
We’re making significant strides in developing next-gen T cell engagers to improve #cancer treatment. In this @DDWJournal article, Paul Moore, PhD, & Nina Weisser, PhD, share insights into our impact on antibody-drug conjugates & T cell engagers. See here: www.ddw-online.com/finding-protein-therapeutics-for-cance…
-
Zymeworks Inc.
@ZymeworksInc
In the spirit of #pride2024, @vancouverpride will be kicking off Canada Pride 2024 today in Davie Village to celebrate the limitless potential of Canada’s diverse & vibrant 2SLGBTQAI+ community as part of this year’s theme, “Infinite Horizons”. Learn more: www.vancouverpride.ca/events/opening-ceremony
-
Zymeworks Inc.
@ZymeworksInc
Save the date! Join us on August 1 for the inaugural Pride in Biotech event hosted by our ZYME&Proud team. We look forward to welcoming members of the Vancouver #biotech and #lifesciences community next week! Register now: www.tickettailor.com/events/zymeworksinc/1304050
-
Zymeworks Inc.
@ZymeworksInc
#icymi, our Director of Preclinical, Multispecific Antibody Therapeutics, Nina Weisser, PhD, explains how our next generation TriTCE Co-Stim platform is engineered to address solid tumors in this @DrugTargetRev Q&A. See here: www.drugtargetreview.com/article/149685/improving-treatme…
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to receive clearance from the FDA of our investigational new drug application for our novel folate receptor-⍺ targeted topoisomerase I inhibitor antibody-drug conjugate. Read more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re searching for an Associate Director of Immunology to work with our team of #immunology researchers to deliver an innovative pipeline across a diversity of modalities, from inception through IND in autoimmune diseases. Learn more: careers.zymeworks.com/job/Vancouver-Associate-Director%2C…
-
Zymeworks Inc.
@ZymeworksInc
Join our CEO Kenneth Galbraith and executive leadership team on August 1 at 4:30pm ET for a conference call and webcast to discuss Q2 2024 financial results and corporate updates.
See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we believe in the importance of inclusivity and equal opportunities for all. Learn more about our culture and check out available opportunities: careers.zymeworks.com.
-
Zymeworks Inc.
@ZymeworksInc
Happy #independenceday to our colleagues, partners, and friends in the U.S.!
-
Zymeworks Inc.
@ZymeworksInc
Happy #canadaday to all our Canadian colleagues and friends! Our offices will be closed this week for summer break to allow our team members to rest, relax, and enjoy quality time with their families and friends.
-
Zymeworks Inc.
@ZymeworksInc
We’re excited to launch #pride in Biotech, a Vancouver-based event to empower #lgbtq+ professionals in the life sciences industry through networking, education, advocacy, professional development, and peer support.
Zymeworks Inc.
@ZymeworksInc
Our inaugural event, led by our ZYME&Proud team, will take place on August 1 at BrewHall in Vancouver. We look forward to welcoming members of the #vancouver #biotech, life sciences community, and prospective graduates! To register for the event, visit www.tickettailor.com/events/zymeworksinc/1304050
-
Zymeworks Inc.
@ZymeworksInc
Earlier this week our team participated in the Concord Pacific Dragon Boat Festival, North America’s largest dragon boat festival celebrating community, culture, and competition.
Zymeworks Inc.
@ZymeworksInc
We are thrilled to share that our team won gold in the Premier Mixed Tail Final with an impressive time of 2:54!
-
Zymeworks Inc.
@ZymeworksInc
Our early-stage development team will attend ESMO’s Gastrointestinal Cancers Congress to explore how we can collectively work towards improved outcomes in the fight against #cancer. Learn more: www.esmo.org/meeting-calendar/esmo-gastrointestinal-cance…
-
Zymeworks Inc.
@ZymeworksInc
Today kicks off the 38th ACS National Medicinal Chemistry Symposium! Zymeworks’ Mark Petersen will deliver a presentation on June 25 at 8:35am PT exploring the development of our novel TOPO1i ADC platform. Access the agenda: www.boss-symposium.org/v2/produits.php?langue=english&cle…
-
Zymeworks Inc.
@ZymeworksInc
We are excited to partner with @lifesciences_bc for their Annual Summer Social today at our Vancouver office! Join us as we bring together the vibrant BC #lifesciences community to celebrate the incredible work happening in our industry. Learn more: lifesciencesbc.ca/event/lsbc_summer_social/
-
Zymeworks Inc.
@ZymeworksInc
Today on #juneteenth, we commemorate the end of slavery in the U.S. & continue towards the promise of equality for all. Together, let’s build a future where every individual is valued and empowered. Learn about the history of Juneteenth: www.juneteenth.com
-
Zymeworks Inc.
@ZymeworksInc
We’re excited to announce that the U.S. FDA has cleared the investigational new drug (IND) application for our novel 2+1 T-cell targeting #bispecific #antibody for mesothelin (MSLN)-expressing cancers! Learn more in our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Join our management team during the Goldman Sachs 45th Annual Global Healthcare Conference for one-on-one meetings and a fireside chat on June 12 at 2:00pm ET. See our press release for additional details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our #businessdevelopment team had an incredible week at #bio2024. It was a pleasure connecting with industry leaders to discuss how we are advancing our pipeline of novel multifunctional therapeutics to make a meaningful difference in the lives of patients.
-
Zymeworks Inc.
@ZymeworksInc
#icymi In this @DrugTargetRev article, Zymeworks’ Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, explore our unique approach to the design and development of antibody-drug conjugates (#adcs). Read the full article: www.drugtargetreview.com/article/148392/unlocking-the-pot…
-
Zymeworks Inc.
@ZymeworksInc
Today we announced that the CDE of the NMPA in China has accepted the Biologics License Application (BLA) for our investigational HER2-targeted bispecific antibody for second-line treatment of HER2-positive #biliarytractcancer. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Join us on June 20 for @lifesciences_bc’s Annual Summer Social, taking place at our Vancouver office! Join us as we bring together the vibrant BC #lifesciences community to celebrate the incredible work happening in our industry. Learn more: lifesciencesbc.ca/event/lsbc_summer_social/
Life Sciences BC
@lifesciences_bc
Tickets are now on sale for our 2024 LSBC Summer Social! Last year this event sold out fast, so secure your spot now! Kick off the summer and join us on June 20 from 5:00 - 7:00 PM PT to celebrate BC’s life sciences sector.
Get your ticket: lifesciencesbc.ca/event/lsbc_summer_social/ -
Zymeworks Inc.
@ZymeworksInc
Happy #pridemonth! This month we recognize the #lgbtq+ community’s resilience, history, and pursuit for equality and acceptance & champion diversity and inclusivity within our workplace and beyond. #pride2024
-
Zymeworks Inc.
@ZymeworksInc
Today, our management team will be participating in one-on-one meetings during the #jefferies Global Healthcare Conference in New York and will present a fireside chat at 10:30am ET. See our press release for additional details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We are proud to support this year’s keynote session presented by Dr. George Church, the founder of Synthetic Biology at the Wyss Institute, Harvard University, during today’s @SBME_UBC’s #sbmesymposium6. Don’t miss the presentation at 3:15pm! Learn more: bme.ubc.ca/sbme-symposium-2024/
-
Zymeworks Inc.
@ZymeworksInc
Join our BD team at #bio2024! On June 5 at 1:45pm PT, our Associate Director of Business Development, Emily Chen, PhD, will deliver a presentation discussing our pipeline of novel multifunctional therapeutics. Learn more: convention.bio.org/sessions/zymeworks@IamBiotech
-
Zymeworks Inc.
@ZymeworksInc
In a recent publication in @MCT_AACR, we present the development of our TOPO1i platform tailored for antibody-drug conjugate (#adc) application. Access the publication: www.zymeworks.com/publications/
-
Zymeworks Inc.
@ZymeworksInc
The @ASCO Annual Meeting is taking place this week! We look forward to attending #asco2024 & collaborating with researchers, professionals, and leaders on the latest research in cancer care and treatment. Learn more: conferences.asco.org/am/attend
-
Zymeworks Inc.
@ZymeworksInc
Today is the last day of #nationalcancerresearchmonth, but we remain steadfast in our commitment to advancing novel therapeutics with the potential to improve the lives of patients and families impacted by difficult-to-treat cancers. #ncrm24
-
Zymeworks Inc.
@ZymeworksInc
Together with @JazzPharma, we are pleased to share that the FDA has accepted & granted Priority Review for the Biologics License Application for our investigational HER2-targeted bispecific antibody for the potential treatment of metastatic HER2-positive biliary tract #cancer.
Jazz Pharmaceuticals
@JazzPharma
The FDA has accepted and granted Priority Review for the Biologics License Application (BLA) for our potential treatment for metastatic HER2-positive biliary tract #cancer (BTC). Learn more about this significant step forward: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
Our team had a great time participating in @biocom’s Bay Area Life Science Career Expo! It was a pleasure to engage with industry peers within the region and cultivate relationships with candidates eager to explore new career opportunities in the #lifesciences industry.
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in three upcoming conferences in June. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Join us this #memorialday as we honor the individuals who have served and continue to serve our country.
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, career growth and development are a key focus area for our employees, and we are proud to provide programs & resources that empower our team and enable them to do their best work. Check out our available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
Dr. Nina Weisser, Director of Preclinical, Multispecific Antibody Therapeutics, recently authored an article published in @DrugTargetRev discussing the development of trispecific T cell engagers (TriTCEs) with integrated CD28 costimulation. Read more: www.drugtargetreview.com/article/149685/improving-treatme…
-
Zymeworks Inc.
@ZymeworksInc
Attending #bio2024 next month? In preparation for the conference, @lifesciences_bc will be hosting a BC Delegation Spotlight: BIO San Diego webinar on May 23 at 9:30am PT featuring our Associate Director of Business Development, Emily Chen, PhD. See here: lifesciencesbc.ca/event/bc-delegation-spotlight-bio-san-d…
-
Zymeworks Inc.
@ZymeworksInc
We are proud to support @AmericanCancer’s Washington ResearcHERS Symposium Luncheon that will discuss how women can support women through their careers & explore the impact of artificial intelligence in cancer research. Learn more: secure.acsevents.org/site/STR?pg=entry&fr_id=108371
-
Zymeworks Inc.
@ZymeworksInc
Today in honor of #clinicaltrialsday, we extend our gratitude to our team members, colleagues, partners, and collaborators around the world who are working to advance our pipeline of novel multifunctional therapeutics, as well as the people who participate in #clinicalresearch.
-
Zymeworks Inc.
@ZymeworksInc
During #pegsummit today, Dunja Urosev will deliver a presentation at 9:50am ET about screening novel format antibodies to design bispecific ADCs that address target heterogeneity. www.pegsummit.com/bispecific-antibodies
-
Zymeworks Inc.
@ZymeworksInc
Our management team will be available for one-on-one meetings during the Bank of America Merrill Lynch Global Healthcare Conference today in Las Vegas. See our press release for additional details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
As we continue to recognize #nationalcancerresearchmonth, it's important to highlight the critical role of clinical research in driving progress towards more effective cancer care and ultimately, improving the lives of patients worldwide. #ncrm24
-
Zymeworks Inc.
@ZymeworksInc
Gursev Anmole and Prajwal Raghunatha will deliver a poster presentation exploring our Trispecific T cell Engager Co-Stimulatory technology platform at #pegsummit this week. Learn more: www.pegsummit.com/poster-titles #antibody #therapeutics
-
Zymeworks Inc.
@ZymeworksInc
We're excited to attend the @biocom Bay Area Life Science Career Expo, taking place this Wednesday, 5/15 & hosted by the @BiocomInstitute. Join us to learn about exciting career opportunities at Zymeworks: www.biocom.org/event/Bay-Area-Life-Science-Career-Expo-2024/
-
Zymeworks Inc.
@ZymeworksInc
#icymi in this @biospace article, our CSO Paul Moore, PhD, provides his insights into the current landscape of ADCs and how our team is working to develop a new generation of promising cancer therapeutics. Read here: www.biospace.com/article/opinion-the-next-generation-of-a…
-
Zymeworks Inc.
@ZymeworksInc
We’re currently on the lookout for talented students & graduates to join our co-op program! These roles provide an opportunity to collaborate with our R&D teams and support our pipeline of novel multifunctional therapeutics. Learn more: careers.zymeworks.com/go/Co-Op/2660117/
-
Zymeworks Inc.
@ZymeworksInc
It was a pleasure to welcome these talented students into our lab & provide them with hands-on experience to work alongside our R&D teams through our undergraduate co-op student training program. Interested in being part of our innovative team? Learn more: careers.zymeworks.com/go/Co-Op/2660117/
-
Zymeworks Inc.
@ZymeworksInc
Our Managing Director of Early-Stage Development (Asia Pacific), Josemund Menezes, will attend #biokorea2024 this week to share how we are leveraging our multi-hub strategy to reshape the future of oncological drug development. www.biokorea.org/index.asp
-
Zymeworks Inc.
@ZymeworksInc
Every May, @AACR marks #nationalcancerresearchmonth to raise awareness and support around lifesaving #cancer research. We’re proud to join our colleagues in #oncology & drug development as we work to make a difference on behalf of patients & families. #ncrm24
-
Zymeworks Inc.
@ZymeworksInc
Join our CEO Kenneth Galbraith and executive leadership team today at 4:30pm ET for a conference call and webcast to discuss Q1 2024 financial results and corporate updates.
See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Advancements in ADCs are redefining #cancer treatment. Our own Dr. Paul Moore, Dr. Raffaele Colombo and Dr. Jamie Rich discuss how personalized medicine approaches are optimizing outcomes for cancer patients: www.drugtargetreview.com/article/148392/unlocking-the-pot… @DrugTargetRev
-
Zymeworks Inc.
@ZymeworksInc
May is #mentalhealthawarenessmonth, a moment to reaffirm our commitment to promoting mental and emotional well-being among our team members by fostering a culture of openness and understanding. #takeamentalhealthmoment #mentalhealthmonth
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in two upcoming conferences in May. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we believe in inclusivity and equal opportunities for all. Join our team and explore our current openings to learn more about our culture: careers.zymeworks.com careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
We’re searching for an Associate Director, Clinical Quality Assurance, to be based in our Redwood City office and take a leadership role on our Clinical Quality Assurance team. For more details on the role, visit careers.zymeworks.com/job/San-Francisco-Associate-Directo…
-
Zymeworks Inc.
@ZymeworksInc
Together with our partner @JazzPharma, we look forward to presenting updated data from the Phase 2b HERIZON-BTC-01 trial of a HER2-targeted bispecific, biparatopic antibody, in previously treated HER2-positive BTC during #asco24.
Jazz Pharmaceuticals
@JazzPharma
At #asco24, we will present 8 abstracts from our expanding #oncology pipeline, including data from a Phase 2b study for our HER2-targeted #bispecific drug candidate for biliary tract #cancer (BTC). Learn more: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
Happy #administrativeprofessionalsday! Today we recognize and celebrate the commitment and dedication of our admin teams in supporting our mission to make a meaningful difference within our organization and in the lives of those we serve.
-
Zymeworks Inc.
@ZymeworksInc
Meet with Josemund Menezes, Managing Director, Early-Stage Development (Asia Pacific), as he delivers a presentation on April 24 at 11:45am SGT during the Asia Bio Partnering Forum in Singapore. Learn more about #asiabio: informaconnect.com/asia-bio-partnering-forum/
-
Zymeworks Inc.
@ZymeworksInc
Today we celebrate #earthday and reaffirm our commitment to taking science-driven actions to protect our planet and environment. Learn how we are championing sustainability within our organization and check out our ESG report: ir.zymeworks.com/static-files/dce2ec53-0524-4341-89e7-633…
-
Zymeworks Inc.
@ZymeworksInc
Congrats to Lauren Durland & Thomas Worthington, this year's recipients of the @ubcmsl & Zymeworks Fellowship in Advanced Protein Therapeutics! We’re proud to support the next generation of innovators & can’t wait to watch them make a meaningful impact: www.msl.ubc.ca/lauren-durland-and-thomas-worthington-rece…
-
Zymeworks Inc.
@ZymeworksInc
On April 17 at 12:10 pm PT, Genevieve Desjardins, Principal Scientist inMultispecific Antibody Therapeutics, will present at @festofbiologics exploring the next generation of trispecific T cell engagers (TriTCE). See the agenda: www.terrapinn.com/conference/festival-of-biologics-usa/ag…
-
Zymeworks Inc.
@ZymeworksInc
Join us at the @LifeScienceWA Innovation Northwest Conference April 17-18 in Seattle, where Lucas Donigian, VP of Business & Commercial Development, will present a corporate overview on April 17 at 1:29pm PT. Learn more about #lsinw24: lifesciencewa.org/events/life-science-innovation-northwes…
-
Zymeworks Inc.
@ZymeworksInc
Join our management team at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto for one-on-one meetings and a corporate presentation tomorrow at 2:00 pm ET. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and a fireside chat during the Stifel Virtual Targeted Oncology Days conference on April 16 at 12:30 pm ET. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our Chief Scientific Officer, Paul Moore, PhD, will participate in one-on-one meetings and a panel discussion on April 15 at 3:00 pm ET at the Canaccord Horizons in Oncology Virtual Conference, focusing on how to improve ADCs. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Join our CEO Kenneth Galbraith and executive leadership team on May 2 at 4:30 pm ET for a conference call and webcast to discuss Q1 2024 financial results and corporate updates. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’ve engineered TriTCE Co-Stim, with the potential to enhance T cell responses against DLL3-expressing tumors in aggressive small cell lung cancer, in the pursuit of improved therapeutic outcomes for patients. #aacr24 www.zymeworks.com/wp-content/uploads/2024/04/DLL3-TriTCE-…
-
Zymeworks Inc.
@ZymeworksInc
Limited T cell infiltration & anergy pose challenges in treating solid tumors with conventional bispecific TCEs. Our next-gen TriTCE Co-Stim platform, integrating target-dependent CD3 and CD28 signaling, has the potential to improve patient responses by enhancing T cell activity.
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and deliver a corporate presentation tomorrow at 11:45 am ET during the 23rd Annual Needham Virtual Healthcare Conference. See our press release for additional details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re currently expanding our R&D team and have exciting job openings available. If you’re passionate about making a difference in the world of #cancerresearch and want to be part of a dynamic team driving innovation, check out our careers page: careers.zymeworks.com #aacr24
-
Zymeworks Inc.
@ZymeworksInc
The successful development of ADCs requires the right combination of target, antibody, linker, conjugation, and payload. Learn about our unique approach to the design and development of ADCs at #aacr24: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
In this article from @biospace, our CSO Paul Moore, PhD, shares insights on the resurgence of antibody-drug conjugates and our efforts at Zymeworks to develop next-gen #adcs for cancer: www.biospace.com/article/opinion-the-next-generation-of-a… #aacr24
-
Zymeworks Inc.
@ZymeworksInc
ADCs are effective cancer therapeutics that interact highly with their 3D environment, making it challenging to screen candidates in vitro. We're developing in vitro cancer spheroid models to interrogate these interactions, supporting ADC screening during preclinical development.
-
Zymeworks Inc.
@ZymeworksInc
Antigen heterogeneity poses a challenge for ADCs that target one antigen. Bispecific ADCs targeting multiple antigens offer the potential to expand the addressable patient population and expand treatment options. #aacr24 www.zymeworks.com/wp-content/uploads/2024/04/Bispecific-A…
-
Zymeworks Inc.
@ZymeworksInc
FRα is an established cancer target, driving interest in antibody-drug conjugates. These preclinical studies further support development of a differentiated ADC targeting FRα, composed of a highly effective antibody linked to our novel topoisomerase I inhibitor drug linker.
-
Zymeworks Inc.
@ZymeworksInc
Today we announced five presentations including new data from our preclinical development-stage programs at the 2024 @AACR Annual Meeting being held in San Diego.
For presentation highlights, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… #aacr24 -
Zymeworks Inc.
@ZymeworksInc
Today we join @WHO in recognizing #worldhealthday & the 2024 theme, “My health, my right”. At Zymeworks, we champion the right of everyone, everywhere to have access to quality #healthcare, education, and information. Learn more: www.who.int/news-room/events/detail/2024/04/07/default-ca…
-
Zymeworks Inc.
@ZymeworksInc
MSATs are designed to provide a tailored and effective treatment approach and have emerged as a potential successful treatment option for complex, multifactorial diseases, including #cancer. Explore our MSAT technology during #aacr24: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Ready to make a difference? Join us at #aacr24 and learn about our unique approach to antibody-drug conjugate (ADC) design and development. Let's work together to shape the future of cancer treatment!
Explore current opportunities at www.zymeworks.com/careers/ -
Zymeworks Inc.
@ZymeworksInc
Today at 5:30 pm PT during the @AACR Oncology Industry Partnering Event, @raffcolo, Principal Scientist & Group Lead, Medicinal Chemistry, ADC Therapeutic Development, will deliver a lecture on ADC drug development. See the agenda: www.aacr.org/meeting/aacr-oncology-industry-partnering-ev…
-
Zymeworks Inc.
@ZymeworksInc
Join us at the @AACR Annual Meeting this week as we present 5 posters exploring our pipeline of novel multifunctional therapeutics. For additional details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… #aacr24
-
Zymeworks Inc.
@ZymeworksInc
#aacr24 is around the corner! We have 5 poster presentations that reflect the power and breadth of our protein engineering platforms, and our capabilities and experience to engineer potentially differentiated and novel medicines. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Together with @JazzPharma, we’re pleased to announce the completion of the rolling Biologics License Application (BLA) to the FDA for an investigational HER2-targeted bispecific antibody for previously treated HER2-positive metastatic biliary tract cancer (BTC).
Jazz Pharmaceuticals
@JazzPharma
We completed the submission of a Biologics License Application to the FDA for accelerated review for our bispecific antibody as a potential treatment for previously-treated, unresectable locally advanced, or metastatic HER2-positive biliary tract #cancer. investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
We are on the search for a Medical Director, Early-Stage Clinical Development. This individual will oversee the planning, implementation, and execution of early-stage clinical trials. This role will be based out of our Redwood City office. Learn more: careers.zymeworks.com/job/San-Francisco-Medical-Director%…
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we aim to foster a culture where continuous learning is valued, encouraging individuals to embrace risks, develop new skills, and pursue innovative approaches. Visit www.zymeworks.com/careers/ for details on open positions at #zymeworks locations around the globe.
-
Zymeworks Inc.
@ZymeworksInc
We are excited to welcome Dr. Neil Gallagher to our Board of Directors. Dr. Gallagher brings more than 20 years of experience as a leader in oncological drug development & we look forward to his leadership as our pipeline continues to advance & expand. ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in four upcoming conferences in April. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We are seeking an Executive Director, Pharmacovigilance to join the Zymeworks team! This role can be based out of our Redwood City or Dublin office. Additional details about the position and how to apply can be found at careers.zymeworks.com/job/Dublin-Executive-Director%2C-Ph…
-
Zymeworks Inc.
@ZymeworksInc
Our topoisomerase 1 inhibitor ADC technology uses a novel fit-for-purpose camptothecin payload with moderate potency and strong bystander activity in conjugation with a traceless, cleavable peptide linker. Learn more in our publication in @MCT_AACR: aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-23…
-
Zymeworks Inc.
@ZymeworksInc
We’re in Prague for the European Lung Cancer Congress! Our team will be attending to connect with thought leaders & experts to discuss the latest advancements in the treatment of #lungcancer. See the agenda: www.esmo.org/meeting-calendar/european-lung-cancer-congre… #elcc24
-
Zymeworks Inc.
@ZymeworksInc
Join Jamie Rich, our Senior Director of Technology, ADC Therapeutic Development, today at 9:40am CET for a presentation on engineering stable antibody drug conjugates during the Antibody #biology and #engineering Conference. Explore the agenda: www.grc.org/antibody-biology-and-engineering-conference/2…
-
Zymeworks Inc.
@ZymeworksInc
On March 18 at 3:45 pm CET, our Associate Director of Business Development, David Kroeger, will deliver a presentation to discuss our efforts to develop novel medicines for people living with difficult-to-treat cancers during #bioeuropespring. Learn more: informaconnect.com/bioeurope-spring/
-
Zymeworks Inc.
@ZymeworksInc
Wishing our colleagues, friends and partners around the world a happy #stpatricksday & #irishheritagemonth! Our team attended an event this week hosted by the Consulate General of #ireland in #vancouver to celebrate & recognize the Tánaiste of Ireland's visit to Vancouver.
-
Zymeworks Inc.
@ZymeworksInc
During @KeystoneSymp’s Beyond Immune Checkpoint Blockage & Overcoming Resistance meeting, we will join experts from different aspects of tumor #immunology to assess the next steps in the evolution of cancer immunotherapy. Learn more: www.keystonesymposia.org/conferences/conference-listing/m… #kscheckpoint24
-
Zymeworks Inc.
@ZymeworksInc
Attending @DAVAOnc’s Think Tank on Antibody Drug Conjugates & Bispecifics? Don’t miss a second presentation from our own Raffaele Colombo, PhD, exploring the optimization of topoisomerase payloads in antibody-drug conjugates. Find the agenda: victoriaadc9drvw.powerappsportals.com
-
Zymeworks Inc.
@ZymeworksInc
As we focus on making a meaningful difference in the lives of people impacted by cancer, we look forward to attending @SGO_org's Annual Meeting on Women’s Cancer this week, an event focused on gynecologic cancer research & care. See here: www.sgo.org/events/annual-meeting/media/ #sgomtg
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow at 7:15am PT during @DAVAOnc's Think Tank on Antibody Drug Conjugates & Bispecifics, @raffcolo, PhD, our Principal Scientist & Group Lead, Medicinal Chemistry, will deliver a keynote presentation titled “Challenging the Dogmas of ADCs”: victoriaadc9drvw.powerappsportals.com
-
Zymeworks Inc.
@ZymeworksInc
This week we celebrated the opening of our Redwood City office in California. This expansion reflects our strategic commitment to deepening our roots in one of the world's top centers for #biotech research & development.
-
Zymeworks Inc.
@ZymeworksInc
Addressing unmet medical needs and navigating the dynamic biotech landscape requires a multifaceted approach for current & aspiring biotech leaders. Hear more from our CEO Ken Galbraith, who was recently featured on the @Biotech2050pod: soundcloud.com/user-306573075/the-race-to-cure-untreatabl…
-
Zymeworks Inc.
@ZymeworksInc
As Zymeworks continues to grow and expand across the globe, we’re proud to call Vancouver, a region characterized by collaboration and innovation, our home.
Invest Vancouver
@Invest_Van
Welcome to Metro Vancouver—it’s a region like no other.
Renowned companies like @MicrosoftVan, @Framestore, E-One Moli Energy, and @ZymeworksInc have chosen the Metro Vancouver region.
Connect with our team to discover more: investvancouver.ca/about/contact/Pages/default.aspxThis media couldn't be displayed. See it on the original post. -
Zymeworks Inc.
@ZymeworksInc
During @World_ADC, join Raffaele Colombo, PhD, our Principal Scientist & Group Lead of Medicinal Chemistry, on March 14 at 9:30am GMT as he revisits the dogma of antibody drug conjugates. Learn more: worldadc-europe.com #worldadc @raffcolo
-
Zymeworks Inc.
@ZymeworksInc
Meet with Lucas Donigian, our VP of Business & Commercial Development, during the @FierceBiotech Business Development & Licensing Summit to learn how we are developing the next generation of novel multifunctional therapeutics with the help of our partners and collaborators.
-
Zymeworks Inc.
@ZymeworksInc
Women leaders often face unique hurdles, from gender bias to a lack of representation. For Bijal Desai, VP of Finance & Strategy, being a female leader in #stem is an opportunity to inspire the next generation of women pursuing STEM careers. #iwd2024 #inspireinclusion
-
Zymeworks Inc.
@ZymeworksInc
For Cathie Graham, our VP of Legal, #inspireinclusion means creating a welcoming & supportive space for everyone. Cultivating equality, mentorship, and fair representation encourages women to thrive in all aspects of life. #iwd2024
-
Zymeworks Inc.
@ZymeworksInc
Welcoming different ideas not only makes work fair but can also create more innovative solutions. For Raquera Brown, our VP of Quality, supporting diversity and being innovative is key to doing our best in everything we do. #iwd2024 #inspireinclusion
-
Zymeworks Inc.
@ZymeworksInc
Empowering women is more than a day—it's our everyday commitment. Join Laura O’Connor, our VP of HR & DEI, as she shares insights on how we champion support, respect, and equal opportunities for women to thrive in their careers. #iwd2024 #inspireinclusion
-
Zymeworks Inc.
@ZymeworksInc
Today we celebrate #internationalwomensday and honor the incredible achievements of female leaders within our organization. Join us as we work towards a more inclusive future and celebrate the incredible women who inspire us each day. #iwd2024 #inspireinclusion
-
Zymeworks Inc.
@ZymeworksInc
Today kicks off #esgo2024! Looking forward to joining clinicians, researchers, and professionals from around the world to explore the best clinical practices and research discoveries in the field of #gynecology. Learn more: esgo.org/esgo-2024-congress/
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our fourth quarter and full year 2023 financial results. Join our executive leadership team at 4:30 pm ET where they will discuss financial results and provide a corporate update. See our press release:
ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and deliver a corporate presentation on March 6 at 11:10 am ET during the TD Cowen 44th Annual Health Care Conference in Boston. See our press release for additional details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today we announced the presentation of 5 posters during the @AACR Annual Meeting in San Diego from April 5-10. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… #aacr24
-
Zymeworks Inc.
@ZymeworksInc
Connect with Dr. Josemund Menezes, Managing Director, Early-Stage Development (Asia Pacific), at the @BioCentury East-West Biopharma Summit in Singapore to talk about how our global offices are accelerating drug development to make a meaningful difference: conferences.biocentury.com/east-west-summit
-
Zymeworks Inc.
@ZymeworksInc
Today, and every day, we thank our colleagues worldwide for their ongoing commitment to improving the lives of people affected by cancer and serious diseases. Your dedication & passion make a real difference. #employeeappreciationday
-
Zymeworks Inc.
@ZymeworksInc
Today is #rarediseaseday! Join us in showing support for the >300 million people worldwide who live with a #raredisease or a #rarecancer. Get involved in #rdd2024: www.rarediseaseday.org
-
Zymeworks Inc.
@ZymeworksInc
We’re hiring several different roles across our Early-Stage Development team based in our California office. Join us and take your career to the next level! Check out available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
Join Jamie Rich, our Senior Director of Technology, ADC, tomorrow at 3:30pm ET for a panel discussion on the utilization of novel conjugates to widen the scope of #cancer targets during the Next-Generation Conjugates Summit. Learn more: next-gen-conjugates.com/whats-on/full-event-guide/ #worldadc
-
Zymeworks Inc.
@ZymeworksInc
Next month we will be participating in two investor conferences. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For additional details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Tomorrow, Charles Chen, Senior Director, Clinical Pharmacology & Translational Sciences, will deliver a presentation on advancing PK/PD modelling to predict dosage for #bispecific & #multispecific ADCs at the Next-Generation Conjugates Summit: next-gen-conjugates.com #worldadc
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we are always looking for individuals who are looking for a new challenge and want to be part of a team that comes to work each day ready to make a meaningful difference. Visit www.zymeworks.com/careers/ for details on open positions in Vancouver.
-
Zymeworks Inc.
@ZymeworksInc
Meet David Kroeger, Associate Director of Business Development, at the #bioeuropespring conference next month. This is an opportunity to connect with potential partners to discuss our efforts to develop novel medicines for patients with cancer. See here: informaconnect.com/bioeurope-spring/
-
Zymeworks Inc.
@ZymeworksInc
We are seeking an Executive Director, Regulatory Affairs to join the Zymeworks team in California! A PhD and 10+ years of work experience in pharmaceutical regulatory affairs is preferred. Details about the position and how to apply can be found at careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
Join us during the @EASLnews Liver Cancer Summit 2024, which will bring together clinicians, researchers, nurses, patient advocates, and industry professionals to address the latest challenges and successes in #livercancer care. #livercancersummit
-
Zymeworks Inc.
@ZymeworksInc
During Citi’s 2024 Virtual Oncology Leadership Summit tomorrow, Chris Astle, our Senior Vice President & CFO, will participate in a fireside chat at 8:00 am PT to discuss our growing pipeline of novel multifunctional therapeutics. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re excited to share with you the opening of our office in #california! We’re currently on the lookout for talented and passionate individuals to join our Clinical Development team in the Bay Area. Explore our current opportunities: careers.zymeworks.com #hiring #cajobs
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to share our latest publication in Molecular Cancer Therapeutics, exploring the development of our TOPO1i platform tailored for antibody-drug conjugate (ADC) application. Access here: aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-23… @MCT_AACR
-
Zymeworks Inc.
@ZymeworksInc
Join Zymeworks CEO Kenneth Galbraith and executive leadership team on March 6 at 4:30 pm ET for a conference call and webcast to discuss Q4 2023 financial results and corporate updates.
See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Today we will attend a launch event recognizing the BC Life Sciences Sector Labour Market Intelligence Study, a labour market & workforce profile research project led by @lifesciences_bc & @KPMG_US. Learn more: lifesciencesbc.ca/bc-life-sciences-labour-market-intellig…
-
Zymeworks Inc.
@ZymeworksInc
Today is #internationaldayofwomenandgirlsinscience. We are proud to have many female leaders on our team who drive our work as we make a meaningful difference in the lives of patients. Join us as we champion #womeninstem and empower the aspiring scientists of tomorrow.
-
Zymeworks Inc.
@ZymeworksInc
Today marks the first day of #lunarnewyear. We wish prosperity to our team and partners and may the Year of the Dragon bring new opportunities, growth, and collaboration.
-
Zymeworks Inc.
@ZymeworksInc
We are excited to welcome Dr. Alessandra Cesano to our Board of Directors. Dr. Cesano brings more than 25 years of experience in drug development, diagnostics & cancer #immunology, and we look forward to her guidance and expertise. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow our management team will participate in one-on-one meetings and a fireside chat during the Guggenheim Oncology Conference at 2:30 pm ET in New York City. Learn more and see our press release for additional details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to introduce Lindsey Foulkes, PhD, who joined our team as Vice President of Corporate Development. In her role, Dr. Foulkes will work to implement corporate decisions and strategies to grow our organization & pursue potential strategic partnerships & collaborations.
-
Zymeworks Inc.
@ZymeworksInc
In honor of #worldcancerday, we stand united with the global #cancer community and the @uicc, striving for a cancer-free world where everyone has equal access to care, support & treatment. Learn how you can help #closethecaregap: www.worldcancerday.org/take-action
-
Zymeworks Inc.
@ZymeworksInc
We are currently looking for an individual with #hr experience in #biotech or #pharma to join our team in California as Senior Human Resources Business Partner. Learn more about the position: careers.zymeworks.com/job/San-Francisco-Senior-Human-Reso… #hrjobs
-
Zymeworks Inc.
@ZymeworksInc
This month we are celebrating #blackhistorymonth, recognizing the achievements, contributions, and resilience of the Black community. Join us as we acknowledge and amplify the voices that have shaped our history and continue to influence our present.
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we prioritize #career growth and professional development. We’re currently on the lookout for talented individuals to join our team. If you’re ready to thrive in a nurturing and engaging environment, check out our available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in three upcoming investor conferences in February. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We are pleased to introduce Barbara Schaeffler, who serves as our Vice President of Clinical Development Operations. With more than 27 years of experience in #biotech and #biopharma, she will provide strategic and operational leadership to our clinical development programs.
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow at @lifesciences_bc’s 5th Annual Career Connect Day, our VP of Human Resources & DEI, Laura O’Connor, will deliver a presentation at 9:55am PT to explore the exciting job opportunities available within Zymeworks. Learn more: lifesciencesbc.ca/event/life-sciences-bcs-5th-annual-care…
-
Zymeworks Inc.
@ZymeworksInc
The integration of complementary & antibody-based therapeutics, embedded in our proprietary multispecific and ADC therapeutic modalities, enables the development of differentiated and fit-for-purpose therapeutics. Learn about our technology: www.zymeworks.com/technology/
-
Zymeworks Inc.
@ZymeworksInc
By harnessing our Azymetric™ technology, our team has worked to develop novel approaches to build differentiated and next generation Trispecific T Cell Engagers. Learn more: www.zymeworks.com/technologies/t-cell-engagers/
-
Zymeworks Inc.
@ZymeworksInc
Earlier this month our management team delivered a corporate presentation during the 42ndAnnual J.P. Morgan Healthcare Conference in San Francisco. Watch a replay of the webcast: ir.zymeworks.com/events/event-details/jp-morgan-healthcar…
Life Sciences BC
@lifesciences_bc
We had an extraordinary experience at this year's J.P. Morgan Conference Week in San Francisco!
With a remarkable 57+ BC companies participating in JPM Week, we take great pride in promoting our region’s exceptional talent, innovation, and growing life sciences sector.
#jpm24 -
Zymeworks Inc.
@ZymeworksInc
This week during #gi24, Shubham Pant, MD, of @MDAndersonNews will present a poster exploring the impact on patient-reported pain outcomes in the Phase 2b HERIZON-BTC-01 study in HER2+ biliary tract cancer. Learn more about #gi24: conferences.asco.org/gi
Jazz Pharmaceuticals
@JazzPharma
At ASCO #gi24 this week, we’re sharing new research from our pipeline, which includes our novel HER2-targeted #bispecificantibody with multiple methods of action. Learn about our new approach to targeting HER2-expressing cancers such as gastric: www.jazzpharma.com/about/global-footprint/canada
-
Zymeworks Inc.
@ZymeworksInc
During the 23rd Annual PepTalk conference, Meghan Verstraete, Protein Engineering Scientist, will present the engineering of a pure & stable heterodimeric IgA for the development of multispecific therapeutics: www.chi-peptalk.com/bispecific-antibody-therapeutics
-
Zymeworks Inc.
@ZymeworksInc
Today we celebrate the life and legacy of Dr. Martin Luther King Jr. and honor his impact on social justice and racial equality. #mlkday
-
Zymeworks Inc.
@ZymeworksInc
Today our management team will deliver a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco at 8:15am PT. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our Associate Director of Business Development, David Kroeger, will attend the #biotechshowcase this week to connect with potential partners and explore our preclinical & clinical pipeline. Arrange a meeting to learn more: informaconnect.com/biotech-showcase/
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we recognize that our greatest asset is our people. Elevating talented individuals reflects our confidence in their abilities, and today we are proud to announce updates to our leadership team. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today our Chief Executive Officer Kenneth Galbraith, along with our senior leadership team, provided a review of key accomplishments in 2023 and an update on key priorities and strategic initiatives for 2024 and 2025. Read more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We are currently looking for individuals to join our Co-Op program! This is an opportunity to be an integral part of our growing research and development teams to support our growing pipeline of novel multifunctional therapeutics. Learn more: careers.zymeworks.com/go/Co-Op/2660117/
-
Zymeworks Inc.
@ZymeworksInc
#happynewyear! As we reflect on 2023, we are grateful to our team, our partners, participants in our clinical studies & their families and the study investigators who support our mission to make a meaningful difference for people impacted by cancer & other serious diseases.
-
Zymeworks Inc.
@ZymeworksInc
Kick off the new year by joining our Zymeworks team! We are always looking for passionate individuals who are eager to make a meaningful difference in the lives of patients. Ready to take the next step in your career? Visit our website: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
Wishing a very safe and #happyholiday to our team, partners, & advocates in our patient communities. We’re grateful for your ongoing commitment & support as we work towards making a meaningful difference for people impacted by difficult-to-treat cancers & other serious diseases.
-
Zymeworks Inc.
@ZymeworksInc
ProTECT™ is the first conditionally active antibody technology designed to address both ends of the therapeutic window, potentially reducing toxicity and increasing antitumor activity. Learn more about our ProTECT™ technology: www.zymeworks.com/technologies/protect/
-
Zymeworks Inc.
@ZymeworksInc
Recently our Zymeworks team decorated a Christmas tree to support Convenant House, a nonprofit organization that provides shelter and support to local youth. Check out the Zymeworks Christmas tree on Alberni Street in Vancouver!
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to introduce Shrinal Inamdar, Director of Investor Relations. With over a decade of experience in IR strategy, PR & communications, Shrinal brings valuable experience that will help amplify our efforts to reach investors, analysts, & other important stakeholders.
-
Zymeworks Inc.
@ZymeworksInc
Our Effector Function Enhancement and Control Technology (EFECT™) platform has the potential to create unique antibody modifications designed to tailor therapeutic response by directing the activity of recruited immune cells. Learn more: www.zymeworks.com/technologies/efect/
-
Zymeworks Inc.
@ZymeworksInc
We’re looking for an individual to join our team as Scientist, Clinical #pharmacokinetics. This individual will support our late-stage discovery programs from preclinical development to IND filing and throughout clinical development in Vancouver. See here: careers.zymeworks.com/job/Vancouver-Scientist%2C-Clinical…
-
Zymeworks Inc.
@ZymeworksInc
This @CD_AACR article explores the surge of investments in ADCs, including perspectives from our CEO Kenneth Galbraith about Zymeworks’ approach to highly differentiated ADC therapeutics. Read here: aacrjournals.org/cancerdiscovery/article-abstract/doi/10.…
-
Zymeworks Inc.
@ZymeworksInc
Last month the @IDAIRELAND team visited our office in Vancouver to learn more about our pipeline of novel multifunctional biotherapeutics. With the recent opening of our new HQ in Dublin, it was great to meet the #idaireland team as we enter an exciting stage of global expansion.
-
Zymeworks Inc.
@ZymeworksInc
Thank you to Lota Zoth who will be stepping down as a member of our Board of Directors. Ms. Zoth has been an important member of our team since 2016 and we express our gratitude for her incredible contributions and wish her all the best in her future endeavors.
-
Zymeworks Inc.
@ZymeworksInc
We are excited to welcome Nancy Davidson, M.D. to our Board of Directors. Dr. Davidson is an oncologist & researcher with decades of expertise in the field of #breastcancer biology & treatment, and we look forward to her guidance & expertise as we continue our work.
-
Zymeworks Inc.
@ZymeworksInc
Together with our partner @JazzPharma, we are proud to share updated data from a Phase 2a trial of an investigational HER2-targeted, bispecific antibody in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic #breastcancer, presented today during #sabcs23.
Jazz Pharmaceuticals
@JazzPharma
We are presenting late-breaking data at #sabcs23 showing the potential of an investigational treatment approach for patients with HER2+/HR+ metastatic breast cancer, a particularly aggressive and devastating disease in need of more treatment options. investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
Meet with our Associate Director of Business Development, David Kroeger, next month at the #biotechshowcase where he will connect with potential partners to discuss our efforts to develop novel medicines for patients with cancer. Learn more: informaconnect.com/biotech-showcase/
-
Zymeworks Inc.
@ZymeworksInc
Recently our CEO Ken Galbraith visited our newly launched Singapore office to meet with members of our Early-Stage Development team & attend #esmoasia, where we presented an analysis of our Phase IIb HERIZON-BTC-01 study. Great to meet with our collaborators in the Asia Pacific!
-
Zymeworks Inc.
@ZymeworksInc
#icymi Last month, we attended @sitcancer’s 38th Annual Meeting, where our R&D team presented two posters exploring our TriTCE platforms for the treatment of solid tumors. Learn about our research shared during #sitc23: www.zymeworks.com/zymeworks-presents-preclinical-data-on-…
-
Zymeworks Inc.
@ZymeworksInc
Together with our partner @JazzPharma, we look forward to the presentation of two abstracts at the 2023 San Antonio Breast Cancer Symposium #sabcs23 reviewing an investigational HER2-targeted bispecific antibody in solid tumors. #sabcs23
Jazz Pharmaceuticals
@JazzPharma
We are presenting two #oncology abstracts at #sabcs23, 11 at #ash23, and two at #naclc23, including SABCS data of our novel #bispecific antibody in HER2+/ HR+ metastatic breast cancer, an area of high unmet need. Learn more: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
We’re #hiring! We’re looking for a Senior Director, Regulatory Affairs, to provide high level strategic and operational regulatory direction and mentorship on projects related to #regulatoryaffairs. Learn more about the position: careers.zymeworks.com/job/San-Francisco-Senior-Director%2…
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in 1x1 meetings & deliver a corporate presentation on January 11 at 8:15am PT during the 42nd Annual J.P. Morgan Healthcare Conference, exploring our pipeline of multifunctional biotherapeutics. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew… #jpm2024
-
Zymeworks Inc.
@ZymeworksInc
Our team is growing! We’re looking for an individual with experience in biological sciences, #chemistry, or a relevant discipline to lead the Zymeworks Preclinical/R&D Quality Assurance program. Learn more about the position: careers.zymeworks.com/job/Seattle-Associate-Director-Prec…
-
Zymeworks Inc.
@ZymeworksInc
This week, we’re attending the 6th Annual Evercore ISI #healthconx Conference, where we will participate in one-on-one meetings and deliver a fireside chat. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
#icymi in this @OncoZine article, Joseph Woolery describes the critical role global hubs play in accelerating the delivery of therapeutic options to patients & reshaping the future of drug development in #oncology. Read the full article: www.oncozine.com/think-globally-act-globally-the-key-role…
-
Zymeworks Inc.
@ZymeworksInc
Wishing our friends and families in the U.S. a Happy Thanksgiving!
-
Zymeworks Inc.
@ZymeworksInc
Proud to be considered an “anchor company,” in our local community, helping British Columbia draw talent from around the world to sustain and grow the #lifesciences sector. Great article starting on page 8 of @BIVNews, read it here: biv.com/magazine/life-sciences-2023
-
Zymeworks Inc.
@ZymeworksInc
We’re currently looking for passionate individuals to join our team as we work towards improving the lives of people with difficult-to-treat cancers and other serious diseases. See available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
Azymetric™ is a heterodimeric antibody technology that provides the ability to engineer, screen and effectively choose the optimal geometry and valency for our targeted treatments. Learn more: www.zymeworks.com/technologies/azymetric/
-
Zymeworks Inc.
@ZymeworksInc
We are excited to introduce Dr. Pranshul Chauhan, our Associate Medical Director in Dublin. With diverse & extensive experience in #oncology, Dr. Chauhan will help coordinate clinical trials in the EU and advance early-stage clinical programs through the drug development process.
-
Zymeworks Inc.
@ZymeworksInc
We look forward to attending the @Citeline #scripawards ceremony tomorrow in London! Together with @JazzPharma, we have been selected as a finalist in the “Licensing Deal of the Year” category. Congratulations to our team on this incredible recognition and accomplishment!
-
Zymeworks Inc.
@ZymeworksInc
Join our management today at the @Stifel 2023 Healthcare Conference in New York City as we participate in one-on-one meetings and a fireside chat. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and a fireside chat during the @Jefferies London Healthcare Conference. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Today we take pause in a silent moment of remembrance and honor those who have served and continue to serve. Thank you for your bravery and sacrifice. #canadaremembers #usaremembers
-
Zymeworks Inc.
@ZymeworksInc
#stem education cultivates a culture of innovation by encouraging creative thinking, experimentation, and the development of novel technologies that drive progress in research and science. #nationalstemday
-
Zymeworks Inc.
@ZymeworksInc
In our industry, diversity of thought is crucial for innovation. Different backgrounds, experiences, and viewpoints enhance problem-solving and lead to more creative and effective solutions, and can create more equitable healthcare outcomes for all. #nationalstemday
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, our team includes experts representing many #stem disciplines. Together, we strive to expand the therapeutic options for patients so no one has to face a future without treatment. Today we celebrate #nationalstemday and all those contributing to a brighter future.
-
Zymeworks Inc.
@ZymeworksInc
While women are often underrepresented in #stem careers, Zymeworks is thriving with talented and dynamic women driving our work forward. Today we celebrate #nationalstemday and all those contributing to future progress.
-
Zymeworks Inc.
@ZymeworksInc
Today we recognize #nationalstemday, an observance that celebrates roles within the science, technology, engineering, & mathematics fields. We’re grateful to have a group of #stem professionals working together to make a meaningful difference in the lives of patients with cancer.
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our third quarter 2023 financial results. Join us for a conference call and webcast at 4:30 pm ET hosted by our management team, where they will present recent corporate highlights. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to share the news of @JazzPharma’s five-year strategic research collaboration with @MDAndersonNews, which will investigate the potential of a #her2-targeted bispecific antibody in multiple HER2-expressing #cancers.
Jazz Pharmaceuticals
@JazzPharma
Our new five-year collaboration with @MDAndersonNews will evaluate our investigational, novel HER2-targeted bispecific antibody in multiple HER2-expressing cancers, an area of significant unmet need. Learn more about the collaboration: investor.jazzpharma.com/news-releases/news-release-detail…
-
Zymeworks Inc.
@ZymeworksInc
Meet our Executive Director, Head of Business Development, Lucas Donigian, this week at the #bioeurope conference where he will connect with potential partners who share our passion for making a meaningful difference in the lives of people around the world impacted by cancer.
-
Zymeworks Inc.
@ZymeworksInc
This weekend at #sitc23, Meghan Verstraete, PhD and Maya Poffenberger, PhD, will present a poster exploring our next-generation TriTCE CPIs in solid tumors.
View the poster: www.zymeworks.com/wp-content/uploads/2023/11/MV_SITC_2023… -
Zymeworks Inc.
@ZymeworksInc
This weekend at #sitc23 Lisa Newhook and Desmond Lau will explore our next generation TriTCE Co-stim and its potential to provide tolerable and more durable anti-tumor responses and re-invigorate poorly infiltrated tumors.
View the poster: www.zymeworks.com/wp-content/uploads/2023/11/LN_SITC_Post… -
Zymeworks Inc.
@ZymeworksInc
Today kicks off the @sitcancer 38th Annual Meeting in San Diego, where we will present two posters exploring our tri-specific t-cell engager (TriTCE) programs. Learn more about #sitc23 and view the agenda: www.sitcancer.org/2023/schedule/sitc23-annualmeeting
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in three upcoming investor conferences this month. Presentations and webcasts will be available on our website at: ir.zymeworks.com/events-and-presentations. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We look forward to attending the @sitcancer 38th Annual Meeting this week in San Diego, where we will present two posters exploring our tri-specific t-cell engager (TriTCE) programs. Learn more about #sitc23 and view the agenda: www.sitcancer.org/2023/schedule/sitc23-annualmeeting
-
Zymeworks Inc.
@ZymeworksInc
We are currently seeking dedicated individuals to join our team and be part of the collective effort to make a meaningful difference. If you’re ready to use your skills to make a real impact, check out our available opportunities: careers.zymeworks.com
-
Zymeworks Inc.
@ZymeworksInc
Multispecific antibody therapeutics (MSATs) are engineered to target multiple specific antigens simultaneously to provide higher antitumor activity and novel mechanisms of action compared to mono-specific antibody therapeutics. Learn more: www.zymeworks.com/our-science/
-
Zymeworks Inc.
@ZymeworksInc
#esmo23 begins today, bringing together clinicians, researchers, patient advocates, and experts in #oncology. Together with our collaboration partners, we look forward to listening to and learning about the latest updates and developments in #cancer care.
-
Zymeworks Inc.
@ZymeworksInc
We’re searching for a Manager, Clinical Contracts and Budgets. This individual will take an active role in creating and overseeing global #clinicaltrial site budgets. Learn more about the job position: careers.zymeworks.com/job/San-Francisco-Manager%2C-Clinic… #hiring #vancouverjobs #biotechjobs
-
Zymeworks Inc.
@ZymeworksInc
Join Andrea Hernandez Rojas, our Scientist & Group Lead, In Vitro Biology, ADC Therapeutic Development, tomorrow at 12:30pm PT at the 14th World ADC conference in San Diego as she explores our NaPi2b-targeting antibody drug conjugate. See the agenda: worldadc-usa.com/about/about-event/
-
Zymeworks Inc.
@ZymeworksInc
Join Zymeworks CEO Kenneth Galbraith and executive leadership team on November 7 at 4:30pm ET for a conference call and webcast to discuss Q3 2023 financial results and corporate updates. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to announce Dr. Nancy Davidson will be nominated for election to Zymeworks’ Board of Directors at our upcoming annual general meeting of stockholders on December 7, 2023. See our press release for details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We are excited to present at #esmo23 with our partners @JazzPharma and @BeiGeneGlobal to share data exploring the potential of a #bispecific antibody in HER2-expressing biliary tract and gastric cancers.
Find details: investor.jazzpharma.com/news-releases/news-release-detail…
Jazz Pharmaceuticals
@JazzPharma
We are presenting 6 #oncology abstracts with partners at #esmo23, including data showing the potential of a #bispecific antibody in HER2-positive biliary tract and gastric cancers. Our expanding pipeline demonstrates our commitment to addressing unmet needs in cancer care.
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow during the #worldadc conference in San Diego, Laurence Madera, Senior Scientist, In Vitro Biology, ADC Therapeutic Development, will deliver a presentation during the Translational Session on our novel glypican-3 targeting ADC. Find details: worldadc-usa.com/about/about-event/
-
Zymeworks Inc.
@ZymeworksInc
National #hispanicheritagemonth recognizes and celebrates the contributions and influence of Hispanic Americans on history and culture. At Zymeworks, we are proud to have created a diverse and inclusive culture where all are seen and celebrated.
-
Zymeworks Inc.
@ZymeworksInc
Join us tomorrow during #targets23 for a presentation led by @raffcolo, PhD, Principal Scientist & Group Lead, Medicinal Chemistry, exploring current understanding and the future potential of ADC development. Learn more: www.aacr.org/meeting/aacr-nci-eortc-international-confere…
-
Zymeworks Inc.
@ZymeworksInc
We’re thrilled to see Zymeworks lighting up Times Square in honor of our 20 year business anniversary. Thanks Nasdaq for the recognition!
-
Zymeworks Inc.
@ZymeworksInc
As we recognize #worldmentalhealthday, we reaffirm our commitment to promoting the importance of physical & mental well-being among our team members and fostering a culture of openness and understanding around #mentalhealth. #stopthestigma
-
Zymeworks Inc.
@ZymeworksInc
Senior Scientist Mark Peterson will deliver a presentation tomorrow at 5:10 p.m. CEST at the #festivalofbiologics, focusing on how topoisomerase 1 inhibitors have emerged as highly effective ADC payloads for the treatment of solid tumors. Learn more: www.terrapinn.com/conference/festival-of-biologics/agenda…
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to announce new and updated clinical and preclinical data presentations at multiple medical conferences this month. For full details, click here: www.zymeworks.com/zymeworks-to-present-on-clinical-and-pr…
-
Zymeworks Inc.
@ZymeworksInc
Congratulations to Stu Barnscher on winning our inaugural Zymeworks Leadership Award, which recognizes an individual’s efforts & success in not only delivering on our corporate objectives but also shows leadership by demonstrating behaviors aligned with our values.
Zymeworks Inc.
@ZymeworksInc
Stu leads the discovery & development of novel ADC technologies & drug candidates with a focus on antibody discovery & engineering, in vitro pharmacology, and in vivo pharmacology & pharmacokinetics.
Zymeworks Inc.
@ZymeworksInc
Stu is truly passionate about the programs he is working on, and inspires and motivates others through his enthusiasm, commitment and attitude. We are proud to work with Stu and are thrilled to share in this achievement with him.
-
Zymeworks Inc.
@ZymeworksInc
In this @OncoZine article, Zymeworks' Joe Woolery describes how our organization is helping to reshape the future of drug development in oncology through the creation of global hubs to accelerate the delivery of therapeutic options to patients. Read more: www.oncozine.com/think-globally-act-globally-the-key-role…
-
Zymeworks Inc.
@ZymeworksInc
Last week our global team of 200+ gathered at our Vancouver HQ to celebrate our 20th corporate anniversary. Two decades of hard work & commitment have brought us here, & we thank our team, partners, supporters & researchers who have been with us every step of the way.
-
Zymeworks Inc.
@ZymeworksInc
During @CHI_Healthtech’s 15th Annual Immunology for Biotherapeutics Conference, our Chief Scientific Officer Paul Moore, PhD, will discuss the benefits of multi-specifics and drug conjugates. Learn more: www.immunogenicitysummit.com/Immunology-for-Biotherapeutics #chiimmunobio
-
Zymeworks Inc.
@ZymeworksInc
Today at 1:30pm ET, Nina Weisser, our Director of Multispecific Antibody Therapeutics, will lead a seminar on engineering trispecific T-cell engagers during the 14th World Bispecific Summit. Learn more about her presentation: bispecific.com/about-event/
-
Zymeworks Inc.
@ZymeworksInc
National Day for Truth & Reconciliation commemorates the victims & survivors of Indigenous residential schools. Today we join our Canadian colleagues in reflecting on the ongoing impact of Indigenous Residential School policies with the goal of fostering reconciliation & healing.
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow is #rarecancerday, organized by @RareDiseases to highlight the challenges patients face & unify those living with rare cancers for awareness & early diagnosis. Visit NORD to learn more about how you can shine a light on rare cancers: rarediseases.org/get-involved/rare-cancer-day/
-
Zymeworks Inc.
@ZymeworksInc
Today marks a special milestone as we celebrate our 20th anniversary! As we look towards an exciting future, we extend our gratitude to our team, both past & present, industry partners and collaborators who have contributed to our success and been with us every step of the way.
-
Zymeworks Inc.
@ZymeworksInc
Together with @JazzPharma, we're proud to share that we have been selected as a finalist in the “Licensing Deal of the Year” category at the @Citeline #scripawards, recognizing our partnership for the development & commercialization of our investigational bispecific antibody.
-
Zymeworks Inc.
@ZymeworksInc
Today our management team participated in one-on-one meetings and a fireside chat during the Cantor Global Healthcare Conference in New York City at 9:45am ET. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
On Monday, October 2, Nina Weisser, our Director of Multispecific Antibody Therapeutics, will present during the 14th World Bispecific Summit. Visit the conference website for details: world-multispecifics.com
-
Zymeworks Inc.
@ZymeworksInc
Today we join the international research community in celebrating #worldcancerresearchday and highlighting the vital role research and innovation plays in improving cancer survival rates as well as the quality of life for patients and their families.
-
Zymeworks Inc.
@ZymeworksInc
Last month during the Antibody Drug Digital Conference, our CSO Paul Moore explored the functionality in ADC design and highlighted how we’re leveraging clinical learnings to drive design features. Learn more in this @GENbio article: www.genengnews.com/topics/cancer/enhanced-efficacy-for-ne…
-
Zymeworks Inc.
@ZymeworksInc
Last Sunday, our team participated in the #terryfoxrun, an annual charity 3km/10km walk/run event to raise awareness & much-needed funds for #cancerresearch. Thanks to the incredible support of our team members, we surpassed our goal, raising more than $5,500 for @TerryFoxCanada
-
Zymeworks Inc.
@ZymeworksInc
Join our team as a Research Associate II, Analytics! We are seeking someone with #chemistry experience to provide characterization & quantitative analytics expertise to support projects at different stages of our pipeline in Vancouver. Learn more: careers.zymeworks.com/job/Vancouver-Research-Associate-II…
-
Zymeworks Inc.
@ZymeworksInc
Our early-stage development team had an incredible time at the @IASLC’s 2023 World Conference on Lung Cancer in Singapore! It was great to meet with our international colleagues to discuss emerging data focused on advancing therapies for #lungcancer patients. #wclc23
-
Zymeworks Inc.
@ZymeworksInc
We’re hiring for several different roles across multiple teams, including our corporate, scientific, and technical & manufacturing teams. Check out available opportunities: careers.zymeworks.com #hiring #biotechjobs
-
Zymeworks Inc.
@ZymeworksInc
Join our management team today at @MorganStanley's 21st Annual Global Healthcare Conference in New York City as we participate in one-on-one meetings and a fireside chat at 7:30am EDT. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re attending the H.C Wainwright 25th Annual Global Investment Conference this week in NYC. Our management team will participate in one-on-one meetings and present a corporate overview today at 3pm EDT.
Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and a fireside chat today at 3pm EDT during the @WellsFargo Healthcare Conference in Boston. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Live from the @Citi Annual Biopharma Conference in Boston! Our CSO Paul Moore, Ph.D., participated in a panel discussion to explore ADC technology, innovation & how Zymeworks is working to make a meaningful difference for patients. Watch the webcast: ir.zymeworks.com/events-and-presentations
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings and a co-panel discussion today at 10:30am ET at @Citi's 2023 18th Annual BioPharma conference in Boston.
Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
ADCs have emerged as a promising approach in precision medicine. This article in @ClinicalLeader1 authored by Zymeworks’ own Stuart Barnscher discusses the latest research breakthroughs & potential impact of ADCs in revolutionizing patient care: www.clinicalleader.com/doc/the-clinical-landscape-of-adcs…
-
Zymeworks Inc.
@ZymeworksInc
Antibody-payload conjugation methods and linker chemistry are important for producing successful ADCs. The right combination allows for optimal drug release at the target site, maximizing the therapeutic effect while minimizing damage to healthy cells: www.zymeworks.com/technology/
-
Zymeworks Inc.
@ZymeworksInc
In honor of #womensequalityday today, we recognize and celebrate the achievements and resilience of women around the world. We are dedicated to promoting diversity, equity, and inclusion in everything we do, & we strive to create an environment where all genders can thrive.
-
Zymeworks Inc.
@ZymeworksInc
We’re #hiring! We’re searching for a Scientist to join the In Vivo Biology & PK team. This individual will represent the In Vivo Biology group on pipeline oncology project teams from preclinical development to Investigational New Drug filing. Apply today:
careers.zymeworks.com/job/Vancouver-Scientist%2C-In-Vivo-… -
Zymeworks Inc.
@ZymeworksInc
Antibodies specifically selected for ADC use can increase the likelihood of developing a successful ADC. We leverage internal antibody discovery expertise to select antibodies with superior internalization, payload delivery& tumor penetration for use in our ADC product candidates
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to welcome Dr. Josemund Menezes as Managing Director of our new Early R&D hub in Singapore. With more than 18 years of industry experience across the #biotech, #oncology, & #immnuology space, we look forward to the wealth of knowledge he will bring to Zymeworks!
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow during the Antibody Drug Conjugates Digital Conference, Paul Moore, PhD, our Chief Scientific Officer, will explore ADC design and present a case study of our clinical stage anti-HER2 ADC. Find details: informaconnect.com/antibody-drug-conjugates/agenda/1/
-
Zymeworks Inc.
@ZymeworksInc
We’re #hiring! We’re searching for a Senior Payroll Specialist who will process monthly EMEA/APAC payroll, be responsible for payroll tax activities, and act as a main point of global payroll contact for internal/external stakeholders. Apply today: careers.zymeworks.com/job/Vancouver-Senior-Payroll-Specia…
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our second quarter 2023 financial results. Join us for a conference call and webcast at 4:30pm ET hosted by our management team where they will provide recent corporate highlights. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings this week at the BTIG Virtual Biotechnology Conference. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Identifying a specific target molecule on the surface of cancer cells is critical in order to develop clinically impactful antibody-drug conjugates successfully. Learn more: www.zymeworks.com/technology/
-
Zymeworks Inc.
@ZymeworksInc
Successful development of ADCs requires the right combination of four essential components: (1) the target, (2) the antibody, (3) the linker & conjugation, and (4) the payload to meet the specific challenges of the target indication. Learn more: www.zymeworks.com/technology/
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in five upcoming conferences in September. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
#icymi During the ADC Toxicity Summit in Boston, Stuart Barnscher, our Director of Preclinical Programs, ADC Therapeutic Development, discussed optimizing linker stability in ADC design. See the agenda here: adc-toxicity.com
-
Zymeworks Inc.
@ZymeworksInc
We’re excited to share that we’ve launched our new Early R&D hub in Singapore! Singapore is one of the leading #pharma & #biotech hubs in Asia, and we’re grateful to be part of this thriving ecosystem as we strive to make a meaningful difference for patients everywhere.
-
Zymeworks Inc.
@ZymeworksInc
ADCs have emerged as a game changer in the field of #cancer therapeutics & enabled advances that have reshaped how care providers address advanced solid tumors. Learn about key strategies that are expected to maximize therapeutic value in @NatRevClinOncol: www.nature.com/articles/s41571-023-00783-w
-
Zymeworks Inc.
@ZymeworksInc
Join Zymeworks CEO Kenneth Galbraith and executive leadership team on August 10 at 4:30pm ET for a conference call and webcast to discuss Q2 2023 financial results and corporate updates. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
In this exclusive interview with @DrugTargetRev, Dr. Paul Moore, our Chief Scientific Officer, explores the significance and potential of T cell-engaging bispecific antibodies to address solid tumors. Read the full interview: www.drugtargetreview.com/article/110093/breakthrough-drug…
-
Zymeworks Inc.
@ZymeworksInc
Recently Diana Shpektor, Director, Biomarkers, participated in a panel session at @AmericanCancer's ResearcHERS Symposium, an initiative that addresses the gender gap in scientific leadership and brings together influencer leaders to fuel the work of women scientists.
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we strive to foster an inclusive environment, and we are so proud of Diana for sharing her diverse perspectives and inspiring the next generation of female researchers! Learn more about #researchers: secure.acsevents.org/site/TR/ResearcHERS/HERSCY23NOR?pg=e…
-
Zymeworks Inc.
@ZymeworksInc
Our Executive Director of Quality, Raquera Brown, recently spoke with @PharmaReview to talk about the importance of quality assurance in the drug development process & our work in antibody therapeutics. Read the article here: www.europeanpharmaceuticalreview.com/article/183412/quali…
-
Zymeworks Inc.
@ZymeworksInc
Wishing our colleagues, partners, and friends in the U.S. a safe and happy #independenceday!
-
Zymeworks Inc.
@ZymeworksInc
Our management team will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference August 7-8. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Wishing you a safe and happy #canadaday! Our offices will be closed for summer break from June 29 -July 7 to rest, relax and recharge with our families and friends.
-
Zymeworks Inc.
@ZymeworksInc
We are excited to announce the appointment of Carlos Campoy to our board of directors. We look forward to his guidance as we continue to develop novel medicines for people with difficult-to-treat cancers & other serious diseases. See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We look forward to hosting @lifesciences_bc’s annual Summer Social at our Vancouver office on June 28! Join us as we bring together the vibrant BC #lifesciences community for a day of connection & collaboration to kickoff the summer. Learn more: lifesciencesbc.ca/event/summer-social/
-
Zymeworks Inc.
@ZymeworksInc
Join @OurSeattlePride for the 49th annual Pride Parade taking place this weekend, June 25! This fun community-wide celebration aims to promote equal human rights and respect for all. Register now: seattlepride.org/events/seattle-pride-parade-2023 #pridemonth #pride2023
-
Zymeworks Inc.
@ZymeworksInc
We are excited to announce the launch of our new Clinical & Regulatory Operations European Headquarters in Dublin, Ireland! This new research hub will support our global efforts to address difficult-to-treat cancers and other serious diseases.
IDA Ireland
@IDAIRELAND
This morning, @ZymeworksInc announced it is to establish a Clinical & Regulatory European HQ in #dublin, with plans to create 20 jobs. Zymeworks is the first #canadian biopharma company to establish an international headquarters in Ireland.
Read more: www.idaireland.com/latest-news/press-release/zymeworks-to… -
Zymeworks Inc.
@ZymeworksInc
This week at @Citi’s European Healthcare Conference, our management team will participate in one-on-one meetings on June 20-21 in London, UK.
Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
#juneteenth is a day of reflection, remembrance, and hope as we commemorate the end of slavery in the United States and recognize the struggles and injustices of the African American community.
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we are committed to creating a diverse and inclusive workforce where everyone feels valued and respected. Read more about Juneteenth and learn a few ways you can honor this day: www.juneteenth.com
-
Zymeworks Inc.
@ZymeworksInc
In honor of #pride2023, @vancouverpride is hosting a variety of events to reflect the pride of the 2SLGBTQAI+ community with this year’s theme “Reconnect,” signifying an opportunity to reconnect with history, physical spaces, and each other. Learn more: www.vancouverpride.ca/our-blog/reconnect-vancouver-pride-…
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to share our latest publication in the Journal of Medicinal Chemistry, investigating bis-intercalating peptides as antibody-drug conjugate (#adc) payloads. Read here: pubs.acs.org/doi/10.1021/acs.jmedchem.3c00760
-
Zymeworks Inc.
@ZymeworksInc
Our CSO Paul Moore, PhD, recently participated in an interview with @DrugTargetRev to discuss the potential of our preclinical candidates and multiple platform technologies in treating solid #cancer tumors. Read the full article: www.drugtargetreview.com/article/110093/breakthrough-drug…
-
Zymeworks Inc.
@ZymeworksInc
We’re attending the @Jefferies Global Healthcare Conference this week. Our management team will participate in one-on-one meetings and present June 8 at 1:00pm ET in New York, NY.
See details: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re in Boston for #bio23! Our Executive Director of Business Development, Lucas Donigian, will present a company overview and be available for 1x1 meetings throughout the week. Sign up to meet with us through @IAmBiotech’s partnering platform. #standupforscience
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we’re developing novel, multifunctional biotherapeutics to address difficult-to-treat cancers. We envision a future where every individual affected by cancer has the opportunity to become a survivor, living a life filled with joy & purpose. #ncsd2023
-
Zymeworks Inc.
@ZymeworksInc
Attending #asco23? We’re always looking for creative and motivated innovators dedicated to the discovery, development and commercialization of next-generation, multifunctional biotherapeutics. Browse our open positions: www.zymeworks.com/careers/ #hiring
-
Zymeworks Inc.
@ZymeworksInc
Together with our partner @JazzPharma, we are pleased to share results presented today during #asco23 from a Phase 2b clinical trial investigating a #her2-targeted bispecific antibody in previously treated HER2-amplified biliary tract cancers. Details: ir.zymeworks.com/news-releases/news-release-details/jazz-…
Jazz Pharmaceuticals
@JazzPharma
Together with @ZymeworksInc, we're proud to present positive Phase 2b trial data at #asco23 evaluating the potential of bispecific antibodies in HER2-amplified biliary tract #cancers. We're committed to advancing our work to potentially transform the lives of patients in need.
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to share our latest publication in Bioorganic & Medicinal Chemistry Letters, examining the application of TLR7 agonists as payloads for immunostimulatory #adcs. Congratulations to the ADC Therapeutic Development team on this accomplishment! www.sciencedirect.com/science/article/abs/pii/S0960894X23…
-
Zymeworks Inc.
@ZymeworksInc
Happy #pridemonth! At Zymeworks, we are committed to creating a diverse workplace where all voices are heard, represented and celebrated. We strive to be inclusive in all that we do and continually look for new ways to ensure we are building a culture of belonging. #pride2023
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in two upcoming conferences, the @Jefferies Global Healthcare Conference and @Citi's European Healthcare Conference. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Together with our partners @JazzPharma & @BeiGeneGlobal we’re pleased to announce new & updated data from two ongoing clinical trials evaluating an investigational #her2-targeted bispecific antibody for the treatment of solid tumors at #asco23. Details: www.zymeworks.com/zymeworks-showcases-new-and-updated-cli…
-
Zymeworks Inc.
@ZymeworksInc
We are #hiring! Our team is seeking an Associate Director, Clinical #pharmacology/#pharmacometrics to help work on the next generation of bispecific and multifunctional #biotherapeutics. Apply now: careers.zymeworks.com/job/Seattle-Associate-Director%2C-C…
-
Zymeworks Inc.
@ZymeworksInc
At Zymeworks, we strive to be inclusive in all that we do & foster a culture of openness and understanding around #mentalhealth. As we recognize #mentalhealthawarenessmonth, we reinforce our commitment to maintain a safe & supportive work environment where everyone can thrive.
-
Zymeworks Inc.
@ZymeworksInc
#clinicaltrialsday is an opportunity to recognize the vital importance of research & innovation in the field of #oncology. We’re grateful to all who participate in clinical research, offering their time to help pave the way for improved treatments for #cancer patients worldwide.
-
Zymeworks Inc.
@ZymeworksInc
Today we announced the departure of Neil Klompas, President & Chief Operating Officer. We thank Neil for his many significant contributions during his tenure and wish him the best in his future endeavors. See our press release for details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow, Diana Shpektor, Director, Biomarkers at Zymeworks, will participate in a panel session at the ResearcHERS Symposium, an event organized by the @AmericanCancer, to talk about her work & career journey. Learn more: secure.acsevents.org/site/SPageServer?pagename=researcher…
-
Zymeworks Inc.
@ZymeworksInc
Join our Executive Director of Business Development, Lucas Donigian, and other leaders from local BC companies during @lifesciences_bc’s BC Showcase: #bioboston webinar on Wednesday, May 18. Register here: lifesciencesbc.ca/event/bc-showcase-bio-boston/ #bio23
-
Zymeworks Inc.
@ZymeworksInc
This May is #nationalcancerresearchmonth, dedicated to raising awareness about the vital efforts in understanding, treating, and ultimately conquering cancer. Learn how we're harnessing the power of #adcs & #msats to contribute to the fight against cancer: www.zymeworks.com/our-science/
-
Zymeworks Inc.
@ZymeworksInc
#pegs23 begins today in Boston, where we’ll be presenting our multifunctional biotherapeutics programs in preclinical development. Learn more: www.pegsummit.com/bispecific-antibodies
-
Zymeworks Inc.
@ZymeworksInc
Graham Garnett, Scientist, Medicinal Chemistry will present at the STING and TLR Targeting Therapies Summit today in Boston at 5pm ET, discussing the evaluation of TLR7-agonists as payloads for immune-stimulating antibody conjugates. Find details: sting-tlr-targeting-therapies.com/whats-on/full-event-guide/
-
Zymeworks Inc.
@ZymeworksInc
This week at the @BankofAmerica Global Healthcare Conference, our management team will participate in one-on-one meetings and present on May 11 at 8:55 am PT in Last Vegas, NV. Find details here: ir.zymeworks.com/events/event-details/bank-america-global…
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our first quarter 2023 financial results. Join us for a conference call & webcast hosted by our $ZYME management team as they discuss financial results and provide a corporate update. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Thank you @Invest_Van for featuring us in your ‘Embrace the Lab Coat’ campaign! We are proud to be part of the #lifesciences community in Vancouver as we develop novel, multifunctional therapeutics to address difficult-to-treat cancers. Take a look: www.linkedin.com/pulse/zymeworks-developing-novel-medicin…
-
Zymeworks Inc.
@ZymeworksInc
We are excited to share that our own Nina Weisser has been nominated for the @YWCAVAN Women of Distinction Award for her contributions to research, science & technology. Join us in congratulating Nina on this well-deserved recognition!
Read more: ywcavan.org/women-distinction-awards -
Zymeworks Inc.
@ZymeworksInc
We are excited to present at #asco23 with our partners at @JazzPharma to share pivotal data on a #bispecific antibody drug candidate in patients with HER2-expressing biliary tract cancers.
Jazz Pharmaceuticals
@JazzPharma
At #asco23, Jazz & partners will present 9 #oncology abstracts, including data showing HER2-targeted pan-tumor potential of a novel #bispecific drug candidate. Our growing pipeline reflects our commitment to raising the standard of care for those living with aggressive cancers.
-
Zymeworks Inc.
@ZymeworksInc
As Manager, Office Services, Alissa Wunder takes special pride in ensuring our Zymeworks office is kept organized and well-stocked – keeping our employees happy and productive! Thanks, Alissa, for all you do to maintain our engaging office culture and environment.
-
Zymeworks Inc.
@ZymeworksInc
As the Executive Assistant to our late-stage development teams, Dee Anna Hulbert leverages her decades-long career in #biotech to make sure all teams are aligned. Her contributions have been invaluable as we advance our science to transform areas of high unmet medical need.
-
Zymeworks Inc.
@ZymeworksInc
In her role as an Administrative Assistant to the R&D team, Shawna Bradley uses her passion for helping others to ensure that our research and development projects are executed efficiently so we can make a meaningful difference in the lives of cancer patients everywhere.
-
Zymeworks Inc.
@ZymeworksInc
The goal of our administrative teams is to provide support & structure to our organization. Faith Gray serves as Executive Assistant to Chris Astle, our SVP & CFO, and acts as a strategic partner bringing everything together to ensure our business runs seamlessly.
-
Zymeworks Inc.
@ZymeworksInc
Jenna Ho has been a #zymer for more than 7 years and is currently the Executive Assistant to CEO Kenneth Galbraith and COO Neil Klompas, working behind the scenes to ensure our leadership team is set up for success. #administrativeprofessionalsday
-
Zymeworks Inc.
@ZymeworksInc
In honor of #administrativeprofessionalsday, we’re celebrating the task jugglers, masters of multitasking, and project management pros who keep our organization running smoothly and efficiently every single day. Thank you for all that you do at Zymeworks!
-
Zymeworks Inc.
@ZymeworksInc
Tomorrow our management team will participate in a fireside chat at 2:30 pm ET during Stifel 2023 Targeted Oncology Days. See details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
This week we’re participating in the #lsinw23 conference taking place April 25-26. Lucas Donigian, our Executive Director and Head of Business Development, will present a corporate overview on April 25. See you there!
-
Zymeworks Inc.
@ZymeworksInc
We’re attending the 2023 @bloomburton Healthcare Investor Conference this week. Our management team will participate in one-on-one meetings and present on April 25th in Toronto, CA. Find details here: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
An incredible week! A huge thanks to our Zymeworks team for all of their efforts during #aacr23 & for everyone who stopped by to learn more about our portfolio of novel antibody-drug conjugates & multispecific antibody therapeutics.
Find poster details: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Join our team as a Compensation Analyst! We are seeking someone with #compensation, finance, and/or #humanresources experience to support the planning and budgeting process and maintenance & execution of stock administration processes. Learn more: careers.zymeworks.com/job/Vancouver-Compensation-Analyst-…
-
Zymeworks Inc.
@ZymeworksInc
We are proud to have been selected as an #sapinnovation Award Winner! This award is a testament to our unwavering commitment to innovation & excellence as we work diligently to drive best practice, and advance our product commercialization, growth & expansion strategy.
-
Zymeworks Inc.
@ZymeworksInc
Today we announced 11 presentations, including new data from our clinical & preclinical stage programs, at #aacr23. Join us for a conference call & webcast for investors & analysts today at 6:30 pm EDT.
For presentation highlights, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Our investigational #her2-targeted bispecific antibody drug conjugate (ADC) developed using proprietary platform technologies is currently being evaluated in a Phase 1 clinical trial for patients with locally advanced or metastatic HER2-expressing cancers. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/ZW49-Poster-…
-
Zymeworks Inc.
@ZymeworksInc
Our proprietary Azymetric™️ and EFECT™️ platforms support generation of a panel of TriTCE Co-Stim Ab formats to optimize selectivity & activity and promote maximal therapeutic index & efficacy. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/TriTCE-Costi…
-
Zymeworks Inc.
@ZymeworksInc
FRα is overexpressed in numerous cancers. More effective ways of targeting FRα expressing tumors could lead to potential therapeutic advances for patients living with high unmet need. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access poster: www.zymeworks.com/wp-content/uploads/2023/04/ZW191-poster…
-
Zymeworks Inc.
@ZymeworksInc
Our investigational antibody-drug conjugate is engineered to target a protein called glypican-3 (GPC3), which is found on hepatocellular carcinoma (HCC), a common type of liver cancer that is difficult to treat. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access poster: www.zymeworks.com/wp-content/uploads/2023/04/ZW251-Poster…
-
Zymeworks Inc.
@ZymeworksInc
IL-12 is a pleiotropic cytokine that potently stimulates anti-tumor cytotoxic T and NK cell mediated immunity. To widen the therapeutic index of this highly active cytokine, we engineered a masked attenuated IL-12 that is activated via ‘extended release’ protease cleavage.#aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/ZW270-Poster…
-
Zymeworks Inc.
@ZymeworksInc
Mesothelin (MSLN) is a GPI-linked membrane glycoprotein that is overexpressed in many different cancers, including pancreatic, mesothelioma, and ovarian, for which there is a high unmet medical need. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the abstract: www.zymeworks.com/wp-content/uploads/2023/04/ZW171-Poster…
-
Zymeworks Inc.
@ZymeworksInc
PROTECT™ is a conditionally-active antibody technology that simultaneously addresses safety and efficacy by combining a tumor-specific masking/unmasking approach with a unique trispecific format providing immunomodulatory activity. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/PROTECT-Post…
-
Zymeworks Inc.
@ZymeworksInc
CD3-bispecific T cell engager therapies have exhibited clinical utility against hematological malignancies, but successes in solid tumor indications have been limited. TriTCE CPI antibodies have the potential to improve T cell responses in immunosuppressed solid tumors. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/TriTCE-CPI-P…
-
Zymeworks Inc.
@ZymeworksInc
NaPi2b is a promising therapeutic target, highly expressed in ovarian and lung carcinomas. Therapies targeting NaPi2b could provide a meaningful benefit to ovarian and lung cancer patients. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/ZW220-AACR-P…
-
Zymeworks Inc.
@ZymeworksInc
Gaining a better understanding of successful ADCs is critical to improve these therapeutics. Emerging clinical data suggest a current over-emphasis on ADC stability and insufficient acknowledgement of the complex combination of mechanisms driving efficacy and toxicity. #aacr23
Zymeworks Inc.
@ZymeworksInc
Access the poster: www.zymeworks.com/wp-content/uploads/2023/04/Revisiting-t…
-
Zymeworks Inc.
@ZymeworksInc
We look forward to welcoming @Invest_Van & local leaders to our office tomorrow to host an event discussing the #lifesciences industry in Metro #vancouver. Our COO Neil Klompas will participate in a panel discussion on local innovation. Learn more: investvancouver.ca/industries/life-sciences/Pages/default…
-
Zymeworks Inc.
@ZymeworksInc
Are you looking to join a creative, motivated, and innovative team? Visit us at #aacr23 this week during our poster sessions to learn more about our mission to develop novel, multifunctional biotherapeutics. #hiring #applynow
-
Zymeworks Inc.
@ZymeworksInc
We are seeking a motivated Scientist, DMPK/ADME to join the #medicinalchemistry group within our #adctherapeutics Department. This candidate will support pipeline program advancement & contribute to core platform technology improvements. #applynow: careers.zymeworks.com/job/Vancouver-Scientist%2C-DMPKADME… #aacr23
-
Zymeworks Inc.
@ZymeworksInc
The @AACR Annual Meeting begins today! We look forward to sharing new preclinical data on our anticipated 2024 IND candidates and other programs that represent potential future therapeutic opportunities and areas of interest. Find details on #aacr2023: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We are excited to announce the appointment of Derek Miller to our Board of Directors. Derek brings over two decades of strategic, operational and commercial leadership to our board. Join us in welcoming him to the team! Learn more in our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re driven to make a difference in the lives of patients with difficult-to-treat cancers and other serious diseases. Want to join us? Explore available positions to see if there’s a match: www.zymeworks.com/careers/ #hiring #aacr23
-
Zymeworks Inc.
@ZymeworksInc
Today we recognize #worldhealthday! Every day our team works hard to advance science that has the potential to improve the health and well-being of people living with difficult-to-treat cancers and other serious diseases.
Zymeworks Inc.
@ZymeworksInc
Join Zymeworks & @WHO as we tackle the health challenges of today and tomorrow to achieve #healthforall. #who75
-
Zymeworks Inc.
@ZymeworksInc
We’re encouraged to see a recommended new initiative to improve #patientdiversity in clinical trials – a topic we're passionate about as we work to ensure inclusiveness is built into every aspect of our research, development, & clinical process. www.nature.com/articles/d41586-023-00469-4
-
Zymeworks Inc.
@ZymeworksInc
We’re participating in two upcoming conferences, the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto and @Stifel’s 2023 Targeted Oncology Days. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We’re attending Cantor: The Future of #oncology Virtual Symposium this week and will participate virtually in a #fireside chat and one-on-one meetings April 3-4. Find more information at ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
#icymi Stuart Barnscher, our Director of Preclinical Programs, ADC Therapeutic Development, discussed #antibodydrugconjugates and their potential to change the treatment paradigm for people living with cancer in a guest column for @BioProcessOL. Read: www.bioprocessonline.com/doc/focus-areas-to-expand-the-su…
-
Zymeworks Inc.
@ZymeworksInc
As an industry leader in #proteinengineering and #drugchemistry, we’re harnessing the power of #adcs and multispecific antibody therapeutics to address unmet medical needs in hard-to-treat #cancers. Learn about our science: www.zymeworks.com/our-science/
-
Zymeworks Inc.
@ZymeworksInc
We were recently recognized on @HRD_Canada's 2023 list of Innovative HR Teams! The award recognizes organizations that are breaking boundaries to move the #humasnresources industry forward. Congrats, team! See the full list at www.hcamag.com/ca/best-in-hr/innovative-hr-teams-2023/436…
-
Zymeworks Inc.
@ZymeworksInc
Congratulations to the recipients of the 2022 Zymeworks Fellowship in Immunotherapeutics, an award offered each year to grad students at @UBC. We’re honored to support the next generation of innovators & look forward to seeing where their research takes them!
Michael Smith Labs
@ubcmsl
PhD candidates @petyagpopova of the @AnnaBlakney lab and Stephanie Besoiu of the Jefferies lab each received the 2022 Zymeworks Fellowship in Immunotherapeutics.
Learn more about their research in #rna & #immunotherapeutics: www.msl.ubc.ca/petya-popova-and-stephanie-besoiu-receive-…
#idwgs #idwgis #womeninstem -
Zymeworks Inc.
@ZymeworksInc
Greetings from Ireland! Our new Early-Stage Development office in Dublin will be a hub for technological and clinical development as we expand our global presence to make a meaningful difference for cancer patients everywhere.
-
Zymeworks Inc.
@ZymeworksInc
#dyk we were recognized as one of the Power 500 Healthcare Technology Companies of 2023? The Power 500 designation is awarded to the most innovative & impactful organizations in the #healthcare technology space. We are honored to be included. Check it out: thehealthcaretechnologyreport.com/the-power-500-healthcar…
-
Zymeworks Inc.
@ZymeworksInc
Today at #festivalofbiologicsusa our CSO Paul Moore will participate in a panel discussion focused on the future of #antibody development, and tomorrow will present an overview of $ZYME technology & our multi-specific & ADC platforms. Explore the agenda: www.terrapinn.com/conference/festival-of-biologics-usa/
-
Zymeworks Inc.
@ZymeworksInc
We’re attending the upcoming #biospringeurope conference taking place March 20-22 in Basel, Switzerland! Lucas Donigian, our Executive Director, Head of Business Development, will present a corporate overview on March 20 at 12:45 CEST. We look forward to connecting with you!
-
Zymeworks Inc.
@ZymeworksInc
In a guest column for @ClinicalLeader1, Zymeworks’ Stuart Barnscher examines the rising interest & clinical landscape of ADC technologies, including our own biparatopic antibody currently in clinical development for #her2 expressing tumors. Read now: www.clinicalleader.com/doc/the-clinical-landscape-of-adcs…
-
Zymeworks Inc.
@ZymeworksInc
We are actively looking for an individual to join our #investorrelations and #communications team as an Investor Relations Analyst! In this role, you will support annual IR and #comms efforts that contribute to our corporate goals. Apply now: careers.zymeworks.com/job/Seattle-Associate-Director%2C-B…
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to share our latest publication in @NatureComms examining the mechanism of action of an anti-HER2 IgG1 bispecific, biparatopic antibody in mediating antitumor activity in #her2-expressing tumors.
Congratulations to the team! www.nature.com/articles/s41467-023-37029-3 -
Zymeworks Inc.
@ZymeworksInc
Today we announced the acceptance of 11 abstracts for poster presentation during the upcoming @AACR Annual Meeting taking place in Orlando, Florida, April 14-19.
See our press release for details: ir.zymeworks.com/news-releases/news-release-details/zymew… #aacr23 -
Zymeworks Inc.
@ZymeworksInc
This week, company management will participate in one-on-one meetings during the @Barclays Global Healthcare Conference in Miami Beach, FL. Our CEO Ken Galbraith will present a corporate overview tomorrow at 10:45am EST. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
This week at #worldadc, Sam Lawn, Senior Scientist & Group Lead, In Vivo Biology & PK, will present an overview of an investigational folate receptor alpha targeting ADC featuring our topoisomerase-1 inhibitor technology. Find more information: worldadc-europe.com/whats-on/day-two/
-
Zymeworks Inc.
@ZymeworksInc
Candice, our Director of Operations, has been a #zymer for nearly 12 years. As a champion for #womeninstem, Candice is proud to serve as a mentor to help young women build careers reflective of their unique talents & interests. #iwd2023 #internationalwomensday #embraceequity
-
Zymeworks Inc.
@ZymeworksInc
As VP, Biometrics, Dr. Milan Mangeshkar understands the importance of supporting equal access to tools & programs that enable women and other underrepresented groups in #stem to excel in their career and rise to decision-making positions. #internationalwomensday
-
Zymeworks Inc.
@ZymeworksInc
Nina Weisser, our Director of Multispecific Antibody Therapeutics, has been a #zymer for over 10 years and is an incredible example of a female role model for fellow colleagues and others pursuing or navigating a career in STEM. #internationalwomensday #iwd2023 #embraceequity
-
Zymeworks Inc.
@ZymeworksInc
In her role as Senior Scientist, Anna von Rossum is enabling the advancement of our antibody therapeutics while also championing a more diverse & inclusive workforce as the founder & chair of the Women’s Initiative at Zymeworks (WIZ). #internationalwomensday #embraceequity
-
Zymeworks Inc.
@ZymeworksInc
In celebration of #internationalwomensday, we’re amplifying the voices of some of the talented, dynamic and successful #womeninstem on our team. Kicking off our series is Bijal Desai, our Executive Director, FP&A & Corporate Finance. #iwd2023 #embraceequity
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our fourth quarter and full-year 2022 financial results. Join us for a conference call & webcast hosted by $ZYME management to discuss financial results & provide a corporate update.
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
In celebration of #employeeappreciationday, we extend our heartfelt thanks to every Zymeworks team member for their continued commitment & contributions as we work to make a meaningful difference in the lives of patients with difficult-to-treat cancers & other serious diseases.
-
Zymeworks Inc.
@ZymeworksInc
Today is #rarediseaseday! We’re joining with colleagues around the world & 65+ global patient organizations to help shed a light on the >300 million people worldwide who live with a #raredisease, and their families and caregivers. #showyourrare #showyourstripes
-
Zymeworks Inc.
@ZymeworksInc
In alignment with our dedication to celebrating diversity, we’re amplifying Black voices & contributions to research & medicine in honor of #blackhistorymonth. @BlackinCancer provides support & networking opportunities in the #cancer space. Learn more: www.blackincancer.com
-
Zymeworks Inc.
@ZymeworksInc
Great to see Rachna Schroff, MD, MS, (@rachnatshroff) sharing in our excitement over the potential of #her2 targeted therapies for #biliarytract cancer during #ascogi23 last month! Watch from @VJOncology: www.vjoncology.com/video/g4alm_xzu1a-advances-in-treating…
-
Zymeworks Inc. reposted
Jazz Pharmaceuticals
@JazzPharma
We’re committed to supporting people living with rare cancers like #cholangiocarcinoma (CCA). This #worldccaday, Jazz and @Zymeworks are joining the international effort to encourage more awareness and research around this rare bile duct cancer. Visit @WorldCCADay to learn more.
-
Zymeworks Inc.
@ZymeworksInc
Today is World Cholangiocarcinoma Day. Join us in shining a light on #cholangiocarcinoma and learn how you can make a difference in the global CCA community: globalccaalliance.com/en/world-cca-day #worldccaday #seecca @curecc @CharityAMMF @CCA_Alliance
-
Zymeworks Inc.
@ZymeworksInc
#rarediseaseday is approaching! #rarecancers, like #cholangiocarcinoma, are those that affect fewer than 40,000 people per year in the U.S. As a group, they make up just over a quarter of all cancers. See how you can participate in #rdd2023: www.rarediseaseday.org
-
Zymeworks Inc.
@ZymeworksInc
Today our CEO Kenneth Galbraith will participate in a virtual fireside chat during the SVB Securities Global Biopharma Conference at 10:40AM ET. Click here to access the webcast: ir.zymeworks.com/events/event-details/svb-securities-glob…
-
Zymeworks Inc.
@ZymeworksInc
Happy #womeninscienceday to all of our #womeninstem! With women making up more than half of our R&D workforce, we are proud of the diverse & inclusive culture we’ve built & grateful to have an incredible group of #female leaders driving our work to make a difference for patients.
-
Zymeworks Inc.
@ZymeworksInc
The Tigerlily Foundation (@tigerlilycares) empowers women before, during and after their #breastcancer journey. Learn more about their programs: tigerlily.heymarvelous.com/event/details/616997 #tigerlilyempowers
-
Zymeworks Inc.
@ZymeworksInc
In a guest column for @BioProcessOL, Stuart Barnscher, our Director of Preclinical Programs, ADC Therapeutic Development, discusses #antibodydrugconjugates (#adcs) & their potential to change the treatment paradigm for patients.
Read now: www.bioprocessonline.com/doc/focus-areas-to-expand-the-su… -
Zymeworks Inc.
@ZymeworksInc
Today our CEO Kenneth Galbraith will participate in a fireside chat during the Guggenheim #oncology Conference in New York City. Click here to access the webcast: ir.zymeworks.com/events/event-details/guggenheim-oncology… @GuggenheimPtnrs
-
Zymeworks Inc.
@ZymeworksInc
Connect with other #stomachcancer patients through @StomachCancer_’s virtual monthly support groups lead by psychologist Jessica Ketterer, PhD.
Share personal experiences with others and learn more information about #stomachcancer at the next meeting: secure.debbiesdream.org/np/clients/debbiesdream/eventRegi… -
Zymeworks Inc.
@ZymeworksInc
“To say it out loud is one thing but when you’re actually on the schedule to get your stomach removed, that’s another thing. When it becomes a reality, it’s terrifying”.
Read Lauren’s #stomachcancer journey on @Patient_Story: www.thepatientstory.com/patient-stories/stomach-cancer/la… -
Zymeworks Inc.
@ZymeworksInc
Today we join with our global allies in #cancercare for #worldcancerday, an initiative created by the @uicc to reduce the global cancer burden and promote greater equity in diagnosis, treatment and access to patient services. #closethecaregap
-
Zymeworks Inc.
@ZymeworksInc
This month we’re joining the global #cholangiocarcinoma (CCA) community to bring attention to #bileduct cancers. We support the work of @curecc & others who provide critical support to patients and their families. Find out more about their efforts: cholangiocarcinoma.org
-
Zymeworks Inc.
@ZymeworksInc
Recently received a #stomachcancer diagnosis? @StomachCancer_ offers many support services that will help patients understand their diagnosis, staging, treatment options, #clinicaltrials and more. Learn about the program: debbiesdream.org/patient-resource-education-program/
-
Zymeworks Inc.
@ZymeworksInc
If cooking is on your list of #newyearresolutions, then check out @mygutfeelingca recipes. All of these healthy and delicious recipes are submitted by #stomachcancer patients & caregivers. Add some new recipes to your collection: www.mygutfeeling.ca/patient-recipes
-
Zymeworks Inc.
@ZymeworksInc
Thanks @ASCOPost for sharing the results of a Phase II trial evaluating our @JazzPharma partnered #her2-targeted therapy in combination with #chemotherapy in #her2-expressing gastroesophageal adenocarcinoma, or #mgea.
Read more: ascopost.com/news/january-2023/first-line-zanidatamab-plu… -
Zymeworks Inc.
@ZymeworksInc
Together with our partner @JazzPharma, we are pleased to share results presented today during #ascogi from a Phase 2 clinical trial investigating a #her2-targeted bispecific antibody in metastatic gastroesophageal #adenocarcinoma (#mgea).
Details: ir.zymeworks.com/news-releases/news-release-details/jazz-… -
Zymeworks Inc.
@ZymeworksInc
Today we celebrate the life and legacy of Dr. Martin Luther King, Jr. and honor his impact on social justice and racial equity. #mlkday
-
Zymeworks Inc.
@ZymeworksInc
Today, we’re attending the 41st Annual @jpmorgan Healthcare Conference in San Francisco. We’ll be participating in one-on-one meetings all day and will present a corporate overview at 10:30AM PT.
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Congratulations to Neil Klompas, our President & COO, for being recognized as one of the top 25 #healthcare technology leaders of Vancouver for 2022 by the Healthcare Technology Report. View here: thehealthcaretechnologyreport.com/the-top-25-healthcare-t…
-
Zymeworks Inc.
@ZymeworksInc
Having difficulty coping with the physical and emotional challenges associated with #stomachcancer? Join patients, survivors, caregivers & healthcare professionals during @mygutfeelingca’s monthly support groups: www.mygutfeeling.ca/new-page-2
-
Zymeworks Inc.
@ZymeworksInc
This week, we're attending the 41st Annual @jpmorgan Healthcare Conference. Our management team will participate in one-on-one meetings on January 12 & a corporate presentation on January 12 at 10:30AM PT.
Find details: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Today CEO Kenneth Galbraith provided a review of key accomplishments in 2022 and an update on key priorities and strategic initiatives for 2023 & 2024. Read more: ir.zymeworks.com/news-releases/news-release-details/zymew…
$ZYME #antibodydrugconjugates #multispecificantibodies -
Zymeworks Inc.
@ZymeworksInc
That’s a wrap on 2022! This was a transformative year for our organization, with a growing portfolio of exciting preclinical product candidates and continued progress with our lead investigational bispecific antibody in clinical trials across multiple #her2-expressing cancers.
Zymeworks Inc.
@ZymeworksInc
We are grateful to each and every participant in our clinical studies, their families, the trial investigators and their teams, and our incredible advocacy partners for their steadfast support. Wishing you all a happy and healthy #newyear!
-
Zymeworks Inc.
@ZymeworksInc
This month, @curecc is encouraging individuals to light a candle in honor of the #cholangiocarcinoma community during the holidays. This is a beautiful way to pay tribute to your loved ones and brighten the lives of #patients & #caregivers. Learn more: cholangiocarcinoma.org/ccf/candles-home/
-
Zymeworks Inc.
@ZymeworksInc
The #holiday season can be challenging for those living with #stomachcancer. Join @hanscooks from @GastricCancerFD as he shares some of his favorite meals that he’s made as a #gastriccancer #survivor. Learn how to nutritious recipes this holiday season: gastriccancer.org/nutrition/gesundheit-kitchen/
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to announce @JazzPharma has exercised their option to continue our exclusive development and commercialization agreement for our investigational bispecific antibody for #her2-expressing cancers. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/jazz-…
-
Zymeworks Inc.
@ZymeworksInc
In a recent interview with @bcbusiness, @galbraithken discusses his experiences leading the team at Zymeworks nearly a year after his appointment as CEO. Read the article: www.bcbusiness.ca/Leadership-2022-Zymeworks-CEO-Ken-Galbr…
-
Zymeworks Inc.
@ZymeworksInc
Today we announced topline results from the pivotal Phase 2b HERIZON-BTC-01 clinical trial investigating our HER2-targeted bispecific antibody in patients with previously treated HER2-amplified & expressing #biliarytract cancer (BTC).
Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
We’re thrilled to see $ZYME lighting up Times Square! Thanks @Nasdaq for the shoutout!
Nasdaq Exchange
@NasdaqExchange
.@ZymeworksInc is shaping new possibilities for patients everywhere. 🧬
We’re thrilled to welcome $ZYME to the @NasdaqExchange family as a biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. #nasdaqlisted -
Zymeworks Inc.
@ZymeworksInc
Next month we will present mature Phase 2 data in #her2-expressing gastroesophageal adenocarcinoma (#gea) at the @ASCO Gastrointestinal Cancers Symposium.
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zanid… #gi23 -
Zymeworks Inc.
@ZymeworksInc
On December 16, join @StomachCancer_, @marshalj23 and Liza Marshall at 1pm EST for a candid conversation about #patient and #caregiver advocacy. Learn more: debbiesdream.org/inspire_events/a-candid-conversation-abo…
-
Zymeworks Inc.
@ZymeworksInc
Tune in on December 14 for a 90-minute workshop focusing on how to cope with #stomachcancer during the #holidays. Join @CancerCare & @StomachCancer_ as they share tips for navigating conversations with friends & family. Register now: debbiesdream.org/inspire_events/coping-with-stomach-cance…
-
Zymeworks Inc.
@ZymeworksInc
Today we presented new clinical data for our #her2-targeted bispecific antibody in heavily pretreated patients with HER2-positive #breastcancer.
See our press release for details: ir.zymeworks.com/news-releases/news-release-details/new-c… #sabcs22 -
Zymeworks Inc.
@ZymeworksInc
#icymi Last month, we attended the @sitcancer Conference, where we presented preclinical data associated with our TLR7 ISACs technology. The poster was presented by Graham Garnett, a scientist on our medicinal chemistry team. #sitc22: www.zymeworks.com/news/zymeworks-presents-preclinical-dat…
-
Zymeworks Inc.
@ZymeworksInc
Join @chefnathanlyon & Mary-Eve Brown, a clinical #oncology dietician specialist, as they share how to prepare delicious meals modified for #gastriccancer patients in a special webinar on 12/9 hosted by @StomachCancer_ Register today: debbiesdream.org/inspire_events/holidaymeals22/
-
Zymeworks Inc.
@ZymeworksInc
Network with clinicians and researchers at this year’s @SABCSSanAntonio Symposium beginning tomorrow, 12/6. This year’s event will showcase the most important and impactful clinical advances in breast cancer treatment. Learn more: www.sabcs.org/2022-Symposium-Overview #sabc22
-
Zymeworks Inc.
@ZymeworksInc
See you in Texas! @SABCSSanAntonio Breast Cancer Symposium begins 12/6. This annual event is the largest scientific gathering focused on #breastcancer research, hosting 10,000 #clinicians & #scientists from around the world. Learn more: www.sabcs.org/2022-Symposium-Overview #sabc22
-
Zymeworks Inc.
@ZymeworksInc
Join us across Canada as we recognize #stomachcancerawarenessday today, November 30. #stomachcancer is the fifth most common #cancer worldwide, with more than 1 million new cases diagnosed globally each year.
Zymeworks Inc.
@ZymeworksInc
Landmarks throughout the country will be lit up in periwinkle blue to show support for patients, survivors, caregivers, and medical professionals fighting #gastriccancer. To learn more, visit: @mygutfeelingca or mygutfeeling.ca #powerofperiwinkle
-
Zymeworks Inc.
@ZymeworksInc
On Saturday we gathered with industry leaders, advocates, and colleagues in #gastriccancer research at the 6th Annual Stomach Cancer Conference organized by @mygutfeelingca in Toronto.
Zymeworks Inc.
@ZymeworksInc
With #stomachcancerawarenessmonth coming to a close, this weekend emphasized that together we can accomplish incredible things to significantly improve the journey of #stomachcancer patients globally. Thank you to all who attended & shared their stories & perspectives
-
Zymeworks Inc.
@ZymeworksInc
Still time to register for @StomachCancer_ ‘Optimizing Outcomes Following A #gastrectomy’ webinar taking place tomorrow, November 30. This virtual event is free for patients, survivors, caregivers, and advocates. Learn more: debbiesdream.org/inspire_events/optimizing-outcomes-follo…
-
Zymeworks Inc.
@ZymeworksInc
Though #stomachcancerawarenessmonth is coming to an end, our commitment to people living with #gastriccancer is our focus all year long. Learn more about @CanadianGastric, a platform for researchers to share information with the goal of helping #patients: gastriccancer.ca
-
Zymeworks Inc.
@ZymeworksInc
This week we’re attending the 5th Annual Evercore ISI #healthconx Conference, where we will be participating in one-on-one meetings & a fireside chat today at 4:45 pm EST.
Access a replay of the presentation on our website: ir.zymeworks.com/events/event-details/5th-annual-evercore… $ZYME -
Zymeworks Inc.
@ZymeworksInc
Today we join with the #gastriccancer community for the 6th Annual Stomach Cancer Conference organized by @mygutfeelingca We look forward to meeting with and learning from fellow industry leaders and patient advocates throughout the program. Find details: www.mygutfeeling.ca/2022-stomach-cancer-conference-program
-
Zymeworks Inc.
@ZymeworksInc
Next month at the San Antonio Breast Cancer Symposium, we will present a poster highlighting new clinical data for our #her2-targeted bispecific antibody in heavily pretreated patients with HER2-positive #breastcancer.
See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… #sabc22 -
Zymeworks Inc.
@ZymeworksInc
Last month we hosted an Early R&D Day to review our early research & development pipeline efforts and our “5 by 5” plan to have 5 $ZYME developed programs in clinic by 2025. Watch a replay of the webinar at vimeo.com/webinars/events/466054bf-c54d-4568-a045-494a61f…
-
Zymeworks Inc.
@ZymeworksInc
We are proud to sponsor the @targetcancer Gastroesophageal Cancer Think Tank November 17-18 in Boston! The #thinktank is a two-day scientific meeting addressing the challenges facing researchers and clinicians in #gastroesophageal cancer. Learn more: www.targetcancerfoundation.org/thinktank/
-
Zymeworks Inc.
@ZymeworksInc
We stand with the #stomachcancer community. @mygutfeelingca continues to empower patients & survivors by providing an opportunity to share their experiences at this year’s Annual Stomach Cancer Conference, taking place 11/26. View the program at www.mygutfeeling.ca/2022-stomach-cancer-conference-program
-
Zymeworks Inc.
@ZymeworksInc
Today company management participated in a fireside chat at the Jefferies London Healthcare Conference at 10:55AM GMT.
Access a replay of the presentation on our website: ir.zymeworks.com/events/event-details/jefferies-london-he… $ZYME #jefferieshealthcare -
Zymeworks Inc.
@ZymeworksInc
This week, we’re attending the Stifel 2022 Healthcare Conference, where we will be participating in one-on-one meetings & a fireside chat tomorrow at 11:30AM ET. Access a replay of the presentation on our website: ir.zymeworks.com/events/event-details/stifel-2022-healthc… $ZYME
-
Zymeworks Inc.
@ZymeworksInc
Today we take pause to remember and honour those who have served. Thank you for your bravery and sacrifice. #canadaremembers #usaremembers
-
Zymeworks Inc.
@ZymeworksInc
Today we presented preclinical data associated with our TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference. Find key data highlights at www.zymeworks.com/news/zymeworks-presents-preclinical-dat… #sitc22
-
Zymeworks Inc.
@ZymeworksInc
#tbt to the 4th Annual CCA Summit last month! We were grateful to sponsor this valuable program that unites the #cholangiocarcinoma community and expands the knowledge of healthcare professionals worldwide.
-
Zymeworks Inc.
@ZymeworksInc
Today we announced our third quarter 2022 financial results. Join us for a conference call & webcast hosted by $ZYME management to discuss financial results & provide a corporate update. For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
In 2008, Debbie was diagnosed with stage IV #stomachcancer. She created @StomachCancer_ to advance research, support patients, and educate others. This November, we celebrate the life and legacy of Debbie and honor the work of Debbie’s Dream: debbiesdream.org
-
Zymeworks Inc.
@ZymeworksInc
Next week, our team will be in Boston for the @sitcancer 37th Annual Meeting to present a poster on purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs). The abstract will be made available on our website at the time of presentation. #sitc22
-
Zymeworks Inc.
@ZymeworksInc
No Stomach for Cancer works to raise awareness about stomach cancer worldwide. Join us in exploring their program initiatives and participating in the @NoStomach4Cancr Walk this November. Learn how to participate: nostomachforcancer.org/get-involved/annual-walk/no-stomac…
-
Zymeworks Inc.
@ZymeworksInc
Our exclusive licensing agreement with @JazzPharma represents our shared vision to improve outcomes for #cancer patients around the world. Read more about this exciting collaboration in an original piece from @OncoZine: www.oncozine.com/jazz-pharmaceuticals-and-zymeworks-agree…
-
Zymeworks Inc.
@ZymeworksInc
November is #stomachcancerawarenessmonth, a time to increase #awareness and education and highlight the resiliency and strength of the #stomachcancer community. Learn more about our #gastriccancer research program at www.zymeworks.com/patients
-
Zymeworks Inc.
@ZymeworksInc
This week we will virtually attend #bioeurope, the industry's largest gathering of biopharma professionals in Europe. Lucas Donigian, our Senior Director of Business Development and Alliance Management, invites potential partners to contact him for informal discussions.
-
Zymeworks Inc.
@ZymeworksInc
Today our senior leadership and scientific experts, led by Chief Scientific Officer Paul Moore, PhD, provided an update on the progress and plans for the development of our novel pipeline assets & applications of proprietary next-generation technology platforms.
Zymeworks Inc.
@ZymeworksInc
The program presented data from multiple preclinical product candidates built upon our industry-leading multispecific and next-generation TOPO1i based ADC platforms. View a replay of our Early R&D Day presentation at ir.zymeworks.com/events/event-details/zymeworks-early-res…
-
Zymeworks Inc. reposted
Cancer Cell
@Cancer_Cell
Online Now: The therapeutic window of antibody drug conjugates: A dogma in need of revision www.cell.com/cancer-cell/fulltext/S1535-6108(22)00445-7?r…
-
Zymeworks Inc.
@ZymeworksInc
Join us for a conference call and webcast for investors and analysts today, October 19, at 8:00 a.m. ET, where management will discuss our new collaboration with @JazzPharma. Webcast replays will be available on our website. Find details: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
We are pleased to share our new exclusive licensing agreement with @JazzPharma for the development and commercialization of our HER2-targeted bispecific antibody in multiple #her2 expressing cancers.
Zymeworks Inc.
@ZymeworksInc
This global partnership represents an exciting step forward in providing a potential #her2-targeted therapy for patients with difficult-to-treat cancers who currently have limited treatment options. Our CEO, Kenneth Galbraith, shares details:
Zymeworks Inc.
@ZymeworksInc
For more information, see the press release: ir.zymeworks.com/news-releases/news-release-details/jazz-…
-
Zymeworks Inc.
@ZymeworksInc
Join Zymeworks CEO Kenneth Galbraith and executive leadership team on November 8 at 4:30 pm ET for a conference call and webcast to discuss Q3 2022 financial results and corporate updates. Learn more: ir.zymeworks.com/news-releases/news-release-details/zymew…
-
Zymeworks Inc.
@ZymeworksInc
Meet Jack Spinks, our Associate Director of #investorrelations and second #zymerspotlight! Join Jack and the rest of our fast-growing team as we work to make a difference in the lives of patients & families impacted by #cancer.
Explore open roles at jobs.jobvite.com/zymeworkscareers -
Zymeworks Inc.
@ZymeworksInc
Today @Cancer_Cell published a commentary written by Zymeworks’ early R&D team members Raffaele Colombo and Jamie Rich discussing the promise of next generation antibody drug conjugates. The online publication is available now: www.sciencedirect.com/science/article/pii/S15356108220044….
Congratulations, team! -
Zymeworks Inc.
@ZymeworksInc
Next week, our R&D team, led by Chief Scientific Officer Paul Moore, PhD, will deliver an in-depth look at our preclinical research programs as well as an update on our future scientific vision at an Early R&D Day in NYC.
See our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… -
Zymeworks Inc.
@ZymeworksInc
Today we honor #worldmentalhealthday and join @WHO to support their global efforts to ensure mental health is valued, promoted, and protected as part of their 2022 campaign, “Make #mentalhealth & Well-Being for All a Global Priority.”
Zymeworks Inc.
@ZymeworksInc
We’re committed to creating a safe and healthy work environment, providing employees with a range of tools and support programs that can help #zymers enjoy good health, peace of mind, and the ability to balance the demands of life & work. #stopthestigma
-
Zymeworks Inc.
@ZymeworksInc
The 4th Annual Cholangiocarcinoma Summit will take place next week, October 13-15, in Colorado. We are proud to be a Patron Sponsor of this event that will unite career oncologists, experts, and industry leaders to collaborate with the global #cholangiocarcinoma community.
-
Zymeworks Inc.
@ZymeworksInc
#hispanicheritagemonth recognizes and celebrates the cultures, histories, achievements, and contributions of Hispanic Americans. At Zymeworks, we champion diversity and aim to ensure everyone's voice is heard and represented in all we do.
-
Zymeworks Inc.
@ZymeworksInc
Zymeworks to present data on purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs) at the #sitc22 37th Annual Meeting on November 10, 2022.
Find details: www.zymeworks.com/news/zymeworks-to-preclinical-data-at-t… -
Zymeworks Inc.
@ZymeworksInc
Next month, we’ll be participating in the @Stifel 2022 Healthcare Conference and the @Jefferies London Healthcare Conference. All presentations will be available on our website at ir.zymeworks.com/events-and-presentations.
For details, see our press release: ir.zymeworks.com/news-releases/news-release-details/zymew… $ZYME -
Zymeworks Inc.
@ZymeworksInc
National Day for Truth & Reconciliation commemorates the victims & survivors of Indigenous residential schools. Today we join our Canadian colleagues in reflecting on the ongoing impact of Indigenous Residential School policies with the goal of fostering reconciliation & healing.
-
Zymeworks Inc.
@ZymeworksInc
Worldwide, rare cancers make up 22% of cancers that are diagnosed each year. Efforts to increase awareness of #rarecancers among patients and clinicians could lead to earlier detection and improvements in survival.
Zymeworks Inc.
@ZymeworksInc
In recognition of #worldcancerday tomorrow, we join the NORD Rare Cancer Coalition® in highlighting the challenges patients face & efforts to unify individuals living with rare cancers for awareness and early diagnosis. Learn more: rarediseases.org/rare-cancer-day-2022-showcases-critical-… @RareDiseases
-
Zymeworks Inc.
@ZymeworksInc
Jamie Rich, PhD, plays a key role in advancing our clinical and preclinical pipeline programs & contributing to core platform technology improvements & innovation. In recognition of #worldcancerresearchday, we asked Jamie why he’s chosen to dedicate his work to #cancer research.
-
Zymeworks Inc.
@ZymeworksInc
Today we join the international research community in celebrating #worldcancerresearchday, a global movement seeking to raise awareness of the importance of #cancer research to increase survival, facilitate access to scientific advances & reduce the global burden of cancer.
Zymeworks Inc.
@ZymeworksInc
#cancer is a major public health problem, requiring coordinated action to reduce global disease burden. We look forward to playing a vital role in advancing innovative therapeutic options for patients in need around the world with difficult-to-treat cancers.
-
Zymeworks Inc.
@ZymeworksInc
September is #ovariancancermonth. #ovariancancer is the 5th deadliest cancer for women & symptoms can be easily mistaken meaning it often goes undetected. Advances in research have led to more targeted treatments, but an existing unmet need remains for this community of patients.
Zymeworks Inc.
@ZymeworksInc
The Ovarian Cancer Research Alliance @ocrahope is dedicated to fighting #ovariancancer & investing in research & awareness initiatives. We applaud their work and share in their mission to support patients and families throughout their cancer journey.
-
Zymeworks Inc.
@ZymeworksInc
We’re pleased to share a recent manuscript published in @FutureOncol_FSG discussing the design of HERIZON-GEA-01, a global Phase 3 study for patients with advanced/metastatic #her2-positive gastroesophageal adenocarcinoma. #gastriccancer #stomachcancer
www.futuremedicine.com/doi/10.2217/fon-2022-0595 -
Zymeworks Inc.
@ZymeworksInc
On Wednesday, 9/21, Anna von Rossum, PhD, Scientist, Multispecific Antibody Therapeutics, will present during the 13th World Bispecific Summit.
Visit the conference website for details: world-multispecifics.com -
Zymeworks Inc.
@ZymeworksInc
Exciting to see this discussion in the #esmodailyreporter on antibody–drug conjugates (ADCs) and their potential as a therapeutic strategy for patients with advanced solid tumors, based on recent study data reported during #esmo22.
Take a look: dailyreporter.esmo.org/esmo-congress-2022/top/antibody-dr… -
Zymeworks Inc.
@ZymeworksInc
We’re attending the @MorganStanley 20th Annual Global Healthcare Conference in New York City and will participate in one-on-one meetings on September 13 & 14. View our presentation tomorrow, 9/14 at 2:05PM EDT. ir.zymeworks.com/events-and-presentations $ZYME
-
Zymeworks Inc.
@ZymeworksInc
Reminder! Join us at the H.C. Wainwright 24th Annual Global Investment Conference, where $ZYME leadership will virtually participate in one-on-one meetings on September 13 & 14. A pre-recorded presentation is available here: journey.ct.events/view/e9109a21-3b52-4698-b95d-a4a5e069b8e1 @HCWCO
-
Zymeworks Inc.
@ZymeworksInc
Today at #esmo22, we reported preliminary results from a Phase 1 study in HER2-positive tumors during a mini-oral presentation reviewed by Komal Jhaveri, MD, FACP, of @MSKCancerCenter.
Find details: ir.zymeworks.com/news-releases/news-release-details/zymew…
Zymeworks Inc.
@ZymeworksInc
We will hold a conference call today, September 12, at 4:30PM ET to discuss the data presented at #esmo22. Dr. Jhaveri’s complete presentation can be found at ir.zymeworks.com/news-releases/news-release-details/zymew…. $ZYME













































































































































































































































































































































































































































































































































































































































































































































































































































